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The major challenge of cancer gene therapy trial is the ability to target transgene expression to 
a particular tumor cell type.  As uncontrolled proliferation is a common characteristic of 
malignant tumor cells, an attractive strategy for cancer gene therapy would be the use of 
vectors carrying therapeutic genes that can be activated upon cellular replication.  This 
strategy may be of special clinical relevance for brain tumor therapy.  One of the clinical 
pathology of glioma is its highly invasive and diffuse nature, thus render complete surgical 
resection impossible. In this study, we have attempted to design vectors by the incorporation 
of regulatory elements that allow proliferation-dependent gene expression. 
 
We have constructed a HSV-1 amplicon viral vector whereby the transgene expression is 
controlled by cell cycle events.  The strategy adopted is based on a G0/G1 specific 
transcriptional repressor protein, CDF-1, that interacts with regulatory elements on the cyclin 
A promoter.  In non-dividing cells, the activation of the cyclin A promoter by an upstream 
transactivator, Gal4/NF-YA fusion protein, is prevented by the presence of the CDF-1 protein.  
In actively proliferating cells, transactivation could take place due to the absence of CDF-1.  
Our results demonstrated that when all of these cell cycle-specific regulatory elements are 
incorporated in cis into a single HSV-1 amplicon plasmid, the reporter luciferase activity is 
greatly enhanced.  As a further safety mechanism, the transgene cassette is placed under a glial 
cell-specific promoter for glial cell specific transcription since most recurrent brain tumors 
originate from glial-derived cells.   When these amplicon plasmids are packaged into 
infectious but replication-defective HSV-1 amplicon viral vectors, the luciferase reporter 
expression could be regulated in a glial cell specific and proliferation-dependent manner in a 
variety of human glioma cell lines.  These viral vectors are also demonstrated to be effective at 
delivering therapeutic genes to actively proliferating tumor cells in glioma xenografts. 
 
In addition, we have screened the phage display library for a glioma-specific sequence with 
the aim of identifying molecules that target to glioma cells.  We have isolated a novel human 
glioma-specific peptide, MG11, which could target exogenous DNA specifically to a wide 
array of human glioblastoma cells, in vitro and in vivo.  The isolation of this MG11 peptide 
provides the means to conjugate therapeutic agents for targeting.  The combination of these 
two strategies would ensure only those rapidly proliferating glioma cells that express the 
receptor for the MG11 peptide would be infected by the amplicon vector, thus greatly facilitate 
the expression of therapeutic gene to glioma cells.  More importantly, the amount of viruses 
needed to achieve a therapeutic response would be significantly reduced; hence, potential side 
effects could be correspondingly minimized.  
 
In summary, we have designed an HSV-1 amplicon based gene delivery system that is (i) 
capable of incorporating a large transgene capacity; (ii) stable; (iii) safe; (iv) regulatable; (v) 
capable of targeting to glioma cells.   
 viii
 
LIST OF TABLES 
 
 
Table 1.1  Vectors and delivery systems for gene therapy     12 
 
Table 5.1   Determination of transduction efficiency of amplicon viruses in vivo  160 
 
Table 5.2 Comparison of percentage of GFP positive cells in both HSV-1  
 amplicon viral vectors infected and AdGFP infected HeLa cells 161 
 
Table 5.3   Lists of peptides isolated from biopanning of human glioma cell  
       lines  166 
 ix
LIST OF FIGURES 
 
Figure 1.1  Pathways to gliomagenesis   3 
 
Figure 1.2  Model of distant recurrences in malignant glioma    6 
 
Figure 1.3  MRI images of recurrent glioma      7 
 
Figure 1.4  Structure of herpes simplex virus type-1     14 
 
Figure 1.5  Diagram of HSV-1 amplicon vectors     18 
 
Figure 1.6  Helper virus-free packaging system      20 
 
Figure 3.1  Summary of cell cycle regulation      56 
 
Figure 3.2  Cyclin A promoter sequence      59 
 
Figure 3.3  Sequence alignment of the CDE/CHR region in the cdc25C, cdc2 and  
  cyclin A promoter        60 
 
Figure 3.4  Summary of the dual-specificity system     64 
 
Figure 3.5  Constructs used in this chapter      70 
 
Figure 3.6  Single vector constructs containing both the activator and  
  the reporter module is much more efficient than cotransfection  72 
 
Figure 3.7  Cell cycle profile of NIH3T3      74 
 
Figure 3.8  Cell cycle regulated luciferase gene expression in NIH3T3   75 
 
Figure 3.9  Analysis of cell cycle regulated transgene expression in human tumor  
  cell lines         76 
 
Figure 3.10  Cell cycle dependent transgene expression can be abolished in the 
  presence of competitor       78 
 
Figure 3.11  Interaction of the CDE/CHR regulatory region with CDF-1 repressor 
  protein         80
         
Figure 3.12  Luciferase transgene expression can be switched on in resting cells  
  transfected with pC8-36 amplicon plasmid     81 
 
Figure 3.13  The effect of viral transduction on cell cycle regulated transgene  
  expression         83 
 
Figure 3.14  HSV-1 infection do not alter the cell cycle profile 85 
 
 
Figure 3.15  The effect of different viral dosage on the regulation of transgene  




Figure 3.16  Kinetics of liver regeneration following PHx    88 
 
Figure 3.17  Transgene expression mediated by pC8-36 in PHx, mock-treated and  
  untreated mice        89 
 
Figure 4.1  Fas/FasL mediated apoptosis      97 
 
Figure 4.2  Cell cycle regulated amplicon vector constructs harboring either the  
  FasL or the FADD gene       104 
 
Figure 4.3  Apoptotic effect mediated by FasL is specific for proliferating cells  106 
 
Figure 4.4  Conditioned medium harvested from FasL-transduced proliferating  
 dGli36 cells induce apoptosis.      107 
 
Figure 4.5  The function of FADD mediated by pC8-FADD is cell cycle-regulated 109 
 
Figure 4.6  Expression of FasL and FADD mediated by pC8-FasL and pC8-FADD 
  is cell cycle-regulated       110 
 
Figure 4.7  Combine effect of FasL and FADD overexpression was observed in  
  glioma cells        112 
 
Figure 4.8  Expression profiles of FasL and FADD in vitro    114 
 
Figure 4.9  Suppression of tumor growth is observed in vivo    115 
 
Figure 4.10  Differential mRNA expression of FADD and FasL in treated tumors 
  compared with control       117 
 
Figure 5.1  Diagram of glioma-specific and cell cycle-regulated vector   141 
 
Figure 5.2  Glial cell-specific and cell cycle-regulated luciferase expression  
  mediated by pG8-18 vectors in different tumor cells  142 
 
Figure 5.3  Luciferase expression is only observed in proliferating glial cells  143 
 
Figure 5.4  Cell cycle- and glial cell-specific transgene regulation mediated by  
  HSV-1 amplicon viral vectors in vivo     145 
 
Figure 5.5  Cell death mediated by pG8-FasL vector is dual specific   146 
 
Figure 5.6  Expression of FasL is specific for proliferating glial cells   148 
 
Figure 5.7  FasL expression mediated by pG8-FasL suppresses growth of glioma  
  in vivo          149 
 
Figure 5.8  Expression of FasL prolonged the survival of mice harboring intracranial 
  dGli36 tumor        151 
 
Figure 5.9  Effect of TMZ on cell cycle was analyzed in dGli36 cells   153 
 
Figure 5.10  Effect of TMZ on luciferase expression mediated by pG8-18    154 
 
Figure 5.11  Stability of pG8-18 amplicon viral DNA in vivo    156 
 xi
 
Figure 5.12  Stability of luciferase expression mediated by pG8-18 amplicon vector  
  in vivo         157 
 
Figure 5.13  Transduction efficiency of and pG8-18 and pC8-36 amplicon viral  
  vector in vivo        159 
 
Figure 5.14  Immunogenicity of pG8-18 and pC8-36 amplicon viral vectors  163 
 
Figure 5.15  Biopanning of glioma targeted phage     165 
 
Figure 5.16  In vitro specificity of MG11 phage to a panel of human glioma cell lines 168 
 
Figure 5.17  In vivo targeting of MG11 phage to tumor cells of glioma origins  169 
 
Figure 5.18  In vivo specificity of MG11 phage to a panel of human glioma cell lines 171 
 
Figure 5.19  In vitro binding of (K16)-MG11 peptide to glioma cells   173 
 
Figure 5.20  (K16)-MG11 peptide mediate transgene expression to a panel of human  
  glioma cell lines        175 
 
Figure 5.21  In vitro specificity of the Lissamine rhodamine-labeled (K16)-MG11  
  Peptide         177 
 
Figure 5.22  Binding of lissamine rhodamine-labeled (K16)-MG11 peptide to primary  
  human glioma culture       178 
 



















Ad    Adenovirus 
ANOVA   Analysis of variance 
BAC    Bacterial artificial chromosome 
BBB    Blood-brain barrier 
bp    Base pair 
CDE    Cell cycle-dependent element 
CDF-1    Cell cycle-dependent factor 1 
CHR    Cell cycle genes homology region 
CMV    Cytomegalovirus 
EGFR    Epidermal growth factor receptor 
FACS    Fluorescence activated cell sorter 
FADD    Fas-associated protein with death domain 
FasL    Fas ligand 
GBM    Glioblastoma Multiforme 
gC    Glycoprotein C  
GCV    Ganciclovir 
GFAP    Glial fibrillary acidic protein 
GFP    Green fluorescent protein 
H&E    Hematoxylin and Eosin  
HSV-1    Herpes Simplex Virus Type 1 
HSV-tk    Herpes simplex virus thymidine kinase gene 
i.c.    Intracranial 
i.v.    Intravenous 
ICP    Infected cell protein 
IE    Immediate early 
kb    kilobase 
kDa    kiloDalton 
MOI    Multiplicity of infection 
MRI    Magnetic resonance imaging 
NF-YA    Nuclear factor Y subunit A 
PFU    Plaque forming unit 
PHx    Partial hepatectomy 
PI    Propidium iodide 
pRb    Retinoblastoma protein 
RLU    Relative light unit 
RR    Ribonucleotide reductase 
r.t.    Room temperature 
s.c    Subcutaneous 
SCID    Severe combined immunodeficient 
SEM    Standard error of mean 
TMZ    Temozolomide 
TU    Transduction unit 
TU/ml    Transduction unit per ml 
TUNEL   Terminal-dUTP nick end labeling 
 
 xiii




1. Ivy AW Ho, Kam M Hui and Paula YP Lam. (2004). Glioma-specific and cell cycle-
regulated Herpes Simplex Virus Type 1 amplicon viral vector. Hum Gene Ther 15(5): 
495-508. 
 
2. Ivy AW Ho, Paula YP Lam and Kam M. Hui. (2004). Identification and 
characterization of novel human glioma-specific peptides to potentiate tumor-specific 
gene delivery. Hum Gene Ther 15(8): 719-732. 
 
3. Ivy AW Ho, Kam M Hui and Paula YP Lam.  (2005). Targeting proliferating tumor 






1. Ivy AW Ho, Paula YP Lam and Kam M. Hui. (2004). Identification and 
characterization of novel human glioma-specific peptides to potentate tumor-specific 
gene delivery.  International Society for Cancer Gene Therapy 2004 Singapore 
Conference, 21st-22nd February, Singapore. Oral presentation, 2nd prize. 
 
2. Ivy AW Ho, Kam M. Hui and Paula YP Lam. (2004). Selective induction of apoptotic 
cell death mediated by FasL using the HSV-1 amplicon viral vector.  International 
Society for Cancer Gene Therapy 2004 Singapore Conference, 21st-22nd February, 
Singapore.  Poster presentation. 
 
3. Paula YP Lam, Jenn-Hui Khong, Kar Sian Lim, Ivy Ho and Kam M Hui. (2004) 
Transcriptional targeting to liver cells.  International Society for Cancer Gene Therapy 
2004 Singapore Conference, 21st-22nd February, Singapore.  Poster presentation. 
 
4. Ivy AW Ho, Kam M. Hui and Paula YP Lam. (2003). A novel molecular strategy to 
target proliferating tumor cells.  Keystone Symposium on Molecular Targets for 
Cancer Therapeutics, 19th March-24th March, Banff, Alberta, Canada.  Poster 
presentation. 
 
5. Ivy AW Ho, Kam M. Hui and Paula YP Lam. (2002). Development of a cell cycle-
regulated and cell type-specific HSV-1 amplicon viral vector.  The 4th Annual meeting 





1. Compositions and methods for treatment disease.  Application No. 2004901220. 
March 2004. 
 
2. Materials and methods relating to the treatment of gliomas.  Application No. 















1.1 Brain tumors 
Tumors of the central nervous system (CNS) are the most prevalent neoplasm of childhood 
and also one of the leading cancer-related causes of death in adults (Alemany et al., 1999).  
Recent World Health Organization (WHO) classification grades the astrocytic tumors into 
pilocytic astrocytoma (grade I), fibrillary astrocytoma (grade II), anaplastic astrocytoma 
(grade III) and glioblastoma multiforme (GBM) (grade IV), with GBM being the most 
malignant and lethal subtype of brain tumor (Kleihues et al., 2002).  GBM are highly 
heterogeneous, consisting of pleiomorphic cells and microvascular infiltrations, as well as 
regions of pseudopalisading necrosis.  Glioma cells can also be detected at the perivascular 
and intrafascicular regions (Holland, 2000).  Genetic abnormalities of GBM consist of various 
deletions, amplifications, and point mutations leading to activation of signal transduction 
pathways downstream of tyrosine kinase receptors, such as epidermal growth factor receptor 
(EGFR) and platelet-derived growth factor receptor (PDGFR).   Other aberrations frequently 
observed in GBM include mutations in the p53 tumor suppressor gene, amplification of cyclin 
dependent kinase 4 (CDK4), loss of the retinoblastoma (pRb) gene as well as mutation in the 
INK4a-ARF locus, which encodes two gene products (p16INK4a and p14ARF) involved in cell-
cycle arrest and apoptosis (Castro et al., 2003a; Lam and Breakefield, 2001; Ng and Lam, 
1998).    
 
GBM that develop de novo are known as primary glioblastomas, while those that progress 
from low grade anaplastic astrocytoma are known as secondary glioblastoma (Figure 1.1).  
Although both tumor types eventually manifest as GBM, the molecular pathway leading to 
the development of GBM is different.  Primary glioblastoma are characterized by the 
amplification of the transmembrane receptor EGFR (Louis and Gusella, 1995; von Deimling 
et al., 1993) and the mouse double minute 2 (mdm2) genes (Biernat et al, 1997).  The 
frequency of EGFR amplification correlates with the progression of tumorigenicity, with 3 % 
of amplifications detected in low-grade astrocytoma and 40 % in high-grade GBM.  A 
common mutation of the EGFR gene in human gliomas consists of an in-frame deletion of  
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exons 2-7 from the extracellular domain.  As a result, constitutively phosphorylated delEGFR 
enhances cellular proliferation and reduces apoptosis of human glioma cells (Nagane et al., 
1996).  Overexpression of mdm2 has been observed in more than 50 % of primary GBM, and 
is a characteristic of primary GBM that lacks a p53 mutation (Biernat et al., 1997).  
Interestingly, mutation in p53 or loss of heterozygosity (LOH) of chromosome 17p, which is 
a characteristic of secondary GBM, is almost never found in these primary GBM (von 
Deimling et al., 1993).  In addition to p53 mutation, which is present in more than 30 % of 
astrocytoma (Nigro et al., 1989; Sidransky et al., 1992), and LOH of chromosome 17p (von 
Deimling et al., 1993), the level of PDGFR-α is also elevated in secondary GBM (Castro et al., 
2003b; Dunn et al., 2000; Sidransky et al., 1992).  
 
In Asian countries such as Singapore, the incidence of astrocytic tumors represent only one 
third or less compared to that of the western countries (Das et al., 2002).  The genetic profiles 
of Asian glioma patients do not appear to follow the conventional molecular pathways that 
define either primary or secondary GBM.  In these studied cases, p53 was frequently detected 
to be overexpressed and did not present as mutually exclusive to the aberrant EGFR gene.  
Thus, molecular pathway leading to the development of GBM may be different in these 
patients.  The trend may also be influenced by the small number of patients being studied as a 
result of lower rate of occurrence. 
 
Two of the frequent abnormalities observed in GBM are the inactivation of the cell cycle 
regulators pRb and p16, and the amplification of cyclin D1 and cdk4 (Fueyo et al., 1996; Ueki 
et al., 1996) (Figure 1.1).  p16 specifically inhibits the binding of cdk4 to cyclin D1, thus 
preventing the phosphorylation of the pRb protein and the subsequent progression of the cell 
cycle.  Another common mutation is the LOH of chromosome 10 (von Deimling, 1997, 1993), 
the location of the tumor suppressor gene MMAC (mutated in multiple advanced 
cancers)/PTEN (phosphatase and tensin homologue deleted from chromosome 10), which is 
mutated in 30 % of malignant gliomas (Li et al., 1997; Steck et al., 1997) (Figure 1.1).  
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MMAC/PTEN is dependent on its lipid phosphatase activity to inhibit the 
phosphatidylinositol-3’-kinase (PI3K)/Akt pathway through the dephosphorylation of 
phosphatidylinositol-(3, 4, 5)-triphospate.  Restoration of its activity leads to suppression of 
the neoplastic phenotype in glioma cells (Cheney et al., 1998).   
 
1.2 Invasiveness of glioma cells 
The prognosis of brain tumors, in particular GBM, remains dismal despite advances in 
neurosurgical techniques, radiation and drug therapies (Kleihues et al., 2002; Walter et al., 
1995).  One of the major difficulties encountered include single cell invasion of surrounding 
histologically normal brain parenchyme, forming perineuronal and perivascular satellitosis 
(Holland 2000), and migration through the white matter tracts to regions distant from the 
original tumor mass.  These invasive cells can be found in normal brain tissues up to 4 cm 
beyond the visible tumor mass (Silbergeld and Chicoine, 1997), with 80 % of cases appearing 
in the opposite hemisphere (Figure 1.2).  Despite therapeutic interventions, the infiltrating 
tumor cells continue to proliferate, leading to recurrences (Burger et al., 1983; Gaspar et al., 
1992) (Figure 1.3) most frequently a few centimeters beyond the margins of resection (Damek 
and Hochberg, 1997). 
 
1.3 Current treatment regime for brain tumors 
Current therapy for glioma includes a combination of surgery, radiotherapy and chemotherapy, 
with majority of the tumor mass removable by surgical resection.  Surgical debulking of the 
tumor mass reduces intracranial pressure and extends the survival of patients, enabling them 
to receive further treatment.  Since majority of the tumor mass has been removed, the amount 
of therapeutic agents required to efficiently eradicate residual tumors is correspondingly 
decreased.  Residual tumor can be removed by exposure to radiation or through chemotherapy.  
Radiation therapy is usually confined to the residual tumor mass and 2 cm of surrounding 
normal tissues (Castro et al., 2003a).  If the tumor is well defined, measures less than 5 cm in 







radioactive pellets are implanted into the tumor mass, can be employed to kill the cancerous 
cells, yet sparing the normal brain tissues (Castro et al., 2003a).  Chemotherapy can be used 
on its own or in combination with surgery and radiotherapy.  However, the drawback is that 
most GBM are refractory to treatment with chemotherapeutic drugs, which damages the bone 
marrow of patients, and also, most chemotherapeutic drugs are not able to pass through the 
blood brain barrier (BBB). 
 
1.3.1Why do current therapies fail? 
Although current combination therapy increases the median survival time of patients, these 
malignant gliomas are eventually lethal.  Lack of defined tumor edge and inaccessibility of 
the tumor to resective surgery when the tumor is located at or near critical areas renders 
complete surgical resection virtually impossible.  In addition, gliomas are very heterogeneous.  
Within a tumor, most cells have varying subsets of genetic alterations as mentioned earlier 
(section 1.1), and some tumor cells may temporarily exit the cell cycle, thus making them 
resistant to therapy that targets proliferating cells (Lam and Breakefield, 2001; Ng and Lam, 
1998).  Moreover, cells within the GBM can have different sensitivity to chemotherapeutic 
drugs, giving rise to chemo-resistant clones (Castro et al., 2003a).  Conventional 
chemotherapy lacks tumor specificity and is only effective against actively proliferating cells 
(Drewinko et al., 1981).  Quiescent cells that survive chemotherapy will eventually re-enter 
the cell cycle resulting in relapse of the tumor.  Residual tumor cells cannot be efficiently 
controlled by radiation therapy due to the high occurrence of radioresistant glioma cells 
(Leibel et al., 1994).  In addition, the presence of efflux pumps such as P-glycoproteins, 
organic anion transporters, and multidrug resistance-associated proteins in the BBB acts as a 
barrier against efficient delivery for most drugs (Castro et al., 2003a).   
 
1.3.2 Gene therapy of gliomas 
One of the formidable tasks of intracranial gene delivery is the difficulty in achieving gene 
delivery to > 5 % of the tumor mass.  It would be advantageous if the transduced cells are 
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able to exert a therapeutic effect on neighboring nontransduced tumor cells (“bystander 
effect”).  One of the strategies for targeting glioma cells is the utilization of the pro-drug 
activation system.  These prodrugs are nontoxic, and can be administered systemically and 
readily cross the BBB.  This approach is called “suicide” gene therapy as the transduced cells 
convert the non-toxic prodrug into a toxic nucleoside analog, allowing it to be incorporated 
into the replicating DNA, thus killing the cells (Ilsey et al., 1995).  The Herpes simplex virus 
type-1 (HSV-1) thymidine kinase (tk)/ganciclovir (GCV) system is one of the well-
characterized prodrug activation systems.  On its own, GCV is non-toxic to both non-
transduced cells and non-proliferating cells.  However, in proliferating cells, phosphorylation 
of GCV by tk converts it into a toxic metabolite which inhibits DNA replication, thus leading 
to cell death (Matthews and Boehme, 1988).  Bystander effect is achieved when 
phosphorylated GCV passes through gap junctions between adjacent cells thus killing non-
transduced cells (Culver, 1992; Elshami et al., 1996; Freeman et al., 1993; Moolten and Wells, 
1990; Takamiya et al., 1993).  Other prodrug activating systems such as the Escherichia coli 
(E. coli) cytosinedeaminase/5-fluorocytosine (CD/5FC),  cytochrome P450 
2B1/cyclophosphamide (CPA) (Jounaidi et al., 2004), E. coli nitroreductase/CB1954 
(Bridgewater, 1995; 1997), and purine nucleoside prodrugs activated by viral thymidine 
phosphorylase (Hughes et al., 1998), have been demonstrated to have selectivity towards 
tumor cells (Aghi et al., 2000).   
 
In addition to inducing bystander effect, tumor cells can be eradicated by the introduction of 
apoptotic genes, thus increasing the chances of immune recognition of tumor antigens.  One 
of the commonly used tumor suppressor genes for the therapy of gliomas is p53, which plays 
a central role in the regulation of cell growth and apoptosis (Ravi et al., 1998).  p53 activates 
the transcription of a series of downstream apoptosis effector genes such as bcl-2, bax, p21 
and others.  Mutations in p53 are found in more than 50 % of human tumors.  Loss or 
mutation of p53 has been shown to promote genomic instability leading to deregulated 
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proliferation of tumor cells, apoptosis, and enhanced angiogenesis in tumor progression 
(Albertoni et al., 1998; Ravi et al., 1998).   
 
Other promising novel therapeutic genes for glioma therapy include genes that target 
angiogenenic factors.  A tumor nodule cannot derive nutrients through diffusion when its 
tumor size exceeds 1-2 mm3; additional growth requires generation of new blood vessels, or 
angiogenesis (Folkman, 1972).  GBM has many characteristics of an angiogenesis-dependent 
tumor.  The rate of tumor growth and neovascularization increases as gliomas progress from 
low-grade astrocytoma to high-grade GBM.  This correlates with the level of vascular 
endothelial growth factor (VEGF), where the level is highest in GBM (Plate and Risau, 1995).  
Strategies employing anti-angiogenic factors have been used for the treatment of gliomas, for 
instance, antisense VEGF (Saleh et al., 1996) , transforming growth factor β (TGF) (Paul and 
Kruse, 2001), dominant-negative vascular endothelial growth factor receptor 2 (Flk-1) 
(Millauer et al., 1994), and platelet factor 4 (Tanaka et al., 1997). 
 
1.4 Criteria of an ideal delivery vector system 
The success of gene therapy is highly dependent on the effectiveness of a vector to deliver the 
therapeutic genes in a specific and controllable manner.  An ideal vector would be one that 
incorporates a large transgene capacity that allows for the insertion of multiple regulatory or 
transgene cassettes.  In addition, the expression of heterologous genes in mammalian cells for 
therapeutic purposes using this vector should meet the following criteria: vector exhibits no 
background gene activity in the “off-state” but rapidly achieves high levels of expression 
upon induction; the system should not respond to endogenous activators or interfere with 
cellular regulatory pathways; has a minimum immunological profile; and expression levels of 
a given gene is regulatable in a stable and controlled manner.  Furthermore, the vector has to 
be targeted to specific cell types.  One of the greatest challenges to cancer gene therapy is the 
lack of tumor specificity, which frequently causes side effects as well as limits the therapeutic 
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dosage.  Targeting the vector to a specific cell type would restrict the amount of DNA 
required to achieve therapeutic responses while minimizing toxicity to non-target cells.   
 
1.5 Delivery Modalities 
The dismal prognosis for malignant glioma patients in spite of improvement in current 
therapeutic modalities has resulted in the exploration of new approaches to therapy, such as 
using viral or non-viral vehicles to deliver “weapons” for eradication of tumor cells.  Each of 
these approaches has its pros and cons relating to its specificity and efficacy (Table 1.1).     
Non-viral vectors plasmid DNA complexed with liposome or polymers.  Gene transfers to the 
brain using non-viral vectors have been demonstrated by Schwartz et al. (1996) and Brooks et 
al. (1998).  Although transgene expression can be detected in the striatum, the efficiency of 
gene transfer still lags behind that of the viral delivery system, which is more efficient at 
delivering genes to cells than any synthetic reagents devised so far.  Different viruses have 
different abilities to target certain cell types. Retroviruses and adenoviruses (Ad) are the two 
most commonly used viral vectors for gene delivery.  Retroviruses confer stable transgene 
expression due to its propensity to integrate into the host genome; however, the random 
insertion might activate the transcription of oncogene or proto-oncogene, which might be 
deleterious.  Retrovirus selectively infect only dividing cells, thus making this vector a 
promising choice for use in brain tumor therapy.  Retrovirus was also employed in a phase III 
clinical trials for glioma therapy (Rainov, 2000).  Adenoviruses have the advantage of 
infecting both dividing and non-dividing cells and are able to confer transient high level of 
gene expression.   However, Ad vector has been shown to induce host immune response, 
which is detrimental to the gene delivery process and the recipient.  Alternatively, adeno-
associated vector (AAV) is non-pathogenic and non-cytotoxic, and can integrate into specific 
sites on the genome of both dividing and non-dividing cells.  The limitation of AAV is its 
relative small size, which can incorporate only ~ 4 kb of transgene.  In comparison, 
advantages of the HSV-1 amplicon vector include its large insert capacity, low toxicity and 
low immunogenicity, however, the transgene expression is relatively instable, and production 
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 Table 1.1 Vectors and delivery systems for gene therapy 
 
Vectors Advantages Disadvantages 
Non-viral 
vectors 
• easy to produce 
 
• low gene transfer efficiency 
• transient gene expression 
Retrovirus • stable gene expression due 
to viral genome integration 
• only infect dividing cells 
 
• random insertion of viral genome, 
may possibly cause mutagenesis; 
• limited transgene capacity (~8kb) 
 
Adenovirus • transient high level of gene 
expression 
• infect dividing and 
nondividing cells 
 
• host immune response 





• integrate into genome of 





• difficult to obtain high titer of 
pure virus 
• helper virus required for 
propagation 









• large transgene capacity  
• transduce dividing and 
nondividing cells 
 
• as above 
• low toxicity and low 
immunogenicity 
 
• immunogenic, some toxicity 
• instability of transgene expression 
 
 
• vector production depends on 
transfection of cells 
• instability of transgene expression 
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of viruses is dependent on transfection, therefore, it is difficult to obtained high titer vector for 
clinical purposes.  Ad (Kumar-Singh and Farber, 1998; Lieber et al., 1997; Morsy et al., 1998; 
Thomas et al., 2000), lentiviruses  (LV) (Baekelandt et al., 2002), retrovirus (Culver et al., 
1992; Rainov, 2000; Rainov and Kramm, 2001), AAV, and HSV-1 have been used for 
delivering therapeutic genes to the brain with varying success. 
 
1.5.1 HSV-1 vectors 
1.5.1.1 Biology of HSV-1 vectors 
HSV-1 is an enveloped virus containing 150 kb of double-stranded (ds) DNA encoding 
approximately 80 genes (Roizman and Sears, 1996).  The virion consists of four components; 
(1) a lipid envelope that contains glycoproteins which are responsible for receptor-mediated 
entry (Burton et al., 2001; Rajcani and Vojvodova, 1998; Spear, 1993); (2) the tegument 
which contains some of the viral regulatory proteins such as the virion host shut-off (vhs) 
protein and the VP16 transcriptional activator; (3) the icosadeltahedral capsid and (4) the core 
containing dsDNA (Burton et al., 2001) (Figure 1.4).  The tegument proteins are responsible 
for the induction of viral gene expression e.g. VP16 (Batterson and Roizman, 1983), or for 
switching-off host protein synthesis following infection e.g., vhs (Kwong et al., 1988; Read 
and Frenkel, 1983).  The viral genome consists of long and short unique segments (UL and US) 
flanked by repeated sequences (Roizman and Sears, 1996) (Figure 1.4).  The approximately 
80 genes encoded by the viral genome can be divided into non-essential and essential genes, 
depending on whether their functions are required for viral replications in vitro.  The non-
essential genes can be deleted in the construction of gene delivery vectors, hence allowing the 
insertion of exogenous DNA and at the same time, reducing cytotoxicity resulting from 







HSV-1 is neurotrophic; in neurons, HSV vectors are transported from the nerve terminal into 
the cell body by retrograde transport.   The virion enters the cell by fusion of the envelope 
with the cell plasma membrane through the envelope glycoproteins, notably glycoprotein D 
(gD) and B (gB).  The viral DNA is subsequently deposited in the nucleus.  Immediately after 
viral entry into the cells, both the viral DNA and the VP16 tegument protein are transported to 
the nucleus (Roizman and Sears, 1996).  The lytic pathway of HSV-1 infection is 
characterized by sequential expression of immediate early (IE), early (E), and late (L) gene 
products.  VP16 induces the expression of the IE gene products, ICP0, ICP4, ICP22, ICP27 
and ICP47 (Wysocka and Herr, 2003).  Both ICP4 and ICP27 genes are required for the 
expression of the E and L genes thus, the replication of the virus in cell culture (DeLuca et al., 
1985; Sacks et al., 1985).  Expressions of these IE genes initiate the transcription of the E 
genes and the L genes (Roizman and Sears, 1996; Sacks et al., 1985).  However, during 
latency, the viral genome remains as an episomal element with no IE, E or L genes expressed.  
During this phase, only a set of nontranslated transcripts, namely the latency-associated 
transcripts (LAT) are produced in the infected cells (Burton et al., 2001).  The viruses remain 
dormant for a long period of time until changes in the host-virus interaction occur.  As a result, 
viral infection might be reactivated, and the transcription of the viral genome resumes in the 
lytic phase. 
 
1.5.1.2 HSV-1 vectors as gene delivery vehicles 
HSV-1 vectors are attractive vehicles for gene therapy due to their broad host range, large 
transgene capacity, and their ability to transduce both non-dividing and dividing cells. Vectors 
that are based on HSV-1 are attractive for gene delivery to the brain because HSV-1 can 
efficiently infect neuronal cells as well as other cell types, and can persist indefinitely in 
neurons (Lachmann, 2004). There are three types of HSV-1 vectors, the recombinant HSV-1, 




1.5.1.2.1 Recombinant HSV-1 
Recombinant HSV-1 vectors contain the full viral genome with mutations in one or more 
viral genes.  First generation HSV-1 vectors contained a mutation in the VP16 transactivator 
which prevents it from interacting with the IE genes (Ace et al., 1989).  However, when 
administered at high concentration, these first generation vectors were capable of undergoing 
full productive replication.  Further attempts at reducing the virulence were introduced, by 
constructing temperature-sensitive deletion mutants that were devoid of ICP4 and contained a 
mutation in ICP0 (Preston et al., 1997; 1998).  These viruses could be propagated in the 
presence of a complementing cell line that expressed ICP0 at 31 °C.  Samaniego et al. (1997; 
1998) further attempted to modify the vectors by deleting other IE gene products.  The mutant 
virus, d109, carries multiple deletions of the IE genes, ICP0, ICP4, ICP22, ICP27 and ICP47.  
Deletion of these IE genes allowed the incorporation of 30-50 kb of foreign DNA into the 
vector genome.  These replication defective virus mutants could thus be packaged in 
complementing cell lines expressing these gene products (ICP0, ICP4 and ICP27) in trans. 
 
1.5.1.2.2 Replication competent HSV-1 
The first replication competent oncolytic HSV-1 vector was constructed in 1991 (Mineta et al., 
1994; Varghese and Rabkin, 2002) for the treatment of glioma.  This replication competent 
HSV-1 was generated from a single mutation of its viral enzymes that are involved in 
nucleotide metabolism, such as TK (Martuza et al., 1991) and ribonucleotide reductase (RR) 
(also known as ICP6) (Mineta et al., 1994; Boviatsis et al., 1994b), which is required for the 
conversion of ribonucleotides to 2’-deoxyribonucleotides that provide the precursors for both 
DNA synthesis and repair (Kolberg et al., 2004).  These viral enzymes are upregulated in 
cancer cells in contrast to normal postmitotic cells.  One such mutant, hrR3, which contains a 
deleted RR gene, selectively replicates in cells that contain high levels of RR, such as tumor 
cells.  The hrR3 also harbors an insertion of the lacZ gene into the ICP6 locus which allows 
the tracking of the virus.  This mutation in the ICP6 locus reduces neurovirulence (Cameron 
et al., 1988; Yamada et al., 1991).  HrR3 has been used for the treatment of gliomas because it 
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also contains the TK gene.  The efficacy of hrR3 has been shown to be specific for 
gliosarcoma tumor cells, hence not affecting the postmitotic neural cells (Boviatsis et al., 
1994a; Mineta et al., 1994; Spear et al., 2000).   
 
Second generation replication competent HSV-1 vectors, such as G207 (MGH-1) were 
constructed with multiple deletions or mutations to enhance safety.  G207 contains deletion in 
both copies of the γ34.5 gene, a virulence factor that suppresses the total shut-off of protein 
synthesis (Chou and Roizman, 1992), as well as inactivation of ICP6.  These modifications 
prevent reversion and ensure that G207 only replicates in cells that contain RR.   No adverse 
effect could be detected when 107 plaque forming units (pfu) of G207 were injected directly 
into the ventricles of mice and non-human primates (Hunter et al., 1999; Sundaresan et al., 
2000; Varghese et al., 2001).  In fact, G207 has been found to be effective against a variety of 
solid tumors, including melanoma, breast, colon, gallbladder, gastric, head and neck, ovarian, 
pancreatic and prostate cancers (Varghese and Rabkin, 2002).  HSV1716, another replication 
competent HSV-1 with deletion in the γ34.5 gene, was also used for the treatment of glioma 
in a proof of principle study (Papanastassiou et al., 2002).  Direct injection of this virus into 
glioma has been shown to prolong the survival of patients in clinical trials (Harrow et al., 
2004).   
 
1.5.1.2.3 Replication defective HSV-1 amplicons 
The HSV-1 amplicons are plasmid-based vectors that consist of (1) sequences from bacteria 
such as the origin of replication and the β-lactamase gene, (2) sequences from HSV-1, 
including a packaging signal (pac) and an origin of DNA replication (oris), allowing them to 
be packaged as concatemers into virions in the presence of HSV helper functions (Spaete and 
Frenkel, 1982; Spaete and Frenkel, 1985), (3) multiple cloning sites for insertion of foreign 
DNA, and (4) a reporter gene, such as enhanced green fluorescent protein (eGFP) for titering 
of vector stocks (Figure 1.5).  These vectors have broad host range and yet retain the 
neurotrophic properties of HSV-1.  Since they are largely devoid of any viral sequences   
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except for pac and oris, theoretically, these vectors can accommodate transgenes of up to 150 
kb (Oehmig et al., 2004).  As DNA replication occurs by the rolling circle mechanism, the 
resulting virions contain multiple copies of the recombinant DNA including the transgene, up 
to the maximum limit for packaging (Oehmig et al., 2004).  The amplicon DNA is packaged 
into virions using helper virus-based or helper virus-free packaging systems (Oehmig et al., 
2004).  First generation amplicons were packaged in the presence of helper virus.  The 
resulting virions were contaminated with the helper virus particles, consequently, these 
viruses are cytotoxic due to the presence of immune responses elicited against the IE genes 
encoded on the helper virus.  A recent improvement is the introduction of the helper virus-free 
packaging system (Fraefel et al., 1996).  Amplicons can be packaged by cotransfection with 
either a set of 5 overlapping cosmids (cos6∆a, cos14, cos28, cos48∆a and cos56) 
(Cunningham and Davidson, 1983; Fraefel et al., 1996) or a bacterial artificial chromosome 
(BAC) (Saeki et al., 1998; Stavropoulos and Strathdee, 1998; Saeki et al,, 2001) that represent 
the HSV-1 genome with the pac deleted (Figure 1.6).  Cunningham and Davidson (1983) 
showed that when a set of overlapping cosmids that represent the entire HSV-1 genome was 
transfected into cells, the cosmids formed an infectious replication-competent virion through 
homologous recombination.  However, when pac was deleted, the reconstituted viral genome 
was not packaged, yet still conferred all the required helper functions in trans.  The 
generation of a packageable replication-competent HSV-1 would require six recombination 
events and is therefore, rare.  In 1996, Fraefel et al. developed the helper virus-free packaging 
system by co-transfecting the amplicon plasmid DNA together with 5 overlapping cosmids 
that constitute the entire HSV-1 genome but lack the pac signal.  The resulting viruses are 
free of contaminating helper virus.  In an attempt to simplify the packaging procedure, Saeki 
et al. (1998) cloned the HSV genome as an F-plasmid-based BAC.  However, replication-
competent helper viruses were detected at a frequency of 10-4 to 10-6, possibly resulting from 
recombination events between the BAC and the amplicon plasmid (Saeki et al., 1998).  By 
deleting ICP27 and adding a “stuffer” sequence from ICP0 to the BAC (fHSV∆pac∆27 0+), 
the resulting amplicon stocks were virtually free of contaminating replication-competent  
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helper viruses and achieved titers of up to 3-10 x 108 transduction unit (TU)/ml (Saeki et al., 
2001; Saeki et al., 2003).  In comparison to the recombinant HSV, helper virus-free amplicons 
essentially do not have any toxicity or antigenicity due to their lack of viral genes 
(Constantini et al., 2000).  In addition to accommodating transgenes of up to 150 kb, the 
amplicon can be retained for months in non-dividing cells (Wang et al., 1999; Song et al., 
1997; Zhang et al., 2000), and have high infectivity for cells of the CNS and relatively high 
titers (108 TU/ml) (Sena-Esteves et al., 2000). The large transgene capacity, low 
immunogenicity, and broad host range makes this vector an ideal gene delivery vehicle. 
 
1.6 Transcriptional regulation system 
One of the pitfalls of current cancer gene therapies is the lack of tumor specificity.  
Restricting transgene expression to tumor cells would minimize toxicity to normal tissues; 
therefore, it is important to regulate expression of therapeutic genes to specific cell types.  An 
added benefit would be the activation of the transgene expression during particular 
circumstances.  Two approaches have been widely adopted. 
 
1.6.1 Tetracycline-regulated system  
The tetracycline regulatable system is one of the most commonly used methods employed for 
regulating transgene expression (Gossen and Bujard, 1992).  Unlike other drug regulatory 
systems, the tetracycline-regulatable system is more versatile.  The vectors can be designed to 
be activated either in the presence or absence of tetracycline or its derivatives.  The 
tetracycline-repressible system is based on the tetracycline repressor (tetR), which is a 
prokaryotic dimeric DNA binding protein that binds to the tetracycline operator (tetO) of the 
tet-resistance operon (Toniatti et al., 2004).  In this system, the VP16 transactivator is fused to 
tetR, generating a chimeric tetracycline-repressed transactivator (tTA).  In the absence of 
tetracycline, tTA binds with high affinity and specificity to the tetracycline-regulated 
promoter.  To achieve inducible transient gene expression, the tetracycline-inducible system 
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(TiRS) could be adopted.  In the presence of tetracycline, the chimeric transactivator binds to 
tetO, thus stimulating transcription.   
 
1.6.2 Dimerizer-regulated system 
The dimerizer-regulated system is based on the interaction of two subunits with a small 
molecule that contains distinct binding sites.  A classical example of the dimerizer-regulated 
system utilizes the small molecule rapamycin which mediates binding of FK506 binding 
protein 12 (FKBP12) and the FKBP rapamycin-binding (FRB) domain of the FKBP 
rapamycin-associated protein (FRAP) (Pollock and Clackson, 2002).   Fusion of FKBP to 
zinc-finger homeodomain fusion (ZFHD1) generates the DNA binding region; while the 
activator domain is comprised of FRB with NF-κB p65 protein. In the presence of rapamycin, 
the ZFHD1/FKBP chimeric protein binds to the FRB/p65 protein, forming a complex that 
would activate transgene expression.   
 
1.6.3 Limitations of inducible systems 
The drawback with all these systems is the reliance on exogenous pharmacological inducers.  
The major concern with the tetracycline regulatable system is the possibility of developing 
resistance to the antibiotic.  Regulating the effective dosage level of an exogenous factor in 
vivo also poses a challenge. To circumvent the problem of relying on exogenous stimulation 
for regulating gene expression, it would be advantageous to regulate transgene expression that 
is dependent on endogenous cellular factors. 
 
1.7 Strategies to target dividing, recurrent tumor cells 
As uncontrolled proliferation is a common characteristic of malignant tumor cells.  Therefore, 
an attractive strategy for cancer gene therapy would be the use of vectors carrying therapeutic 
genes that can be activated upon cellular replication. This strategy may be of special clinical 
relevance for brain tumor therapy since GBM is highly diffused and invasive, and complete 
surgical resection of the tumor mass is practically impossible. Two different strategies have 
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been designed for the construction of such a cell cycle-regulatable transcription system 
(Jerome and Müller, 1998; Nettelbeck et al., 1999).   
 
1.7.1 Gal4/p56lck system  
In the first strategy, a melanoma-specific promoter drives an artificial heterodimeric 
transcription factor consisting of the Gal4 DNA-binding domain fused to the N-terminal 
domain of human p56lck, a CD4-associated tyrosine kinase (Jerome and Müller, 1998).  The 
transactivating subunit consists of the HSV VP16 fused to the interacting domains of human 
CD4 transcribed from a cell cycle-regulatable promoter.  As a result, only in proliferating 
melanoma cells will both subunits be expressed and form a complex through the CD4-p56lck 
interaction, thus activating transcription of the transgene (Jerome and Müller, 1998).  The 
extent of cell type-specificity and cell cycle-regulation of transgene expression was shown to 
be in the range of 10-fold and 5-fold, respectively.  Though the feasibility of this system is 
well established, it is nevertheless dependent on the specific protein dimerizations between 
fusion proteins of VP16-CD4 and Gal4/p56lck.  Binding of this heterodimeric transcription 
factor to Gal4 binding sites will then lead to transcriptional activation through the strong 
VP16 activation domain.   
 
1.7.2 Gal4/NF-YA system 
The second approach does not depend on the heterodimerization of chimeric transcription 
factors. Rather, transcriptional activation following DNA-binding takes place in a single step 
(Nettelbeck et al., 1999).  A chimeric transcription factor (Gal4/NF-YA), consisting of the 
transactivation domain of the A subunit of nuclear factor Y (NF-YA) and the DNA binding 
domain of Gal4, is expressed from a tissue-specific promoter.  This fusion protein (Gal4/NF-
YA) can subsequently bind to a second promoter, consisting of the regulatory region of the 
cyclin A promoter downstream of the multiple Gal4 binding sites, and transactivate the 
transgene expression.  The authors have shown the feasibility of a dual specific transcriptional 
regulation system that is discussed further in section 3.4.   
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The disadvantage of employing the above co-transfection of plasmid DNA for clinical 
application is due to its low efficiency and specificity.  It would not be feasible for the co-
transfections of two independent DNA plasmids-transduced cells to receive an optimum ratio 
of promoter and transactivator, thus resulting in sub-optimal activity and/or specificity. 
 
1.7.2.1 Current strategy 
The strategy described in our present study presents a more efficient alternative approach 
where a single-vector system combining both the transcriptional activator and the transgene 
reporter cassettes is assembled to confer cell cycle-dependent transgene expression.  This is 
particularly advantageous in brain tumor gene therapy since cellular proliferation is a rare 
event in the normal brain tissues.  In contrast, malignant brain tumor cells divide rapidly 
leading to the invasion of surrounding normal brain parenchyma.   
 
1.8 Aims of this study 
The aim of this study is to develop a better gene delivery system to target recurrent brain 
tumors occurring at or near the resected regions.  This can be accomplished by the 
development of a cell cycle-regulated and cell type-specific viral vector whereby the 
transgene encoded by this vector will be activated only in actively proliferating glioma cells.   
 
Specifically, the aims are: 
1) To generate and characterize a cell cycle-regulated HSV-1 amplicon viral vector; 
2) To evaluate the therapeutic efficacy mediated by this vector in vitro and in vivo; 
3) To develop strategies that target transgene expression specifically to glioma cells by 
(i) employing a tissue specific promoter; 
(ii) isolating glioma-specific peptides for targeting purpose; 
4) To better characterize the dual specificity vector in vivo by  
(i) examining the immunogenicity in an immunocompetent mouse model; 
(ii) determining the stability of the virions; 
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(iii) determining the transduction efficiency of the virions; and 



























2.1.1 Geniticin    
Source: Invitrogen Life Technologies, Grand Island, NY 
Stock concentration: 50 mg/ml. 
Dissolved in Phosphate buffered saline (PBS), filter sterilized, aliquoted, and stored at -20 °C. 
 
2.1.2 Puromycin 
Source: Invitrogen Life Technologies 
Stock concentration: 1 mg/ml 
Dissolved in PBS, filter sterilized, aliquoted and stored at – 20 °C. 
 
2.1.3 Dulbecco’s modified Eagle’s medium (DMEM) culture medium 
DMEM is supplemented with 10 % fetal bovine serum (FBS) (Hyclone Laboratories, Logan, 
UT), 100 U/ml penicillin (Invitrogen Life Technologies), 100 µg/ml streptomycin (Invitrogen 
Life Technologies), and 2 mM L-Glutamine (Sigma-Aldrich Corp., St. Louis, MO).   
 
2.1.4 Cells-freezing medium 
Cells-freezing medium was prepared by adding tissue culture grade dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich Corp.) to fetal bovine serum (FBS) to a final concentration of 10 %. 
 
2.1.5 Lovastatin 
Source: Merck, Singapore 
Stock concentration: 25 mg/ml 
Dissolve 25 mg of lovastatin into 500 µl of 95 % ethanol.  This is followed by addition of 400 
µl of 1N NaOH.  Adjust to pH 7.2 using 1N HCl.  Dilute the solution to 4 mg/mg (10 mM) 




Source: Sigma-Aldrich Corp.  
Stock concentration: 1M 
Dissolve in ddH20 to a final concentration of 1 M.  Store away from light at –20 °C. 
  
2.1.7 Dithio-DL-threitol (DTT) 
Source: Sigma-Aldrich Corp. 
Stock concentration: 1M 
Dissolve 3.08 g of DTT in 20 ml of 10 mM sodium acetate (pH 5.2).  Filter sterilize and 
aliquot.  Store at  -20 °C. 
 
2.1.8 RNase A (DNase Free) 
Source: Sigma-Aldrich Corp. 
Stock concentration: 20 mg/ml 
Dissolve in PBS.  Store as aliquots at -20 °C. 
 
2.1.9 Propidium iodide (PI) solution 
Source: Sigma-Aldrich Corp. 
Stock solution: 100 µg/ml 
Dissolve PI in PBS containing 0.1 % Triton X-100.  Store at -20 °C covered with tin foil.   
 
2.1.10 Sucrose solution 
Dissolve 25 g or 30 g in 100 ml of PBS to a concentration of 25 % and 30 % respectively.  
Filter sterilize and store at 4 °C. 
 
2.1.11 Solution I for DNA extraction 
Prepare by adding 50 mM Glucose, 10 mM EDTA, and 25 mM Tri-HCl, pH 8.0 to ddH20.  
Autoclave and store at 4 °C.   
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2.1.12 Lysis solution for DNA extraction 
Prepare by adding 200 mM NaOH, and 1% SDS to ddH20.  Freshly prepared before use. 
 
2.1.13 Neutralizing buffer for DNA extraction 
Neutralizing buffer contains 5 M potassium acetate solution, pH 5.5.  Prepare by adding 11.5 
ml of glacial acetic acid and 28.5 ml of ddH20 to 60 ml of 5 M potassium acetate.  The 
resulting solution is 3 M with respect to potassium and 5 M with respect to acetate. 
 
2.1.14 Lysis buffer for isolating Hirt’s DNA 
Lysis buffer is freshly prepared by dissolving 0.6 % SDS, 10 mM EDTA pH8.0, 10 mM Tris-
Cl, pH 7.5, in ddH20. 
 
2.1.15 Tris-EDTA (TE) 
Dilute 10 mM Tris (pH 8.0) and 1 mM EDTA (pH 8.0) in ddH20.  Sterilize by autoclaving. 
 
2.1.16 Cesium chloride/TE/ ethidium bromide (EtBr) solution 
1.16 g/ml of cesium chloride was dissolved in this 8 ml of TE, followed by addition of 1 ml of 
EtBr solution 
 
2.1.17 TE-saturated Butanol 
 
TE was added to butanol with intermittent mixing until two phases are observed.  Butanol 
should be in the upper phase. 
 
2.1.18 Diethylpyrocarbonate (DEPC) water 
Add 0.2 ml of DEPC to 100 ml of ddH20.  Shake vigorously and incubate overnight in a fume 
hood.  Inactivate remaining DEPC by autoclaving. 
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2.1.19 Preparation of temozolomide (TMZ) 
Stock concentration: 100 mM 




Source: Sigma-Aldrich Corp. 
Stock concentration: 100 mg/ml 
Dissolve in sterile ddH20.  Filter sterilize and store at -20 °C in aliquots.   
 
2.1.21 Kanamycin 
Source: Sigma-Aldrich Corp. 
Stock concentration: 30 mg/ml 
Dissolve in sterile ddH20.  Filter sterilize and store at -20 °C in aliquots 
 
2.1.22 Chloramphenicol 
Source: Sigma-Aldrich Corp. 
Stock concentration: 34mg/ml 
Dissolve in ethanol. Filter sterilize and store at -20 °C in aliquots 
 
2.1.23 Luria broth (LB) 
Mix 10 g Bacto-Tryptone, 5 g Bacto-Yeast extract and 10 g sodium chloride in 900 ml of 
ddH20.  Adjust pH to 7.0 with sodium hydroxide.  Sterilize by autoclaving. 
 
2.1.24 SOB (1L) 
Mix 20 g Bacto-Tryptone, 5 g Bacto-Yeast extract, 0.5 g NaCl and 2.5 ml of 1M KCl in 900 
ml of ddH20.  Adjust pH to 7.0 with NaOH.  Sterilize by autoclaving.  Add 10 ml of 1M 
Mg2Cl before use.   
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2.1.25 Escherichia coli strain ER2537 
Escherichia coli strain ER2537 was purchased from New England Biolabs (Beverly, MA).  
The genotype of the strain is [F' lacIq (lacZ) M15 proA+B+/fhuA2 supE thi (lac-proAB) 
(hsdMS-mcrB) 5 (rk- mk- McrBC-)] 
 
2.1.26 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal) 
Source: Bio-Rad Laboratories 
Stock concentration: 40 mg/ml 
Dissolve X-Gal in dimethyl sulfoxide to a final concentration of 40 mg/ml. 
 
2.1.27 Isopropyl β-D-thiogalactoside (IPTG) 
Source: Invitrogen Life Technologies  
Stock concentration: 50 mg/ml 
Dissolve IPTG in ddH20 to a final concentration of 50 mg/ml. 
 
2.1.28 Tris-buffered saline (TBS) 




Source: Mimotopes, Victoria, Australia 
The poly-L-lysine-SIPVKFNKP-MG11 ((K16)-MG11) and poly-L-lysine-SIPVKFNKP-H42 
((K16)-H42) peptides were synthesized and purified.  The peptides were dissolved in 0.15 M 
NaCl at 1 mg/ml and stored in small aliquots at -20 ºC.  The purity of both peptides was > 
90%. 
 
2.1.30 Protein lysis buffer 
Protein lysis buffer contains 50 mM Tri-Cl (pH7.6), 0.1 % Triton X-100, and 150 mM NaCl 
in ddH2O.  Add 1x protease inhibitor before use. 
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2.1.31 Luciferase assay buffer 
Mix 25 mM Glycylglycine (pH7.8), 15 mM MgSO4, 4 mM EGTA and 15 mM potassium 
phosphate (pH 7.8) in ddH2O.  Store at 4 °C. 
  
2.1.32 Luciferin buffer  
Mix 25 mM Glycylglycine (pH7.8), 15 mM MgSO4, 4 mM EGTA in ddH2O.  Store at 4 °C. 
 
2.1.33 Luciferin  
Source: Roche Diagnostics GmbH, Mannheim, Germany 
Stock concentration: 10 mM 
Dissolve 10 mg of luciferin powder in 3.57 ml of 25 mM Glycylglycine (pH 7.8).  Aliquot 
and store at -20 °C in the dark. 
 
2.1.34 Preparation of Ponseau S 
Source:  Sigma-Aldrich Corp. 
Stock concentration: 1% 
Dissolve 1 % of Ponseau S (w/v) in 5 % acetic acid (v/v).   
 
2.1.35 Resolving gel (10%) 
10 % (10 ml) gels were cast by mixing 3.3 ml of 30 % acrylamide mix (30 % acrylamide/0.8 
% bisacrylamide) with 2.5 ml of 1.5 M Tris-Cl pH 8.8, 4 ml ddH20 , 50 µl of 20 % SDS, 100 
µl 10 % ammonium persulfate (APS) (Amersham Biosciences AB, Uppsala, Sweden) with 10 
µl of N, N, N’, N’-tetramethylethylenediamine (TEMED).   
 
2.1.36 Stacking gel (5%) 
0.83 ml of 30 % acrylamide mix with 0.63 ml of  1 M Tris-Cl pH6.8, 3.4 ml of ddH20, 25 µl 
of 20 % SDS and 50 µl of 10 % APS with 6 µl of TEMED. 
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2.1.37 Protein loading buffer 
Protein loading buffer is prepared by mixing 62.5 mM Tris-Cl pH 6.8, 10 % glycerol, 2 % 
SDS, 100 mM DTT, 0.0005 % bromophenol blue in ddH2O. 
 
2.1.38 SDS electrophoresis buffer 
Mix 25 mM Tris-base, 192 mM glycine (electrophoresis grade) and 0.1% SDS in ddH2O. 
 
2.1.39 Protein transfer buffer 
Mix 25 mM Tris, 190 mM glycine and 20 % methanol in ddH2O 
 
2.1.40 Western hybridization blocking buffer 
Blocking buffer contains 5% nonfat milk, 10 mM Tris pH7.5, 100 mM NaCl, 0.1% Tween-20 
 
2.1.41 Polyacrylamide gel electrophoresis (PAGE) 
6 % PAGE gel was prepared by adding 12 ml of 30 % acrylamide (29 % acrylamide/1 % 
bisacrylamide), 6 ml of 10 X TBE, 360 µl of 10 % APS, 36 µl of TEMED to 42 ml of ddH20.  
The gel was allowed to polymerize at r.t. 
 
2.1.42 Binding buffer for isolation of nuclear extract for Electromobility shift assay 
(EMSA) (Wu et al., 2001) 
Binding buffer for EMSA was freshly prepared by adding 2.5 % glycerol, 5 mM MgCl2, 0.2 
mM EDTA, 0.05 % NP-40, 250 ng of poly(dA-dT) (Amersham Biosciences AB) and 100 
fmol of biotin-labeled probe to a final volume of 20 µl. 
 
2.1.43 Buffer A for isolation of nuclear extract (Wu et al., 2001) 
Buffer A contains 10 mM Hepes pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM 
EGTA in ddH20. Add 1 mM DTT and 1 mM phenylmethelsolfonyl fluoride (PMSF) before 
use.  Sterilize by filtration and store at 4 °C. 
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2.1.44 Buffer C for isolation of nuclear extract (Wu et al., 2001) 
Buffer C contains 20 mM Hepes pH 7.9, 400 mM NaCl, 1 mM EDTA and 1 mM EGTA in 
ddH20.  Add 1 mM DTT and 1 mM PMSF before use.  Sterilize by filtration and store at 4 °C. 
 
2.1.45 Tris-Acetate EDTA buffer (TAE) 
Mix 40 mM Tris-Acetate, Glacial acetic acid and 1 mM EDTA in ddH2O 
 
2.1.46 Fixative 
Concentration:  4 % of Paraformaldehye (Sigma-Aldrich) 
Paraformaldehyde is dissolved in PBS in a heated water bath set at 65°C, with constant 
stirring.  
 
2.1.47 Blocking buffer for Immunohistochemistry 




Monoclonal mouse anti-human FADD (Zymed Laboratories) Cat no: 35-8000  
Polyclonal rabbit anti-human FADD (Calbiochem-Novabiochem Corp) Cat no: 341282 
 
For western hybridization:  
Monoclonal mouse anti-human FasL, clone G247-4 (BD Pharmingen) Cat no: 37720 
Monoclonal mouse anti-human Fas, clone 13 (BD Pharmingen) Cat no: F22120 
Monoclonal mouse anti-human FADD (BD Pharmingen) Cat no: F36620 
Monoclonal mouse anti-cyclin A antibody (BF683) (Santa Cruz Biotechnology) Cat no: 
sc239 
Monoclonal mouse anti-β tubulin antibody clone 5H1 (BD Pharmingen) 
Rabbit anti-human caspase 8 (BD Pharmingen) Cat no: 559932 
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Goat anti-rabbit HRP conjugated (Dako Cytomation) Cat no: P0448 
Goat anti-mouse HRP conjugated (Dako Cytomation) Cat no: P0447 
 
For immunohistochemitry and immunofluorescence: 
Goat Anti-human GFAP (C-19) (Santa Cruz Biotechnology) Cat no: sc-6170 
Monoclonal rat anti-mouse CD8, clone 53-6.7 (BD Pharmingen), Cat no: 550281 
Monoclonal rat anti-mouse CD4, clone RM4-5 (BD Pharmingen), Cat no: 550280 
Monoclonal rat anti-mouse CD11b, clone M1/70 (BD Pharmingen), Cat no: 550282 
Polyclonal rabbit anti-luciferase (Sigma-Aldrich Corp.) Cat no: L0159 
Alexa-Fluor 647 goat anti-mouse IgG (Molecular Probes) 
Alexa-Fluor 350 goat anti-rabbit IgG (Molecular Probes) 
Biotin-conjugated goat anti-rat IgG, (BD Pharmingen), Cat no: 559286 
Streptavidin-HRP prediluted for IHC (SAv-HRP) (BD Pharmingen), Cat no: 550946 
 
For FACS analysis: 
Anti-BrdU-FITC conjugated (BD Pharmingen), Cat no 347583 
 
2.1.49 Animals 
All Balb-C nu/nu (nude) and severe combined immunodeficient (SCID-CB-17) mice were 
purchased from Animal Resource Center, Western Australia.  Immunocompetent Balb-C mice 
were purchased from Laboratory Animal Center, National University of Singapore, Singapore.   
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2.2 General Methods
2.2.1 Tissue culture 
2.2.1.1 Cell lines  
A549 (lung adenocarcinoma), HeLa (human cervical carcinoma), HepG2 (human 
hepatocellular carcinoma), HK1 (nasopharyngeal carcinoma), NIH3T3 (mouse fibroblast), 
KZ2 (melanoma), KOSC-3 (head and neck carcinoma), M059K (human glioma), PC-3 
(human prostate adenocarcinoma), Saos-2 (osteosarcoma), T98G (human glioma), U87MG 
(human glioma), U373MG (anaplastic astrocytoma), and WT18 (lymphoma) were obtained 
from American Type Culture Collection (Rockville, MD).  CNE2 cells are derived from 
undifferentiated human nasopharyngeal carcinoma (gift from Prof. HM Wang, Cancer 
Institute, Guangzhou, People’s Republic of China).  Gli36, SF767 and U251MG human 
gliomas were kindly provided by Dr. AT Campagnoni (UCLA School of Medicine, Los 
Angeles, CA) and Dr. DF Deen (Brain Tumor Research Center, UCSF, School of Medicine, 
CA), respectively.  dGli36 cells which overexpresses a truncated mutant EGFR commonly 
found in human gliomas was a gift from Dr. M Sena-Esteves (Children’s Hospital of 
Philadelphia, Philadelphia, PA).  The African green monkey kidney 2-2 cells, which are 
VERO-derived cells, constitutively express the HSV-1 ICP27 proteins was kindly provided 
by Dr. R Sandri-Goldin (UCLA) (Smith et al., 1992). 
 
2.2.1.2 Culture conditions of cell lines 
All cell lines, except PC-3, were grown in DMEM culture medium. dGli36 cells were grown 
in DMEM culture medium in the presence of puromycin (1 µg/ml).  PC-3 was cultured in 
F12K culture medium (Invitrogen Life Technologies, Grand Island, NY).  Vero 2-2 cells were 
cultivated in the presence of 500 µg/ml of Geniticin.  All cells were maintained at 37 °C in a 
humidified incubator with 5 % CO2. 
 
Normal human astrocytes purchased from Cambrex Bio Science Walkersville, Inc., 
(Walkersville, MD) were cultured in Astrocyte Basal Medium supplemented with 
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recombinant human EGF, insulin, ascorbic acid, GA-100, L-glutamine and FBS as 
recommended by the supplier (Cambrex Bio Science Walkersville, Inc., Walkersville, MD). 
 
Primary glioma biopsy was kindly provided by Dr. Thomas, J. (Department of Neurosurgery, 
Singapore General Hospital, Singapore) with patient’s consent.  Tissues were immediately 
kept in DMEM with 10 % FBS.  To obtain single cell suspension, the tissues were digested 
for 5 min with 0.25 % trypsin, followed by washing twice with DMEM culture medium.  The 
cells were plated onto a single well of a twenty four-well plate (Nunc, Roskilde, Denmark), 
and incubated at 37 °C in a humidified incubator with 5 % CO2.   
 
2.2.1.3 Subculturing of cells 
Subculturing of cells was carried out using 0.25 % trypsin-EDTA.  Briefly, when the cells 
reach a confluency of ~ 80 %, the medium was discarded and the cell monolayer was washed 
gently with PBS.  After removing the excess PBS, appropriate amount of 0.25 % trypsin-
EDTA was added for approximately 3 to 5 min until most of the cells became resuspended.  
This was followed by resuspending the cells in complete medium and centrifugation for 5 min 
at 1000 rpm (Beckman Coulter, Palo Alto, CA).  The pelleted cells were then resuspended in 
appropriate medium and divided into individual flasks. 
 
2.2.1.4 Cryopreservation of cells 
For cryopreservation, cells were trypsinized and pelleted as above.  Cell pellet was 
resuspended in cell freezing medium (section 2.1.4) and stored in liquid nitrogen using 
cryovials (Nunc). 
 
2.2.1.5 DNA transfections  
NIH3T3, U251MG, SF767, HepG2 and PC-3 were transfected in six-well plates using 
LipofectAmine (Invitrogen Life Technologies) according to the manufacturer’s instructions.  
Briefly, 3 µg of plasmids were mixed with 8 µl of LipofectAmine in OptiMEM (Invitrogen 
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Life Technologies) for 45 min at r.t.  DNA/LipofectAmine complexes were added to 3 x 105 
cells per well in a six-well plate (Nunc) and incubated for an additional 6 h at 37 °C.  Cells 
were subsequently rinsed with PBS twice and replenished with fresh culture medium.  
 
Other cell lines namely Gli36, dGli36, and HeLa (3 x 105 cells /6-well plate) were transfected 
using a novel cationic lipid NCC4.  When compared with LipofectAmine, NCC4 has been 
reported to give more than 2-fold increase in luciferase gene activity in certain cell lines (Gao 
and Hui, 2001).  Briefly, 3 µg of DNA was mixed with 20 µl of liposomes in 1 ml of sodium 
lactated Ringer’s buffer (B. Braun Melsungen AG, Melsungen, Germany) and the complexes 
were allowed to form for 15 min at r.t.  The DNA/liposome complexes were added to each 
well and incubated for another 15 min at r.t. After adding 1 ml of sodium lactated Ringer’s 
buffer, the cultures were incubated for additional 2 h incubation at 37 °C.  Cells were 
subsequently rinsed with PBS and replenished with fresh culture medium.  All transfection 
reactions were performed in triplicates.  
 
2.2.1.6 Synchronization of cells and cell cycle analysis  
For synchronization at G1, cells were washed twice with PBS.  Depending on the cell lines, 
fresh medium was supplemented with 0.1 %-0.5 % FBS and 40-50 µM of lovastatin was 
added. After 48 h, cells were harvested by trypsinization, and resuspended in 500 µl of cold 
70 % ethanol. After an overnight fixation at 4 °C, cells were washed with PBS thrice, before 
resuspending in 100 µl of PBS containing RNase A (2 mg/ml) and PI (100 µg/ml).  The 
samples were kept on ice for an hour before FACS analysis was performed using Cell Quest 
and Modfit software (BD Biosciences, San Jose, CA).   
 
G1-arrested cells were stimulated into the cell cycle by removing medium containing 
lovastatin, followed by two washes with PBS.  Cells were then replenished with DMEM 
containing 10 % FBS and 5 mM mevalonate for additional 48 h. 
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2.2.2 Packaging of HSV-1 amplicon vector using helper virus-free system 
2.2.2.1 BAC fHSV∆pac∆27 0+  packaging 
Packaging of HSV-1 amplicons into HSV-1 virions was performed as described previously.  
Briefly, 3 x 106  Vero 2-2 cells were cotransfected with 1.8 µg of amplicon DNA, 0.3 µg of 
pEBHICP27 helper plasmid, and 3 µg of BAC fHSV∆pac∆27 0+ in OptiMEM (Saeki et al., 
2003), using the LipofectAmine procedure.  After 6 h of transfection, cells were replenished 
with fresh medium and incubated for an additional 60 h.   
 
2.2.2.2 Cosmids C6∆a48∆a packaging 
For packaging of HSV-1 amplicons using cosmids (Fraefel et al., 1996), five overlapping 
cosmids (cos 6∆a, cos 14, cos 28, cos 48∆a and cos 56) were digested with PacI enzyme and 
purified.  For transfections, 3 x 106 Vero 2-2 cells were plated the previous day to achieve a 
confluency of 80-90 % on the day of transfection.  The transfection mixture contains 6 µg of 
PacI digested DNA from cosmids set C6∆a48∆a (Cunningham and Davidson, 1993) and 2 µg 
of amplicon DNA.  After 6 h of transfection, the cells were replenished with fresh complete 
medium and incubated for an additional 60 h. 
 
2.2.2.3 Harvesting of virions 
Sixty hours post-transfection, the cells were scraped into the medium using cell lifter 
(Corning Enterprises, Corning, NY); the suspension was frozen and thawed three times in 
liquid nitrogen and sonicated for 17 sec at 3.5 setting (550 Sonic Dismembrator).  The cellular 
debris was removed by centrifugation for 10 min at 1000 rpm (Beckman Coulter).  After 
centrifugation, the supernatant was transferred to a clean 50 ml centrifuge tube and stored at -
80 °C.   
 
2.2.2.4 Sucrose gradient ultracentrifugation 
The crude viral lysate (CVL) harvested were filtered through 0.45 µm sterile filter (Millipore, 
Billerica, MA).  The filtered CVL was added to pre-cleaned ultraclear tubes (30 ml; Beckman 
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Coulter) followed by addition of 25 % sucrose/PBS solution.  Five ml of 25 % sucrose/PBS 
was carefully pipetted onto the bottom of the centrifuge tubes, and cold complete medium 
was added to a final volume of 30 ml.  This was followed by ultracentrifugation at 25 000 
rpm at 4 °C for 4 h with a Beckman SW28 swingout rotor.  After completion of centrifugation, 
the supernatant was carefully decanted, and the pellet resuspended in 100 µl of Hank’s 
Balanced Salt Solution (HBSS) overnight at 4 °C.  The next day, the purified virus was 
transferred to a clean microcentrifuge tube, aliquoted and stored at -80 °C. 
 
2.2.2.5 Determination of viral titer 
To determine viral titers (TU/ml), 1 x 105 Vero 2-2 cells were plated per well in twenty four-
well plate (Nunc) one day before experiments.  On the day of experiment, 1 µl of viral stocks 
was diluted 1000- and 5000-fold in culture medium and added to duplicate wells.  The 
volume of infection was maintained at 300 µl.  The cells were incubated for 18 h in 37 °C.  At 
the end of 18 h, green fluorescent cells were counted using a fluorescence microscope (Nikon 
Instech Co., Kanagawa, Japan) equipped with an ocular lens fitted with a 10 x 10 counting 
grid and counted under 100x (10 x objective lens and 10x ocular lens) magnification.  About 
three to four random fields selected from each well were included for counting.  The titer of 
the virus was calculated using the formula, TU/ml = number of green cells multiplied by the 
amplification factor and the dilution factor; where the amplification factor under a 100 x 
magnification is 190.   
 
2.2.2.6 Amplicon vector transduction 
For vector transduction, 3 x 105 dGli36 cells per 60-mm-well in triplicate were incubated for 
6 h at 37 °C with various amplicon viral vector stocks so as to achieve a constant multiplicity 
of infection (MOI). At the end of 6 h, cells were washed twice and fresh medium containing 
10 % FBS was added to proliferating cells.  Synchronization of cells and subsequent 
luciferase assays were performed as described above.   
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2.2.3 Nucleic acid isolation 
2.2.3.1 Isolation of plasmid DNA-mini alkaline lysis method 
The plasmid DNA isolation from transformants was carried out using QIAprep Spin Miniprep 
Kit (Qiagen GmbH, Hilden, Germany).  The plasmid DNA was extracted by alkaline lysis 
method following manufacturer’s instruction.  Briefly, bacterial cultures were incubated in 4 
ml of LB containing the appropriate drug selection overnight at 37 °C with 225 rpm shaking.  
The next day, the bacterial cells were pelleted by centrifugation at 4000 rpm for 10 min.  The 
pellet was resuspended in 250 µl of buffer P1 (25 mM Tri-HCl, 10 mM EDTA, 250 µg/ml 
RNase) follow by adding 250 µl of lysis buffer P2 (200 mM NaOH, 1 % SDS) for 5 min, r.t.  
This was followed by addition of 350 µl of neutralizing buffer N3.  After centrifugation at 13 
000 xg for 10 min using a tabletop centrifuge, the plasmid DNA solution was transferred to a 
new column and subjected to an additional round of centrifugation at 13 000 xg for 1 min.  
The column was washed once by adding 700 µl of buffer PE.  Residual buffer PE was 
removed by further centrifugation at 13 000 xg for 1 min.  Plasmid DNA was then eluted by 
the addition of 30 µl of buffer EB (10 mM Tri-HCL, pH 8.5).   
 
2.2.3.2 Isolation of plasmid DNA, BAC and cosmid DNA-by alkaline lysis method 
Large scale plasmid extractions were carried out using QIAGEN maxi plasmid kit (Qiagen 
GmbH).  The plasmid DNA was extracted by alkaline lysis following the manufacturer’s 
instructions.  Briefly, a single colony was picked and inoculated into 5 ml LB medium and 
incubated at 37 °C for 8 h.  After 8 h, the log-phased bacterial culture was transferred into 400 
ml of LB medium containing appropriate antibiotics and further incubated for 16-18 h at 37 
°C with shaking.  Cosmids were inoculated into SOB medium.  The bacterial cells were 
pelleted by centrifugation at 4000 rpm for 10 min (Kendro Laboratory Products, Asheville, 
NC).  The pellet was then resuspended by adding 10 ml of Buffer P1 (25 mM Tri-HCl, 10 
mM EDTA, 250 µg/ml RNase). This was followed by adding 10 ml of lysis buffer P2 (200 
mM NaOH, 1 % SDS) and incubating at room temperature for 5 min with gentle mixing. Ten 
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ml of cold neutralization buffer P3 (3 M KOAc, pH 5.5) was added and the mixture was 
incubated on ice for 20 min.  The chromosomal DNA and cellular proteins were then removed 
by centrifugation at 10 000 rpm for 30 min at 4 °C.  The supernatants were then filtered 
through a sterile cotton mesh before being loaded into a buffer QBT (750 mM NaCl; 50 mM 
MOPS (free acid) pH 7.0; 15 % (v/v) isopropanol and 0.15 % Triton-X100) equilibrated 
QIAGEN-tip 500 and allowed to flow through the resin by gravity.  The QIAGEN-tip was 
washed twice by adding 30 ml of buffer QC (1 mM NaCl; 50 mM MOPS pH 7.0; 15 % 
isopropanol).  Plasmid DNA was eluted by adding 15 ml of buffer QF (1.25 mM NaCl; 50 
mM Tris-HCl pH8.5 and 15 % isopropanol) to the QIAGEN-tip.  The DNA was then 
precipitated by adding 10.5 ml of r.t. isopropanol and centrifuged at 10 000 rpm for 30 min at 
4 °C.  This was followed by washing the pellet in 5 ml of room temperature 70 % ethanol and 
centrifugation at 10000 rpm for 10 min at 4 °C.  The DNA was then air dried and resuspended 
in TE buffer. 
 
2.2.3.3 Isolation of total RNA from cultured cell lines 
To isolate RNA from tumor cell lines, the cell monolayer was rinsed with PBS twice and 
After scraping into 1 ml of PBS, the cells were pelleted by centrifugation at 2000 rpm for 5 
min at 4 °C.  The pellet was then resuspended thoroughly using 1 ml of Trizol solution 
(Invitrogen Life Technologies) and incubated at r.t for 5 min.  This was followed by addition 
of 200 µl of chloroform, and the phases were mixed by vigorous shaking and allowed to 
incubate at room temperature for 5 min before centrifugation.  After centrifugation at 12 000 
xg for 15 min at 4 °C, the clear upper phase was transferred to a clean microcentrifuge tube 
and 500 µl of isopropanol was added.  The mixture was incubated at room temperature for 10 
min before being centrifuged at 12 000 xg for 10 min at 4 °C.  The pellet was washed with 1 
ml of 75% ethanol and then centrifuged at 7500 xg for 5 min at 4°C.  The pellet was dried at 
60 °C using a heat block before resuspending in an appropriate amount of 0.1 % DEPC-
treated water at 65°C for 10 min.  The RNA was stored at -80°C until use. 
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2.2.3.4 Isolation of total RNA from tumor tissues 
Freshly extracted tumor nodules from mice were immediately frozen in liquid nitrogen until 
used.  RNA was extracted according to the method described in section 2.2.3.3.   
 
2.2.3.5 Quantification of nucleic acid concentration 
The DNA or RNA concentration was determined by using an Ultrospec 3000 UV/visible 
spectrophotometer (Amersham Biosciences AB, Uppsala, Sweden).  The samples were 
diluted 100-fold and the readings were taken at wavelength of 260 nm and 280 nm. 
 
2.2.3.6 Extraction of viral DNA from brain tissues 
Viral DNA was recovered from brain tissues using Hirt’s method (Hirt, 1967) with slight 
modifications.  Briefly, the tissues were grind into powder in liquid nitrogen using mortar and 
pestle.  Five hundred microliter of lysis buffer (section 2.1.14) was incubated with the tissues 
for 20 min at RT.  This is followed by the addition of 125 µl of 5M NaCl and incubation at 4 
°C overnight.  The next day, the extract was subjected to centrifugation at 13 000 xg at 4 °C 
for 30 min.  The supernatant was recovered and extracted with phenol, phenol-chloroform and 
chloroform.  DNA was precipitated with isopropanol, rinsed with 70 % ethanol and dissolved 
in 35 µl of TE buffer. 
 
2.2.4 Protein isolation and analysis 
2.2.4.1 Total cell lysate 
Cells were harvested by rinsing the monolayer with PBS and scrapping the cells to 1 ml of 
PBS.  The cells were pelleted by centrifugation at 2000 rpm for 10 min.  The pellet was either 
subjected to three cycles of freezing and thawing, or lysed in protein lysis buffer or 10 min on 
ice.  The cell debris was removed by centrifugation at 13 000 xg for 10 min at 4 °C.  The 
supernatant was transferred to a clean tube, aliquoted and stored at -80 °C until used.   
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2.2.4.2 Determination of protein concentration 
Protein concentration was determined spectrophotometrically using Bradford method with 
protein binding dye (Bio-Rad Laboratories).  For measurements, 5 µl of protein sample were 
added to 795 µl of PBS and 200 µl of the dye.  Readings were recorded at wavelength of 
595nm.   
 
2.2.4.3 Assay for luciferase activity 
Cells were harvested from 6-well plates at the respective time point following transfection, 
washed,  resuspended in 120 µl of Tris-HCl (pH 7.8), and freeze-thawed three times.  Cell 
debris was discarded following centrifugation at 14 000 xg at 4 °C for 10 min.  One hundred 
µl of the supernatant collected was used for assaying luciferase activity using the Auto-Lumat 
LB952 luminometer (EG&G Berthold, Bad Wildbad, Germany).  Five µl of the supernatant 
collected was used for the determination of protein concentration using the Bio-Rad protein 
assay dye reagent (Bio-Rad Laboratories, Hercules, CA) with the Ultrospec 3000 UV/visible 
spectrophotometer (Amersham Biosciences AB). 
 
2.2.4.4 Assay for FasL protein expression  
Cells were harvested from 24-well plates at the respective time point following infection.  
Supernatant was concentrated with Centricon (Millipore) with 10 kDa cut-off.  FasL protein 
expression was determined using ELISA (Oncogene Research Products, San Diego, CA) 
according to manufacturer’s instructions.     
 
2.2.4.5 Assay for FADD protein expression 
Cells were harvested from 24-well plates at the respective time point following infection.  The 
cell monolayer was rinsed twice with PBS followed by centrifugation at 2000 rpm for 5 min.  
The pellet was lysed in lysis buffer containing 50 mM Tris-Cl (pH 8.0), 0.1 % Triton X-100 
and 0.1 mM NaCl for 10 min at 4 ºC.  Cell debris was removed by centrifugation at 14 000 xg 
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for 10 min at 4 ºC.  Supernatant was collected and 1 µl was used for the determination of 
protein concentration.  For the detection of FADD protein expression, the sandwich ELISA 
method was adopted.  0.25 µg/ml of mouse anti-FADD monoclonal antibody were coated on 
a flat-bottom 96-well plate (Nunc) and incubated at 4 ºC overnight.  Excess antibody was 
removed by rinsing thrice in washing buffer containing PBS with 0.1% Tween 20 (Invitrogen 
Life Technologies).  All subsequent washing steps were carried out at r.t.  The coated wells 
were incubated in blocking buffer [0.1 % Tween-20 and 1 % BSA (Sigma-Aldrich Corp.) in 
PBS] for 1 h at r.t.  0.1 µg/ml of cell lysate were added to each well and incubated at r.t. for 1 
h, followed by three rounds of rinsing in washing buffer.  Rabbit anti-FADD polyclonal 
antibody was diluted to a final concentration of 2 µg/ml in blocking buffer and added to each 
well.  After rinsing for five rounds in washing buffer, wells were incubated with HRP 
conjugated goat anti-rabbit antibody (diluted to a final concentration of 2 µg/ml in blocking 
buffer) for 30 min, followed by incubation in detection reagent (R&D Systems Inc., 
Minneapolis, MN) for a additional 30 min.  Colorimetric development was aborted by the 
addition of stop buffer containing 2 N sulfuric acid (R&D Systems Inc.).  Absorbance reading 
was analyzed at wavelength of 450 nm using Spectrafluor Plus (Tecan USA Inc., Research 
Triangle Park, NC). 
 
2.2.4.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The 10 % SDS-PAGE gel was cast using the Mini-PROTEAN III gel apparatus (Bio-Rad 
Laboratories).  The gels were prepared following the method outlined by Ausubel et al. 
(1987).  The resolving gel was allowed to set at r.t for 30 min.  A 5 % stacking gel was 
prepared and loaded onto the resolving gel.  The protein samples were boiled in 1 x loading 
buffer (section 2.1.37) before loading onto the gel.  The gel was run at 180 V for 1.5 h in 1 x 
SDS electrophoresis buffer.  A pre-stained high molecular weight protein marker (14.2 kDa – 
200 kDa; Invitrogen Life Technologies) was run as a reference.  After electrophoresis, the 
proteins were transferred from gel to polyvinylidene difluoride (PVDF) membrane at 20 V 
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constant voltages for 30 min at r.t in transfer buffer.  To determine the efficiency of transfer, 
the blots were stained with Ponseau S (Sigma-Aldrich Corp.).  Excess stain was removed by 
rinsing in water. 
 
2.2.4.7 Western hybridization 
The membrane was placed into blocking buffer (section 2.1.40) for 1 h at r.t.  The primary 
antibody was diluted in blocking buffer according to manufacturer’s recommendation.  
Following blocking, the membrane was incubated in the primary antibody for 1 h at r.t.  
Excess antibody was removed by washing the membrane in wash buffer for 30 min with 
agitation, and changing the buffer every 10 min.  Secondary antibodies conjugated to 
horseradish peroxidase (HRP) were diluted in blocking buffer according to manufacturer’s 
recommendation.  The membrane was then incubated in the secondary antibodies for 1 h at r.t 
with agitation.  To remove unbound secondary antibodies, the membrane was washed in 
washing buffer for 30 min with agitation.  Detection of positive signal was achieved using 
SuperSignal West Pico Substrate (Pierce, Rockford, IL). 
 
2.2.4.8 Hematoxylin and Eosin (H&E) staining 
The H&E staining was performed by incubating the sections in Harris’ hematoxylin (Sigma-
Aldrich Corp.) for appropriate duration followed by rinsing in running water until blue color 
was observed.  The sections were then dipped into 70 % and 90 % ethanol for 30 s each 
followed by counterstaining with eosin for appropriate duration.  This was followed by 
dehydrating the sections in 95 % ethanol for 1 min and 100 % ethanol twice of 1 min each.  
After dehydration, the sections were incubated in xylene twice at 5-min intervals.  Excess 
xylene was drained from the sections before a drop of DPX (Sigma-Aldrich Corp.) was 
applied.  The sections were then mounted with a coverslips and stored at r.t. until examined 




2.2.4.9 Immunohistochemistry staining 
Tissue sections were fixed in 4% paraformaldehye for 10 min, r.t., followed by three washes 
with washing buffer.  To quench endogenous peroxidase activity, the sections were subjected 
to treatment with 0.3 % hydrogen peroxide for 5 min at r.t. followed by three washes.  
Nonspecific binding was removed by incubating the sections in blocking buffer (refer 2.1.47), 
for 30 min at r.t.  Primary antibody was diluted 1:100 in blocking buffer, added to the sections, 
and incubated for 30 min r.t., followed by three washes with washing buffer.  HRP-
conjugated secondary antibody was applied to the sections and incubated for another 30 min, 
r.t.  This was followed by 3 washes of 5-min each. Colorimetric development was visualized 
after the addition of 3, 3’ diaminobenzidine (DAB) substrate solution (Sigma-Aldrich Corp.).  
 
2.2.4.10 Immunofluorescence staining 
To determine the localization of transgene expression, cells were first plated on coverslips and 
then infected with viral vectors for 6 h.  The cells were then replenished with fresh medium 
containing 10 % FBS.  After 24 h, the cells were rinsed with PBS twice and fixed using 4% 
paraformaldehyde at r.t. for 10 min.  Excess fixative was removed by agitating cells with 
washing buffer containing PBS with 0.1% Tween 20 at r.t. for 10 min.  All subsequent steps 
that required rinsing were carried out at r.t.  The cells were permeabilized using 0.1 % Triton-
X 100, rinsed for 10 min, and incubated in blocking buffer [0.1 % Tween 20 and 10 % goat 
serum (Sigma-Aldrich Corp.) in PBS] for one hour.  This was followed by an overnight 
incubation with diluted primary antibodies (final concentration of 2 µg/ml in blocking buffer) 
at 4ºC.  Cells were subsequently rinsed thrice at 5 min intervals and incubated with diluted 
secondary antibody (final concentration of 2 µg/ml) for an hour.  The cells were mounted and 
examined using a LSM 510 Meta confocal microscope (Carl Zeiss Microscopy, Göttingen, 





2.2.5 Recombinant DNA techniques 
2.2.5.1 Electrophoresis of plasmid DNA or PCR fragments 
Electrophoresis of plasmid DNA and PCR fragments was carried out as described by 
Sambrook et al., (1989).  0.7 % agarose gels were prepared with DNA grade agarose 
(Invitrogen Life Technologies) in 1 x TAE buffer and were run in 1 x TAE buffer.   
 
2.2.5.2 Purification of DNA fragments 
The DNA and PCR fragments were purified from agarose gel using Gel purification kit 
(Qiagen GmbH) according to manufacturer’s instructions.  Briefly, DNA or PCR fragments 
were excised from the agarose gel using a scalpel and put into a clean 1.5 ml microcentrifuge 
tube.  Three volume of buffer QG was added to the agarose gel piece and incubated at 50 °C 
for 10 min.  After solubilization, the DNA solution was transferred to a column and subjected 
to centrifugation at 13 000 xg for 1 min using a tabletop centrifuge.  The column was rinsed 
once with buffer PE, excess PE was removed by an additional round of centrifugation.  DNA 
or PCR fragments were eluted in 30 µl of buffer EB (10 mM Tris-Cl, pH 8.5). 
 
2.2.5.3 Removal of nucleotides 
Excess restriction enzymes or oligonucleotides were removed from reaction solution using the 
Nucleotide Removal Kit (Qiagen GmbH) according to manufacturer’s instructions.  Briefly, 
reaction solution was added to nucleotide removal column and centrifuged at 6000 xg for 1 
min.  This is followed by rinsing the column with buffer PE and centrifuging at 6000 xg for 1 
min.  Excess buffer PE was removed by a further centrifugation at 13 000 xg for 1 min.  DNA 
was eluted with 30 µl of buffer EB (10 mM Tris-Cl, pH 8.5). 
 
2.2.5.4 Restriction endonuclease digestions 
The restriction endonuclease digestions reactions were performed as recommend by the 




For cloning of inserts with identical restriction ends, the calf intestinal alkaline phosphatase 
(CIAP) was used to remove the overhanging phosphate group to prevent self ligation of the 
vector.  After restriction digestion with appropriate enzymes, the vector and the insert DNA 
was purified.  The purified vector DNA containing the single restriction ends was then 
transferred to a clean microcentrifuge tube and 1 U of CIAP (New England Biolabs) was 
added to a final volume of 20 µl.  The reaction was incubated at 37 °C for 1 h.  After 
completion of the reaction, the CIAP was heated inactivated at 65 °C for 20 min, and the 
treated DNA was then purified as mentioned in 2.2.5.2.   
 
2.2.5.6 Ligation reaction 
The ligation reaction was carried out in a vector to insert ratio of 1:1 to 1:3.  The ligation 
reactions were performed in a final volume of 10 µl containing 1 x ligation buffer (Invitrogen 
Life Technologies), appropriate amount of vector and insert DNA, and 1 Weiss Unit of T4 
DNA ligase (Invitrogen Life Technologies) and ddH20.  The ligation reaction was incubated 
at 16 °C overnight. 
 
2.2.5.7 Transformation of bacterial cells by the heat shock method 
The competent bacterial cells, STBL-2 (Invitrogen Life Technologies), were thawed and kept 
on ice.  10 ng of supercoiled DNA or 1/10th of ligation product was added to 50 µl of the cells 
and kept on ice for 20 min.  The cells were heat shocked by placing in a 42 °C water bath for 
25 sec, and then immediately on ice for additional 2 min before addition of 950 µl LB.  The 
cells were incubated at 30 °C for 90 min with gentle agitation.  100 µl of the transformed cells 
were plated on to LB agar plate containing 100 µg/ml of ampicillin (Sigma-Aldrich Corp.).   
 
2.2.5.8 Polymerase Chain Reaction (PCR) 
For the cloning of DNA fragments, pfu DNA polymerase (Stratagene Cloning Systems, La 
Jolla, CA) was used to amplify target sequences, since it exhibited the lowest error rate than 
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most thermostable DNA polymerase.  To amplify DNA fragments, reaction mix containing 1 
x Pfu buffer, 2.5 mM MgCl, 10 mM dNTPs, 50 pmol of forward and reverse primers, and 2.5 
Unit of Pfu DNA polymerase were added to a final volume of 25 µl.  The reaction starts with 
an initial denaturation at 95 °C for 5 min.  This is followed by incubating the sample at 95 °C 
for 30 sec.  Annealing temperature of the PCR primers to the template varies, but generally 
falls between 50-60 °C.  Annealing reaction was carried out for 1 min.  The extension 
reaction is programmed at 72 °C, and the duration is dependent on the size of the desired PCR 
product.  Standard PCR reaction is repeated for 30 cycles with a final extension at 72 °C for 
10 min.  After the completion of the reactions, the samples were kept on ice.  If desired, the 
PCR products were analyzed using agarose gel electrophoresis. 
 
2.2.5.9 Reverse Transcriptase-PCR (RT-PCR) 
The first strand complementary DNA (cDNA) was synthesized using 1 or 2 µg of total RNA 
as template.  cDNA was synthesized using random hexanucleotide primers (Invitrogen Life 
Technologies) and oligo-dT12-17 primers, in the presence of Superscript II reverse transcriptase 
(Invitrogen Life Technologies) at 42 °C for 45 min.  The RNA samples were pretreated with 1 
U of RNase free DNase (Invitrogen Life Technologies) by incubating at 37 °C for 15 min 
followed by 70 °C for 5 min to remove contaminating genomic DNA.  DNase I was 
subsequently removed by extracting with phenol and chloroform.  The RT-PCR reaction was 
prepared in a final volume of 25 µl using 1 µl of the first strand cDNA as template.  PCR 
reaction was performed as described in section 2.2.5.8. 
 
2.2.6 Cell viability assay using trypan blue exclusion assay 
To determine the viability of cells following infection, the monolayer of infected cells were 
rinsed with PBS and harvested at particular time points post infection.  Equal volume of cell 
suspension was mixed with 0.4 % of trypan blue solution (Sigma-Aldrich Corp.).  Cells were 
visualized under phase contrast microscope (Nikon).  Cells that are still intact will exclude 
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trypan blue and appear as clear under the microscope.  Assays were performed in triplicate.  
The number of viable cells was expressed as a percentage of the total cells. 
 
2.2.7 Terminal deoxynucleotide transferase dUTP Nick End labeling (TUNEL) assay  
dGli36 cells (3 x 105) was plated on cover slips and infected with pC8-FasL or pC8-FADD 
(MOI of 1.0) for 6 h.  The cells were then replenished with fresh medium containing 10 % 
FBS or medium supplemented with 50 µM lovastatin.  TUNEL staining of apoptotic cells was 
performed according to manufacturer’s protocol (Roche Diagnostics).  Briefly, after 72 h, 
cells were rinsed with PBS twice and fixed using 4% paraformaldehyde at room temperature 
for 1 hr.  Excess fixative was removed by rinsing in PBS, followed by treatment with PBS 
containing 0.1 % Triton X-100 and 0.1 % sodium citrate for 2 min on ice to permeabilize the 
cells.  After washing with PBS to remove excess permeabilizing solution, cells were 
incubated for 1 hr at 37 °C in TUNEL reaction mixture containing terminal deoxynucleotidyl 
transferase (TdT) and TMR red-labeled dUTP, which preferentially labels DNA strand breaks 
generated during apoptosis.  Excess reaction mixture was removed by rinsing with PBS. A 
fluorescence microscope with appropriate filters Was used for visualization. 
 
2.2.8 Animal models 
2.2.8.1 Establishment of subcutaneous (s.c.) tumor model 
After removal of trypsin, tumor cells are resuspended in PBS.  Each mouse, either Balb-C 
nu/nu or CB-17 SCID, was inoculated with 2 x 106 tumor cells in total volume of 100 µl. The 
tumor cells were injected into the mouse using 1-ml syringe connected to a 27-G needle.  
Tumor volume was calculated using the formula: tumor volume (mm3) = 0.52 x (width [mm2] 






2.2.8.2 Establishment of intracranial (i.c.) tumor model 
For intracranial tumor model, mice were injected with 1 or 2 x 106 cells resuspended in a 
maximum volume of 10 µl of PBS.  The tumor cells was stereotactically inoculated into the 
caudate putemen region [bregma (0,0), 2.0 mm lateral, 2.5 mm depth] using stereotaxic 
equipment (Stoelting Co, Wood Dale, IL).  Tumor growth was monitored by magnetic 
resonance imaging (MRI), H&E staining, and loss of body weight. 
 
2.2.8.3 Establishment of dGli36-SCID8 cells 
The formation of s.c. dGli36-derived tumor is not consistent in SCID mice.  To establish a 
more consistent derivative, dGli36 cells was serially passaged in SCID mice.  When the 
tumor reached a volume of approximately 45 mm3, the tumor was harvested into cold DMEM 
containing 10 % serum.  The tissue suspension was treated with 0.25 % trypsin solution at 37 
°C for 10 min, and passed the mixture through a 1 ml serological pipette followed by flame-
polished pasteur pipette.  The suspension was subjected to centrifugation at 100 x g for 5 min.  
The pellet was resuspended in cold DMEM containing 10 % serum.  The recovered cells were 
grown in culture for one passage after which the cells were reinoculated into SCID mice.  The 
cells were passaged in SCID mice three times before used.  In vitro and in vivo growth 
kinetics was determined.  The growth rate of dGli36-SCID8 was similar to dGli36 cells.  In 
vivo, dGli36-SCID8 consistently forms s.c. tumors in both SCID and nude mice.  The 
morphology of dGli36-SCID8 resembles that of the parental dGli36 cells.  Transfection and 
infection efficiency is comparable.   
 
2.2.9 Statistical analysis 
Statistical analysis was performed using Prism 3.0 (Graphpad Software Inc., San Diego, CA) 
and Instat (Graphpad).  Paired Student’s t test was used when comparing two related 
experimental groups.  Unpaired Student’s t test was used when comparing experimental data 
from 2 unrelated groups.  One way analysis of variance (ANOVA) followed by Bonferroni 
Multiple Comparisons Test were used for comparing statistical significance for more than 2 
 52
groups.  p value < 0.05 was considered statistically significant.  The Kaplan-Meier survival 
analysis was used to calculate the percentage of survival as a function of time, the survival 













Characterization of the cell cycle-regulated HSV-1 amplicon vector 
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3.1 Background 
Currently, one of the greatest challenges to cancer gene therapy is the ability to regulate 
transgene expression with minimal adverse effects.  Tissue-specific or tumor-specific 
promoters have been employed to target transgene expression to particular cell types (Shibata 
et al., 2000; Ueno et al., 2001).  However, tissue-specific promoters are generally weak 
inducers of transgene expression.  Moreover, the essential upstream control region that 
governs gene expression from a particular promoter can span several kb; this represents a 
major hindrance in the construction of the transcriptionally-mediated targeted vector systems 
(Agha-Mohammadi and Lotze, 2000).  To circumvent the problem of relying on exogenous 
stimulation for gene expression regulation, endogenous cell cycle regulation has recently been 
introduced as a new concept (Nettelbeck et al., 1999).  As hyperproliferation is a 
characteristic of most malignant tumor cells, the transduction of cell cycle-regulated viral 
vectors carrying therapeutic genes into the tumor region could represent promising tools for 
cancer gene therapy.   
 
3.1.1 Cell cycle regulation 
The eukaryotic cell cycle is divided into four phases, namely, G1, S, G2 and the M phase.  
Nonproliferating quiescent cells, reside in the G0 phase, and enter into the cell cycle when 
stimulated by mitogenic factors.  The cells may proceed to DNA replication, to pause or to 
exit the cell cycle in G1 phase.  DNA replication takes place in the S phase, cell division at the 
end of the G2/M phase.  This complex process is controlled by two major checkpoints, the 
G1/S checkpoint (Figure 3.1) and the G2/M checkpoint, both of which are critical for 
maintaining genomic integrity.  The regulatory molecules that are involved in the G1/S 
transition are cyclin D, cyclin E, cdk (cdk2, cdk4 and cdk6), the protein phosphatase cdc25A, 
transcription factor E2F, pRb, and cdk inhibitors (p15, p16, p21, and p27).  The Rb-E2F 
pathway is the major regulator of cellular progression from G1 to S phase.  In fact, 






3.1.1.1 Transcriptional repression mediated by E2F 
Transcriptional repression is a major mechanism that regulates gene expression during the cell 
cycle.  In mammalian cells, a specific set of cell cycle genes that are transcribed around the 
G1/S border is regulated by factors of the E2F family, a heterodimeric transcription factor 
composed of members of the E2F and DP multigene families.  In G0 and early G1, the 
E2F/DP-1 complex is bound to pRb, and is hence inactive.  As cell cycle progresses, pRb is 
hyperphosphorylated by G1-specific cdk4/6, leading to dissociation from E2F/DP-1, which 
generates free E2Fs and thus enables the activation of E2F-regulated genes. Several genes 
expressed in late G1/early S phase have been shown to be regulated through an E2F-mediated 
mechanism.  These genes are involved in cell cycle regulation, for instance, cdk2, cdk4, cyclin 
A, D and E; and DNA synthesis, such as proliferating cell nuclear antigen (PCNA) and RR 
(Black and Azizkhan-Clifford, 1999).  The presence of E2F binding sites on these genes 
enables the binding of E2F during late G1/early S phase of the cell cycle.   These genes are 
generally repressed by E2F during G0/G1 and activated at late G1/early S phase.   
 
3.1.2 Cyclin A  
Cyclin A is one of the genes that are regulated by the transcription factor, E2F.  Cyclin A is a 
cell cycle regulatory protein that functions in the S phase and M phase of the mammalian cell 
cycle.  Transcription of cyclin A is regulated; its mRNA levels increase at the G1/S boundary 
and reach peak levels in S phase (Pines and Hunter, 1990).  Cyclin A was first identified in 
sea urchin embryos (Evans et al., 1983) and was found to interact and activate cdc 2 (Pines 
and Hunter, 1990) and cdk2 (Swenson et al., 1986).  During S phase of the cell cycle, cyclin 
A forms a complex with cdk2, this interaction then leads to phosphorylation and activation of 
the cellular DNA replication factor (Dutta and Stillman, 1992; Elledge et al., 1992).  Cdk2 
dissociates from cyclin A as the cells progress into G2/M phase, allowing cyclin A to interact 




3.1.3 Regulation of the cyclin A transcription 
The short promoter sequence of cyclin A has been shown to harbor most regulatory elements 
required for cell cycle-regulation and efficient transcription (Henglein et al., 1994; Huet et al., 
1996; Zwicker et al., 1995b). The cyclin A promoter does not contain a TATA-binding site, 
instead it comprises of an inverted CCAAT box binding site and four Sp1 sites, an ATF site 
and two overlapping sites for the murine G1/S-specific transcription factor Yi (Figure 3.2).  A 
single AP-1 site and two NF-Y/CBF sites are also found on the promoter (Henglein et al., 
1994).   Analysis of other S/G2 phase specific promoter sequences revealed a conserved 
regulatory region that is shared among cyclin A, cdc25C, cdc2, and B-myb (Figure 3.3).   
 
These promoters are controlled by transcriptional repression through two contiguous protein 
binding sites termed “cell cycle-dependent element” (CDE) and “cell cycle genes homology 
region” (CHR).  The CDE and CHR region in these promoters are highly conserved (Figure 
3.3). The CDE region is occupied by repressor proteins during G0/G1, but this repression is 
released in G2.  It has been found that mutation of either CDE or CHR abolished the 
repression in G0 (Zwicker et al., 1995b).  Interestingly, genomic footprinting of the cyclin A 
promoter depicted a cell cycle-regulated protein binding to the G residues of the CDE element 
in the major groove, and the A residues of the CHR element in the minor groove.   This cell 
cycle-regulated protein was termed “cell cycle dependent factor-1” (CDF-1). 
 
3.1.4 CDF-1 
The cdc25C promoter was used as a model system to study transcriptional regulation of gene 
expression controlled by the CDF-1 repressor protein (Zwicker et al., 1995a).  The cdc25C 
promoter contains three functionally important NF-Y binding sites upstream of the CDE/CHR 
element.  The CDE element does not interfere with basal transcription from the core promoter 
(Lucibello et al., 1995); however, its function is dependent on a stretch of upstream activating 
sequences (UAS) that is required for transcriptional activation.  A second major transactivator 







CCAATT-box binding factor (CBF)/NF-Y binding sites.  Repression of gene expression 
mediated by CDF-1 is specific for a subset of transactivators.  Significant regulation is 
observed with three different activation domains, namely, the glutamine rich Oct-2, Sp1 and 
the serine/threonine/glutamine-rich domain of the human NF-Y (Zwicker et al., 1997).  In fact, 
the most significant repression was seen with the A subunit of NF-Y.  Binding of NF-YA to 
nucleosomes induces DNA bending, resulting in the opening of the chromatin structure of the 
proximal promoter.  In contrast to NF-YA, no significant transactivation was detected with 
VP16, Myc and the serine/threonine rich ITF-2.   Replacing the UAS of cdc25C resulted in 
partial or complete abrogation of cell cycle regulated repression.   
 
CDF-1, a G0/G1 phase-specific repressor protein, was found to bind with similar efficiency to 
cdc25C, cdc2 and cyclin A, and this binding is dependent on the presence of intact forms of 
CDE and CHR (Liu et al., 1997).  In fact, CDF-1 binds cooperatively to these two elements.  
There is much evidence indicating that CDF-1 is the major repressor of cyclin A promoter.  
As demonstrated by DNA binding assays, the affinity of E2F for the cyclin A CDE is lower 
compared to its affinity for promoters that harbor the E2F-binding sites, such as B-myb. 
Moreover, as mentioned above, the transcriptional repression of the cyclin A promoter is 
highly dependent on the CHR region.  Mutation or deletion of the CHR sequence completely 
abolished the CDF-1 mediated repression.  Similar to cyclin A, the CHR element from the 
cdc25C promoter only interacts with CDF-1, but not E2F (Liu et al., 1997).   
 
One of the factors implicated in cell cycle-regulated repression is E2F, which can form DNA 
binding repressor complexes through its interaction with pocket proteins, such as pRb.  B-myb, 
p107 and orc-1 are among the promoters controlled by transcriptional repression through E2F 
sites.  The distinction between transcriptional repression mediated through E2F and CDF-1 is 
evident from the repression of the B-myb promoter, which requires a second regulatory 
element downstream of E2F site, termed CHR or DRS.  Liu et al. (1997) showed that CDF-1 
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does not bind to the B-myb promoter under conditions where a strong interaction is seen with 
the cdc25C, cdc2 and cyclin A promoters. 
 
CDF-1 is distinct from E2F whereby it neither contains DP1 nor forms a complex with pocket 
proteins (Liu et al., 1997).   Liu et al. (1998) demonstrated that E2F does not play a 
significant role in the repression of the cyclin A promoter in G0/G1 cells.  Constructs which 
contained mutations in the CDE element, abolishing the binding of E2F but not affecting 
CDF-1 activity, demonstrated that repression of the cyclin A promoter in G0 cells was not 
affected (Liu et al., 1998).    However, when the cells progressed to late G1, interaction of 
E2F with the CDE element was clearly observed (Liu et al., 1998).  In the G0/G1 phase, CDF-
1 occupies the CDE/CHR element, leading to repression of promoter activity.  In late G1/S, 
CDF-1 partially dissociates from CDE element; and the free E2F competes for the binding to 
CDE.  At this stage of the cell cycle, complex formation of E2F with the CDE is comparable 
to the binding of CDF-1 to the CDE element.  Promoter variants with mutations in the CDE 
leading to decreased interaction with E2F show a delay in derepression.  In contrast, mutants 
which exhibit increased E2F binding are upregulated prematurely. This induces the onset of 
transcription and the subsequent inactivation of CDF-1 in S/G2 phase, leading to maximum 
levels of gene expression. 
 
3.1.5 Recombinant transcriptional activator (RTA) system  
The construction of the RTA system is based on the modular structure of transcription factors 
which allows the DNA binding domain to interact with the transactivation domain derived 
from different proteins (Nettelbeck et al., 1999).   
 
Essentially, this system is based on the CDF-1 transcriptional repressor protein, which is 
specifically expressed during the G0/G1 phase of the cell cycle (Liu et al., 1997).  A chimeric 
transcription factor, consisting of the Gal4 DNA binding domain and the 
serine/threonine/glutamine-rich transactivation domain of the NF-Y subunit A (Gal4/NF-YA), 
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is expressed as a fusion protein.  The Gal4 DNA binding domain can interact with another 
promoter, consisting of the minimal cyclin A promoter CDE/CHR regulatory element 
downstream of multiple Gal4 DNA binding sites.  In non-dividing cells, the transactivation of 
the cyclin A promoter is repressed because the CDE/CHR element is occupied by the CDF-1 
repressor protein thus abolishing transactivation via the upstream factors.  Absence of CDF-1 
repressor protein in dividing cells allows the binding of the chimeric transcription factor 
Gal4/NF-YA to the Gal4 binding sites located upstream of the minimal cyclin A promoter, 
hence driving the transcription of the reporter/therapeutic gene (Figure 3.4).   
 
3.1.5.1 Methods for synchronizing cells at G1 phase  
Synchronization of cells at specific stages of the cell cycle is particularly useful for studying 
cell cycle-regulated events and to analyze proteins whose expression are dependent on cell 
cycle stages.  The G1 phase of the cell cycle averages between 8-16 h for most cell lines.  To 
synchronize cells at G0/G1, cells may be subjected to serum free medium for 24-48 h (Ausubel 
et al., 1987) to allow the whole population to respond to serum withdrawal.  However, some 
cells do not respond to serum withdrawal and require the use of drugs such as lovastatin and 
mimosine, to induce arrest.  Another method of synchronizing cells at the G0/G1 is the 
depletion of amino acids, such as thymine and methionine, in the culture medium (Sallot et al., 
1996; Wejde et al., 1993).  However, tumor cells recalcitrant to synchronization using either 
serum withdrawal or amino acid depletion, in which case, lovastatin or mimosine can be used 
to arrest the cells.   
 
Lovastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, 
resulting in depletion of mevalonate, which is a precursor of cholesterol synthesis (Bonapace 
et al., 1996).  Mevalonate is also required for the isoprenylation of substrate molecules, such 
as p21 ras (Wejde et al., 1993).    The ability of lovastatin to induce cell cycle arrest at early 
G1 has been demonstrated in a variety of cell lines (Bonapace et al., 1996; Wilcken et al., 




unknown, but it has been shown to block cell cycle in late G1 or at the G1/S boundary.  To 
avoid complications, we have decided to use lovastatin instead of mimosine to induce G1 
arrest since its mechanism is better understood.  
 
3.1.6 Liver regeneration model 
One of the best examples of studying cellular replication in vivo is the regeneration of liver 
following partial hepatectomy (PHx) (Higgins and Anderson, 1931).  In this procedure, two-
thirds of the liver is removed without affecting the remaining lobes.  The remaining hepatic 
tissues will enlarge to compensate for the loss of tissue mass.  The entire process of liver 
regeneration, which is largely due to the rapid proliferation of hepatocytes, takes 
approximately 5 to 7 days (Michalopoulos and DeFrances, 1997).  Analysis of DNA synthesis 
showed that the replication of hepatocytes peaks at about 48 h after PHx, which correlates 
with the expression of cyclin A; cyclin A levels increase from 12 h onwards until 7 days post-
PHx (Michalopoulos and DeFrances, 1997).  We have chosen liver regeneration following 
PHx as a model to study the activation of transcriptional activity associated with the onset of 
DNA replication. In normal adult rodents, increasing numbers of hepatocytes enter S phase 
shortly after hepatectomy, thus providing a good system to study cell cycle-regulated 
transgene expression conferred by the cell cycle-regulated amplicon vector in vivo. 
 
3.1.7 Aim of research 
The strategy described in our present study presents a more efficient alternative approach 
where a single-vector system combining both the NF-YA transcriptional activator and the 
reporter modules is assembled to confer cell cycle-dependent transgene expression.  This is 
particularly advantageous in brain tumor gene therapy since cell proliferation is a rare event in 
the normal brain.  In contrast, malignant brain tumor cells divide rapidly leading to the 




3.2.1 Construction of the cell cycle regulated amplicon plasmids 
pHGCX (HSV-1 amplicon) vector was obtained from Dr. Y Saeki (Massachusetts General 
Hospital, Boston, MA).  CMV.GN and 8GalcycA were obtained from Dr. R Müller (Institute 
of Molecular Biology and Tumor Research, Marburg, Germany).  To construct pHGCX.GN, 
the Gal4 DNA binding domain (amino acids 1-147) and the murine NF-YA transcriptional 
activation domain (amino acids 1-261) in plasmid CMV.GN was inserted into the HindIII and 
BamHI restriction enzyme sites of pHGCX.  The 8GalLuc DNA fragment was released from 
plasmid 8GalcycA and subcloned into the NheI and BamHI restriction enzyme sites of 
pHGCX, and the pre-existing CMV promoter was subsequently removed using SpeI and NheI 
to generate pIH8GalLuc plasmid.  To generate pC8-36 plasmid, the 8GalLuc fragment was 
amplified by PCR using 8GalcycA plasmid as a template (the forward and reverse primers 
were 5'-CCTCTTCGCTATTACGCC and 5'-AAGAAGACAGTCATAAGTGCGG, 
respectively).  The amplified DNA fragment was subcloned into the shuttle plasmid pGemT-
easy (Promega, Madison, WI), released using NotI restriction enzyme sites, and inserted into 
pHGCX.GN.  When this 8GalLuc cassette was inserted in the opposite orientation to 
Gal4/NF-YA, the resulting plasmid was named pC8-34.  All plasmids were amplified in E. 
coli STBL-2 (Invitrogen Life Technologies) and DNA was extracted with a QIAprep spin 
miniprep Kit (Qiagen).  All plasmids were verified by DNA sequencing (Applied Biosystem 
Inc., Foster City, USA). 
 
3.2.2 Transfection of oligomers 
For oligomer competition assay, oligomers (500 nM) were mixed with 3 µl of Oligofectamine 
(Invitrogen Life Technologies Life Technologies) in Opti-MEM for 15 min at r.t.  The 
complexes were added to HeLa cells (3 x 105) and incubated for 4 h at 37 °C.  The cells were 
then rinsed with PBS twice, followed by transfection of pC8-36 plasmids, using 
LipofectAmine reagents.  Refer to section 2.2.1.5 for DNA transfections of cells. 
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3.2.3 Preparation of nuclear extract 
HeLa cells (3 x 106) treated with lovastatin were rinsed with PBS twice, trypsinized and 
resuspended in 800 µl of buffer A (refer 2.1.43).  After incubation on ice for 15 min, the cells 
were lysed in the presence of 50 µl of 10 % Nonidet P40 (NP-40).  Each sample was vortexed 
briefly and centrifuged for 45 sec at 5000 xg at 4 °C to collect the nuclear pellet.  The pellet 
was then resuspended in 100 µl of buffer C (refer 2.1.44).  Samples were incubated for 10 
min on ice followed by centrifugation at 14 000 xg at 4 °C to remove the insoluble materials; 
supernatant, containing the nuclear extract, was stored at -70 °C.  The protein concentration 
was determined as described in section 2.2.4.2. 
 
3.2.4 Labeling of oligonucleotide probes 
Oligonucleotide probes were labeled at the 3’ end, using terminal deoxynucleotidyl 
transferase enzyme in the presence of biotin-N4-dCTP (Pierce Biotechnology) according to 
manufacturer’s conditions.  The labeled oligonucleotides or probes were purified using the 
Nucleotide Removal Kit (Qiagen GmbH) according to the manufacturer’s instructions. 
 
3.2.5 Electrophorectic mobility shift assays (EMSA) 
EMSA reactions were performed with the LightShift Chemiluminescent EMSA kit (Pierce 
Biotechnology) according to the manufacturer’s instructions.  Briefly, 5 µg of HeLa nuclear 
extract was incubated in 2 µl binding buffer (refer 2.1.42) containing 2.5 % glycerol, 5 mM 
MgCl2, 0.2 mM EDTA, 0.05 % NP-40, 250 ng of poly(dA-dT) (Amersham Biosciences AB, 
Uppsala, Sweden).  Biotin-labeled probe (100 fmol) was added in a total volume of 20 µl and 
the reaction mixture was incubated for 20 min at r.t.  The double- stranded probe CDE 
(5’TTACTGGGCTGGCGGAAGGTTTGAATGGTCAATTACTGGGCTGGCGGAAGGTT
TGAATGGTCAA-3’), was used (Liu et al., 1997).  The random oligomer contains an 
irrelevant sequence.  The protein-DNA complexes were then separated on native 6 % PAGE 
at r.t.  Gels were transferred to Hybond N+ nylon membrane (Amersham Biosciences) 
followed by cross-linking at 120 mJ/cm2, using a Stratalinker (Strategene).  Detection and 
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visualization of the protein-DNA complexes were performed using a LightShift 




Animal work was performed under guidelines approved by the National Cancer Centre 
Animal Care and User Committee.  Female BALB/c mice were purchased from the 
Laboratory Animal Unit of the National University of Singapore, Singapore.  The mice were 
of age 6-8 weeks and submitted to a 12:12-hour light/dark cycle, housed five per cage, and 
allowed food and water.  Animals to undergo hepatectomy were anesthetized with an 
intraperitoneal (i.p.) injection of ketamine/xylazine (70/10 mg/kg). A 70% PHx was 
performed through a midline incision as described by Higgins and Anderson (1931).  Forty 
eight h after PHx, the animals were treated with an injection of virus (1 x 106 TU) via tail vein.  
Regenerated liver tissues and tissues from normal livers were removed and assayed for 
luciferase activities. 
 
3.2.7 Isolation of single cells for FACS analysis 
The liver tissues were harvested in cold DMEM containing 10 % serum.  Liver tissues were 
then treated with 0.05 % collagenase solution at 37 °C for 10 min.  This was followed by 
passing the mixture through a 1 ml serological pipette, followed by 18 G and 23 G needle.  
The suspension was subjected to centrifugation at 1000 x g for 5 min.  The pellet was 
resuspended in cold DMEM containing 10 % serum.  For cell cycle analysis, the pellet was 
resuspended in 70 % ethanol overnight followed by treatment with propidium iodide (refer to 
section 2.2.1.6). 
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3.3 Results  
3.3.1 Construction of a cell cycle-regulatable HSV-1 amplicon viral vector 
The HSV-1 amplicon plasmid, pHGCX, contains the gene encoding the eGFP under the 
control of the viral immediate early promoter (IE 4/5).  The transgene of choice can be 
inserted into the multiple cloning sites (MCS) located downstream of the strong 
cytomegalovirus (CMV) promoter, as shown in Figure 3.5a.  The activator plasmid, 
pHGCX.GN (Figure 3.5b), was constructed by subcloning the chimeric transcriptional 
activator module composed of the DNA-binding domain of Gal4 and the repressible 
activation domain of the A subunit of NF-Y into pHGCX.  In the reporter plasmid, 
pIH8GalLuc (Figure 3.5c), the luciferase reporter gene was under the control of a minimal 
cyclin A promoter.  Located upstream of the minimal cyclin A promoter was an eight-tandem 
repeats of the Gal4 DNA-binding sites, which allowed for the interaction of the Gal4 DNA 
binding domain encoded by the plasmid pHGCX.GN.  In proliferating cells, the interaction 
between the activator- and the reporter- modules-containing plasmids, namely pHGCX.GN 
and pIH8GalLuc, respectively, will augment the expression level of the transgene.  In addition 
to these basic constructs (pHGCX, pHGCX.GN and pIH8GalLuc) we have also incorporated 
both the activator module and the reporter module into our single-vector plasmids, pC8-36 
and pC8-34 (Figure 3.5d and 3.5e).  In the construct pC8-36, the activator module (Gal4/NF-
YA) and the reporter module (8GalLuc) were constructed to be in the same direction as 
shown in Figure 3.5d.  To ensure that any transgene activity observed was not due to read-
through by the CMV promoter; the activator module (Gal4/NF-YA) and the reporter module 
(8GalLuc) of pC8-34 were constructed in opposite orientation to one another (Figure 3.5e).  
To exclude the possibility of promoter interference from the upstream CMV promoter, we 
have also constructed pC8-delcycA-Luc, whereby the minimal cyclin A promoter has been 





3.3.2 Enhanced transgene expression via a single-vector construct  
For in vivo gene therapy purposes, it would be desirable to introduce a single-plasmid vector, 
pC8-36 and pC8-34, which contain of all the essential elements for cell cycle regulation.  The 
transfection efficiencies of these single-vector constructs were compared with those obtained 
following the cotransfection of both the activator (pHGCX.GN) and reporter (pIH8GalLuc) 
plasmids in a 1:2 ratio (Figure 3.6).  Transfection of the pIH8GalLuc plasmid was performed 
and served as negative control.  The transfection efficiency among the various plasmid 
constructs in CNE2 cells was comparable (~ 50 %), as analyzed by counting the number of 
GFP positive cells.  The level of luciferase expression in pC8-36 transfected cells (5720 
RLU/µg) was 30-fold higher than that of pIH8GalLuc (189 RLU/µg), which served as 
negative control, and 4-fold higher than the co-transfection of both pHGCX.GN and 
pIH8GalLuc plasmids (1309 RLU/µg), which served as positive control.  Luciferase activities 
mediated by pC8-delcycA-luc plasmid (183 RLU/µg) is similar to the negative control, 
pIH8GalLuc, indicating that transgene expression observed in pC8-36 is mediated by the 
transactivation of the cyclin A promoter by NF-YA, and not due to interference from 
upstream CMV promoter.  Transgene expression mediated by pC8-34 (1175 RLU/µg), in 
which the activator and reporter modules are in opposite orientations, exhibited similar 
luciferase activities as the corresponding co-transfected plasmids.  The lower level of 
luciferase activities observed in pC8-34 thus suggests the possibility of interference between 
CMV and cyclin A promoters.  
 
3.3.3 Synchronization of cells at early G1 phase using lovastatin 
In order to evaluate the cell cycle regulatory abilities of our amplicon plasmid constructs, 
target cells were subjected to treatment with lovastatin for the induction of G1 arrest.  The 
cells were treated with escalating doses of lovastatin starting from 20 µM to a maximum of 
120 µM concentration in the presence of 0.1 – 0.5 % serum for 24-48 h.  The cell cycle 
distribution was determined using FACS analysis.  The optimum concentration of lovastatin 




of G1 population.  NIH3T3 cells were synchronized at the G1 phase of the cell cycle in the 
presence of 40 µM lovastatin and 0.5 % serum for 48 h.  This reduced the percentage of S 
phase cells from 28 % to < 3 % as monitored by flow cytometry and represented in Figure 3.7.   
 
3.3.4 Cell cycle-regulated transgene expression mediated by HSV-1 amplicon plasmid 
vectors in NIH3T3 
To determine the cell cycle regulatory abilities of the amplicon vectors, NIH3T3 cells were 
transfected with pC8-36 and the control plasmid, pIH8GalLuc.  The degree of cell cycle 
regulation was measured as a ratio of luciferase activity of the proliferating and G1-arrested 
cells.  Our results showed that luciferase activities were 9-fold higher in proliferating cells 
(21669 RLU/µg) in comparison to the corresponding G1-arrested cell populations (2283 
RLU/µg) (Figure 3.8a).  No significant difference was observed in cells transfected with 
pIH8GalLuc.  Immunoblotting against cyclin A antibody demonstrated the presence of cyclin 
A in proliferating cells and the reduction of cyclin A protein in the G1-arrested populations 
(Figure 3.8).   In contrast, the luciferase activities in both proliferating cells and G1-arrested 
cells transfected with pHGCX-Luc remained similar (Figure 3.8b).  These results indicated 
that the pC8-36 amplicon plasmid is able to confer cell cycle dependent transgene regulation.   
 
3.3.5 Cell cycle-regulated transgene expression mediated by HSV-1 amplicon plasmid 
vectors in a series of cell lines in vitro 
In addition to using the mouse fibroblast cell line, NIH3T3, we also examined if our 
constructs would allow for proliferation-dependent gene expression in various other tumor 
cell lines.  The sensitivity of these cell lines to lovastatin was predetermined and the optimal 
growth-arrested condition was used for each cell line.  Amplicon plasmids (pC8-36) were 
transfected into six human tumor cell lines of different origins, namely, Gli36 (glioma); HeLa 
(cervical carcinoma), PC-3 (prostate carcinoma), Saos-2 (osteosarcoma), SF767 (recurrent 
primary glioma) and U373MG (glioma) (Figure 3.9a; 3.9b 3.9c, 3.9d, 3.9e, and 3.9f, 











was enhanced by a minimum of 3-fold to 16-fold, depending on the cell type, in pC8-36 
transfected cells.  In contrast, only background level was observed in those transfected with 
pIH8GalLuc.  We have also tested the cell cycle regulatory potential of pC8-34 in these tumor 
cell lines (data not shown).  Except for PC-3 cells, all cell lines exhibited better cell cycle 
regulation ability when transfected with pC8-36 than pC8-34 constructs, thus supporting our 
previous data (Figure. 3.6) that there might be a down-regulation of the cell cycle regulatory 
elements due to promoter interference. Taken together, our results demonstrate that our novel 
amplicon plasmid vectors (pC8-36 and pC8-34) could be regulated in a cell cycle-dependent 
manner in both normal fibroblasts and tumor cells. 
 
3.3.6 Interaction of the CDE/CHR regulatory region with CDF-1 repressor protein 
To confirm that the cell cycle-dependent transgene regulation mediated by pC8-36 amplicon 
plasmids shown in the transfection experiments above is a result of CDF-1-mediated 
repression of the CDE/CHR regulatory region, competition assays were performed. 
Oligonucleotides that span the CDE/CHR region of the cdc25C promoter (CDE oligomer) 
were used as it was previously demonstrated that cyclin A promoter binds the CDF-1 
repressor protein with similar efficiency as the cdc25C promoter (Liu et al., 1998; Liu et al., 
1997).  HeLa cells were transfected with either CDE oligomer or a random oligomer with the 
same number of nucleotides, followed by the pC8-36 amplicon plasmid.  These transfected 
cells were cultured with or without lovastatin to represent proliferating and G1-arrested cell 
populations, respectively.  The extent of cell cycle regulation was then measured as a ratio of 
luciferase activity of the transfected cells in the proliferating status versus the G1-arrested 
status.  When HeLa cells were transfected with the CDE oligomer, the extent of cell cycle 
regulation was reduced by half when compared to cells that were transfected with either pC8-
36 alone or in the presence of the random oligomer (Figure 3.10).  This result suggested that 
the level of cell cycle-regulated transcription is dependent on the CDE/CHR-mediated 
repression site on the cyclin A promoter. 
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compared to G1-arrested cells.  It is also significantly higher than background level.   
To further investigate whether the CDF-1 repressor protein would interact with the CDE 
oligomer described above, nuclear extracts of G1-arrested HeLa cells were analy
EMSA using CDE oligomer as a probe.  The results clearly showed the presence of CDF-1
binding activity in the presence of CDE oligomer (Figure 3.11).   The CDF-1 binding activit
could be specifically competed in the presence of increasing ratio of probe to unlabelled 
competitor.  This binding activity was absent when the random oligomer was employ
probe (Figure 3.11).  Taken together, these data confirmed the specific interaction of CDF-1 
to sequences containing the CDE/CHR motif. 
 
3.3.8 Transgene expression can be switched on in resting cells  
To determine if the cell cycle-regulatable amplicon plasmids can be reactivated in resting
cells, luciferase assays were performed in cells transfected with pC8-36 and the pIH8GalLuc
amplicon plasmids in the proliferating, G1-arrested and the G1-released cell populations.  Both 
NIH3T3 and HeLa cells have been chosen as controlling their cell cycling events is easie
compared with other cell lines tested.  Cells transfected by either pC8-36 or pIH8GalLuc wer
analyzed (24 h post transfection) for luciferase expression in the proliferating cell populatio
Transfected cells were also treated with lovastatin in 0.5 % serum for 48 h to induce G1
After 48 h, a portion of the cells were harvested for analysis of luciferase transgen
expression; while 10 % serum containing 5 mM mevalonate were added to the remaining cells
for an additional 48 h followed by luciferase assay.  Although the absolute values obtaine
with pC8-36 transfected NIH3T3 cells and HeLa cells were much lower as compared t
Figure 3.8a and 3.9b, luciferase activities were still 15-fold higher in proliferating NIH3T3 
cells and 35-fold higher in HeLa cells when compared to the respective G1-arrested c
populations (Figure 3.12a and 3.12b).  Only background level of luciferase expression could
be detected in pIH8GalLuc-transfected cells (Figure 3.12a and 3.12b).  The level of luciferase 




















cytometry which indicates a decrease in the percentage of S phase cells in the G1
population, and the increase in the S fraction in the G1-released cells (Figure 3.12).  These 
results indicated that the regulation of the transgene expression could be activated as the G
arrested cells enter the proliferative stage of the cell cycle.   
 
3.3.9 Packaging of amplicon viral vectors  
To determine if the amplicon plasmids could be packaged into infectious HSV-1 am
virions, we have adopted the helper virus-free packaging system (Fraefel et al., 1996) 
(detailed in 2.2.2.1 and 2.2.2.2) to package our amplicon plasmid constructs.  The titer
obtained for the resulting packaged amplicon viral vectors ranged from 1 x 107 to 1 x 1
TU/ml after concentration through a sucrose gradient.  The ability to package these am
plasmids into infectious amplicon viral vectors demonstrated that the functions of essential
viral elements were not disrupted during the cloning procedure.  
 
3.3.10 Analysis of cell cycle-dependent transgene expression in pC8-36 amplicon viral 
vectors 
We next determined if these viral vectors were capable of conferring similar cell
regulatable properties as determined in dGli36 cells transfected with pC8-36 am
plasmids (Figure 3.13).  The dGli36 cells, which overexpressed the exogenous truncated 
mutant EGFR commonly found in human gliomas (Nagane et al., 1996), were employ
our system as these cells were capable of inducing tumor formation in immunodeficient m
more consistently than their parental derived Gli36 cells (unpublished observations).  After 6
h of transfection (Figure 3.13a) or infection (Figure 3.13b) at an MOI of 1.0, similar num
of cells (~50 %) was observed to be GFP positive.  These cells were then replenished with 
either complete medium or treated with lovastatin to induce cell proliferation or G1
respectively.  Using luciferase gene reporter assay, the level of cell cycle regulation was 




transfected cells (6-fold) (Figure 3.13b and 3.13a, respectively).  This result demonstrated that 
cle-regulated transgene 
he cell cycle 
f 1.0 for 6 h.  
as determine 
nt difference was observed 
ction of viral 
36 cells were 
nd to infection 
GalLuc, was 
-arrested cells 
a mixed cell 
  
then expressed as a ratio 
xpression was 
plicon viral 




consequence of more cells being infected with increasing MOI, which may result in a higher 
level of Gal4/NF-YA fusion protein for transactivation to occur.  
pC8-36 amplicon viral vector was capable of conferring cell cy
expression to human glioma cells in vitro. 
 
3.3.11 Effect of transduction of viral vector on the cell cycle profile 
To determine whether infection of the amplicon viral vector will alter t
distribution, dGli36 human glioma cells were infected with pC8-36 at MOI o
Using FACS analysis, the percentage of cells at various stages of cell cycle w
and compared with control uninfected dGli36 cells.  No significa
after transduction with pC8-36 amplicon vector (Figure 3.14); demonstrating infe
vectors does not affect the cell cycling.   
 
3.3.12 Transgene expression is dosage dependent 
To analyze if the cell cycle regulatability is viral dosage dependent, dGli
infected with pC8-36 for 6 h at an MOI of 0.1, 1.0 and 2.0, which correspo
efficiency of 21.62 %, 92.93 % and 97.11 %. The amplicon viral vector, pIH8
used as negative control (as shown in Figure 3.15).  Proliferating or G1
transduced by pC8-36 or control vectors at a specific MOI were analyzed as 
population (consisting of both transduced and non-transduced cells) for luciferase activities.
For comparison purposes, the level of cell cycle regulation is 
between the two different populations of cells.  The ratio of luciferase e
correspondingly increased by 10-fold and 2-fold when the MOI of pC8-36 am
vector was increased from 0.1 to 1.0 and from 1.0 to 2.0 (Figure 3.15).  In contra
was not observed in the negative control.  These data support that the level 
regulated transgene expression mediated by pC8-36 vectors is viral dosage-dependent.  Take







3.3.13 Transgene expression is restricted to proliferating cells in vivo 
he liver is an excellent tissue for the study of growth regulation because of its potent 
regeneration capacity by a process of compensatory growth following surgical resection or 
toxic injury.  Much of the investigation on the mechanisms of hepatic growth has been done 
in PHx animals in vivo and in hepatocytes in primary culture.  Almost immediately after PHx, 
transcription factors are activated, followed by DNA synthesis in vivo in quiescent 
hepatocytes that have become “competent” to proliferation.  Thus, we have chosen the normal 
liver regeneration following PHx as an animal model to study cell cycle-regulated transgene 
expression conferred by pC8-36 amplicon viral vectors in vivo.  Female BALC/c mice were 
separated into three experimental groups consisting of the normal, sham-operated and those 
that underwent PHx.  Following PHx, the resected liver lobes were weighed immediately.  
The kinetics of liver regeneration was monitored closely and it was noticed that the peak of 
the regeneration process occurred at day 2 following PHx (Figure 3.16a) and consisted of 33-
45 % of S phase cells in comparison to 16-18 % in the normal mice group when analyzed by 
FACS analysis (Figure 3.16b, c).  No significant difference in the percentage of S-phase cells 
could be observed in PHx mice injected with either pIH8GalLuc or pC8-36 amplicon viral 
vector (p=0.113), thus indicating that infection with viral vectors does not alter the cell cycle 
distribution in vivo.  On Day 2 post PHx, hepatectomized, sham-operated and normal mice (n 
= 5) were injected with 1x 106 TU of either pC8-36 or pIH8GalLuc amplicon viral vector 
through tail vein.  The animals were sacrificed and luciferase activities were analyzed after 
24h from the harvested liver tissues.  Reporter luciferase activities were found to be 
significantly higher in livers of hepatectomized mice (one way ANOVA, p=0.038) (Figure 
3.17) compared with those of the sham-operated and normal groups.  These data indicated 
that luciferase expression conferred by pC8-36 amplicon viral vector is specifically switched 









 this study, we have engineered a novel HSV-1 amplicon viral vector that incorporates cell 
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n differed in 
cinoma cells, 
exhibited a 3- and 16-fold increase in the luciferase activities in proliferating versus G1-
In
cycle-specific regulatory elements and demonstrated cell cycle-dependent gene re
 
Nettelbeck et al. (1999) described a system whereby transcriptional activation following
DNA-binding takes place in a single step as mentioned earlier (section 3.1.5).  
the cell type-specificity of transgene expression was in the range of 50-fold and the
cell cycle-regulation was approximately 20-fold in melanoma cells.   
 
For the purpose of possible gene therapy, we have attempted to address the que
cell cycle-dependent transgene regulation can be sustained if both the activator and the
reporter modules were subcloned into a single plasmid vector, and whether th
transgene expression via cell cycle event may be affected by the various genetic aberrations in 
cell cycle proteins such as p53, pRb, p16 and EGFR, that are frequently found 
cancer.  Our results demonstrated that a single-vector system based on amp
conferred 4-fold higher luciferase activities than a co-transfection of both plasmid
the activator and the reporter modules (Figure. 3.6).  The level of cell cycle-regulated
transgene expression was further enhanced using a viral based vector system.  Ou
showed that regardless of the origin of tumor cells, a common trend was observed in the
augmentation of the ratio of luciferase activity in proliferating versus growth-arrested cells. 
Although both pC8-36 and pC8-34 amplicon plasmids displayed cell cycl
transgene expression, pC8-36 plasmid exhibited higher cell cycle regulatory potential tha
pC8-34 plasmid (p=0.02), possibly due to the promoter context and positioning in the latter 
construct.  Such transcriptional interference displayed by two promoters arranged in opp
orientations to each other has previously been reported (Eszterhas et al., 2002). 
phenomenon observed in our studies was that the extent of cell cycle regulatio
different cell types.  For example, prostate (PC-3) and cervical (HeLa) car
 90
arrested cells (Figure. 3.9).  This might suggest a possible variation in the transfection 
he 
bility to regulate in a cell cycle-dependent fashion.  Further studies were performed to assess 
8-36 amplicon plasmids 
igure. 3.12a and 3.12b).  The differential transgene expression between G1-arrested and G1-
efficiencies between the two cell lines.  Alternatively, the various genetic aberrations might 
still exert an effect on the extent of regulation but overall, did not appear to abrogate t
a
whether resting cells transfected with pC8-36 amplicon plasmid, on serum stimulation, would 
re-activate the transcription of the luciferase reporter gene.  We have observed that luciferase 
transgene expression increased by approximately 5-fold in G1-released cells in comparison to 
G1-arrested cells in both NIH3T3 and HeLa cells transfected with pC
(F
released cells, though significant, is not as much as that observed between cells in the 
proliferating and G1-arrested stage (15-fold and 35-fold differences in NIH3T3 and HeLa 
cells respectively; Figure. 3.12a and 3.12b).  Our data have shown that transgene expression 
could be regulated in a cell cycle-dependent manner, which would be an important feature of 
our amplicon viral vectors when applied to a clinical setting.   
 
The cDNA of CDF-1 was not isolated.  In fact, several laboratories have attempted to isolate 
the cDNA encoding for CDF-1, but was not successful.  It was suggested that CDF-1 might 
be a complex of proteins instead of a single protein (personal communications).  Therefore, 
we are unable to demonstrate the requirement for CDF-1 using siRNA against CDF-1 or 
CDF-1 null cells, and the effect of overexpression of CDF-1 cDNA in vitro.  However, 
Zwicker et al (1995) generated a series of mutant constructs with point mutation at position 7 
within the CDE region and also alteration of the conserved sequence within the CHR region 
of cyclin A promoter.  The differential luciferase activities between proliferating versus 
arrested NIH3T3 cells conferred by these mutants were almost abolished (ratio of luciferase 
activities between proliferating and arrested cells is 1.8 in both mutant constructs; in construct 
containing wild-type cyclin A promoter, the induction factor is 41.7-fold).  Also, due to the 
unavailability of antibodies generated against CDF-1, we cannot correlate the level of 
transgene expression to the amount of active CDF-1 repressor proteins.  However, two 
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different approaches were adopted to ensure that the increase in luciferase activity is likely to 
be a consequence of the loss of CDF-1 mediated repression in the G1-fraction of the normally 
cycling cell population.  Firstly, G1-arrested HeLa cells were assayed for the presence of 
CDF-1 activity via EMSA (Figure 3.11).  The specific binding of CDF-1 to sequences 
containing CDE/CHR motif correlates to the repressed cell cycle transcription when CDE 
oligomer is included in the co-transfection (Figure 3.10).  In contrast, the failure of random 
oligomer binding to CDF-1 could explain the lack of competition resulting in a similar level 
of cell cycle regulation as the control, pC8-36 (Figure 3.10).  Secondly, we hypothesized that 
if the cell cycle regulation observed in proliferating cells is due to the absence of CDF-1 
proteins binding to CDE/CHR modules within the cyclin A promoter, then by introducing 
more copies of CDE/CHR elements, the extent of cell cycle-regulated luciferase activities 
would increase correspondingly.  Indeed, our results showed that the level of cell cycle-
regulated transgene expression appeared to be dependent on viral dosage (Figure. 3.15).  
There was also no significant change in the cell cycle distribution before and after dGli36 
ells were transduced by pC8-36 amplicon viral vectors, as determined by FACS analysis c
(Figure. 3.14).  These results suggested that the increased luciferase activity in proliferating 
cells are due to a direct action of CDF-1 on the cyclin A promoter rather than a more rapid 
cell cycle progression of G1-arrested cells induced upon viral infection.  At present, we do not 
know if the presence of HSV amplicon viral proteins may interfere with binding of CDF-1 to 
its cognate binding site.  From studies by Zwicker et al. 1999, the expression of SV40 large T 
oncoprotein can dissociate CDF-1 repressor protein from its cognate DNA binding site, 
resulting in a deregulated transgene expression with respect to cell cycle event.  So far, our 
results reflected a tight transgene expression mediated by HSV amplicon virus in a cell cycle-
controllable manner.  Nevertheless, further analysis is required to determine the precise effect 
of HSV viral proteins on CDF-1.  Potential factors that may affect gene expression from HSV 
vectors would be the virion host shut-off function (Read and Frenkel, 1983), a component of 
the HSV virion that has been shown to cause translational shut-off and mRNA degradation of 
the host cells (Smibert et al., 1992).  In addition, immediate early gene products (ICP4, ICP27 
 92
and ICP0) of HSV and the VP16 tegument protein have also been found to interfere with the 
integrity of tetracycline-regulated transgene expression (Herrlinger et al., 2000).
 
In summary, we have demonstrated the feasibility of employing a single viral vector in 
conferring transgene expression in a cell cycle-dependent manner.  It would be of clinical 
importance to evaluate the efficacy of the system using therapeutic transgenes that would 
cause a direct cell killing effect, such as FADD or FasL.  Once the therapeutic efficacy of this 
cell cycle-regulatable HSV-1 amplicon viral vector system is fully characterized, it may serve 

















Apoptosis, also known as programmed cell death, is characterized by the activation of 
cysteine proteases, termed caspases, followed by induction of caspase-mediated cellular 
mechanisms, such as membrane shrinkage, chromatin condensation, and disintegration of 
dead cells into small pieces that can be pha ocytosed (Jäättelä, 2004). Apoptosis can be 
divided into two pathways depending on whether it is triggered by internal or external signals.  
The intrinsic pathway, which is triggered by i
oxidative stress and irradiation (Choi and B ste, 2004).  This pathway involved the 
lease of cytochrome c from the mitochondria and subsequent activation of caspase-3 and 7 
by the formation of apoptosome.  T ay is dependent on external signals 
transduced by surface receptors and ligands binding.  One of the best characterized molecules 
is the tumor necrosis factor (TNF) superfamily of cytokines including Fas ligand (FasL), 
TNF-α, and TNF-related  the 
recruitment of death adaptor proteins, such as Fas-associated protein with a death domain 
(FADD) and TNF-receptor associated death domain (TRADD), to the receptors leading to 
activation of oligomerized pro-caspase 8 (Choi and Benveniste, 2004).   
 
4.1.2 Fas and Fas Ligand 
Fas (CD95/Apo-1) is a type I transmembrane protein that belongs to the TNF receptor 
superfamily (Cosman, 1994). The Fas receptor contains three cysteine-rich extracellular 
domains which function to engage FasL, and an intracellular death domain (DD) that interacts 
with the DD of adaptor proteins to initiate downstream apoptosis signaling.  
 
FasL is a type II membrane protein (Kayagaki et al., 1995; Tanaka et al., 1995). Unlike the 
ubiquitous expression of Fas, FasL is express in activated T cells and natural killer (NK) cells 
of the “immune privileged” organs, such as the eye, the reproductive organs, and the brain 
(Choi and Benveniste, 2004).  In the brain, FasL is expressed in both normal and disease 
g




apoptosis inducing ligand (TRAIL).  Apoptosis is activated by
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states.  For instance, FasL is expressed in astrocytoma cells and in normal glial cells, 
and astrocytes (Saas et al., 1997).  Expression of FasL in tumors has been 
d, caspase 8 cleaves 
id, a proapoptotic member of the Bcl-2 family of proteins, which in turns induced the 
 the mitochondria resulting in the activation of caspase 9 and 
ily of apoptosis 
gulators consists of proapoptotic proteins, as well as antiapoptotic proteins.  Bax, Bak, Bcl-
microglial cells, 
implicated in the promotion of tumor evasion by eliminating host anti-tumor response 
mediated by Fas-positive effector lymphocytes (O'Connell et al., 1996; Shinohara et al., 2000).  
FasL can be cleaved by several metalloproteinases to generate soluble- and membrane-bound 
FasL (Kayagaki et al., 1995; Tanaka et al., 1998), with the latter having higher apoptotic-
inducing effect (Schneider et al., 1998; Suda et al., 1997; Tanaka et al., 1998).   
 
4.1.3 FasL-induced apoptosis 
FasL binding induced the recruitment of FADD to the C-terminus of Fas receptor, leading to 
the establishment of the death-inducing signaling complex (DISC) (Figure 4.1). Clustering of 
FADD to Fas induced the recruitment of pro-caspase 8 to the death effector domain (DED) of 
FADD, resulting in proximity-induced proteolytic processing and autoactivation of pro-
caspase 8.  In type I cells, the activated caspase 8 initiates activation of downstream caspases, 
which eventually leads to the proteolysis of specific protein targets that is central to apoptosis.  
However, in type II cells which are not dependent on surface receptor-ligand interactions, the 
activation of caspase 8 is not sufficient to activate pro-caspase 3.  Instea
B
release of cytochrome c from
Apaf-1, which then activates pro-caspase 3.   
 
The activation and execution of apoptosis by Fas/FasL system is regulated in part by 
members of the Bcl-2 family of apoptosis regulators.  The Bcl-2 fam
re
xs, and Bid are members of the proapoptotic homologues, whereas Bcl-2 and Bcl-xL are 
antiapoptotic (Choi and Benveniste, 2004).  This balance between the proapoptotic and the 
antiapoptotic proteins controls the susceptibility of the cell to apoptosis.  In addition to Bcl-2 


















apoptosis.   
 
4.1.4 Gene therapy using FasL and FADD 
One of the major hurdles in glioma therapy is the acquisition of chemoresistant clones.  Using 
death receptor as a therapeutic agent would circumvent this problem as direct activation of 
caspases would result in cell death. Crosslinking of Fas with anti-Fas antibody has 
shown to induce apoptosis in human glioma cell lines (Kondo et al., 1998; Weller et al., 1994;
Weller et al., 1995).  Ambar et al. (1999) demonstrated that adenoviral mediated transferre
of exogenous FasL into F98-glioma bearing rats prolonged the survival of the animals by
% when compared to the control group.  In addition, Maleniak et al. (2001) showed that 
overexpression of the murine FasL in chemo-resistant primary glioma culture induced the 
cells to undergo apoptosis.  Although the efficacy of FasL in tumor progression has been
demonstrated by several groups, tumors with low or undetectable level of Fas expression ar
found to be resistant to Fas dependent cell death (Hao et al., 2001; Kondo et al., 1998; Welle
et al., 1994).  In addition, tumors that have dysfunctional DISC, arising from low level FADD 
and/or caspase 8 were also found to be resistant to FasL induced cell death. 
 
4.1.5 Aims of this study 
Several reports have indicated that neurons, astrocytes and oligodendrocytes express Fa
receptor, thus are sensitive to Fas-mediated apoptosis.  It is therefore crucial to restrict the 
expression of FasL in tumor tissues to avoid damaging normal brain cells.  Since gliom
very heterogeneous, with different clonal populations within a tumor mass respondi
differently to different therapeutic agents, exposure to more than one therapeutic m
might be advantageous.  
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The aims of this study are as follows: 
(i) To examine the efficacy of the FasL and FADD apoptotic genes in the cell cycle 
regulatable amplicon vector in vitro and in vivo. 
sion of both FasL and FADD genes can enhance (ii) To determine whether co-expres




To construct plified using pHGCX-FasL 
plas
CCCAAGC GCAGCAGCCC-3’ and FasLR; 5’-
CCGGGATCCCGCTCGGTGCCTGTAAC-3’, respectively).  The amplified DNA fragment 
was subcloned into the HindIII and XbaI restriction enzyme sites of 8GalcycA plasmid 
(Nettelbeck et al., 1999).  The 8GalcycAFasL DNA fragment was then subcloned into the 
NheI and BamHI restriction enzyme sites of pHGCX amplicon vector (Figure 3.5a) and the 
pre-existing CMV promoter was subsequently removed using SpeI and NheI to generate 
pIH8GalFasL plasmid.   To construct the cell cycle-regulated FasL vector, pC8-FasL, the 
8GalcycAFasL fragment was amplified by PCR using the primers 8GalF (5'-
CCTCTTCGCTATTACGCC) and 8GalR (5'-AAGAAGACAGTCATAAGTGCGG), 
respectively.  The amplified DNA fragment was subcloned into the shuttle plasmid pGemT-
easy; released using NotI restriction enzyme sites and inserted into pHGCX.GN (Figure 3.5b), 
thus, generating pC8-FasL.   
 
4.2.2 Construction of pIH8GalFADD and pC8FADD 
For the construction of pIH8GalFADD and pC8-FADD amplicon plasmid, the human FADD 
cDNA fragment was PCR amplified from pCIneo-FADD (a kind gift from Dr. MV Clement, 
National University of Singapore, Singapore) using the primers FADD-ORF-F (5’-
AAACCCAAGCTTGGGATGGACCCGTTCCTGGTGCTG-3’) and FADD-ORF-R (5’-
AGCTAGTCTAGACTATCAGGACGCTTCGGAGGTAGA-3’), followed by subcloning 
into the HindIII and XbaI restriction enzyme sites of 8GalcycA plasmid.  Subsequent cloning 
procedures were similar to the construction of pC8-FasL amplicon plasmid vector.  All 
plasmids were amplified in E.coli STBL-2 and DNA was extracted using QIAprep Spin 
Miniprep Kit.  All plasmids were verified by DNA sequencing. 
 Construction of pIH8GalFasL, pC8-FasL 
pIH8GalFasL, the human FasL gene was PCR am
mid as a template (the forward and reverse primers were FasLF; 5’-
TTGGCACCATGGC
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4.2.3 Real time RT-PCR 




malization was performed in each sample by 
ng the copy number of either FasL or FADD to that of 18S rRNA. The relative 
malized value to 1. 
6 
6
intratumorally.  Tumor volume was measured every 3-4 days and calculated according to 





Total RNA was isolated from tumor mass using TRIzol (Inv
method according to manufacturer’s conditions.  One µg of total RNA was used for 1  strand 
cDNA synthesis.  cDNA was synthesized using random hexanucleotide primers (Invitrogen 
Life Technologies) and oligo-dT12-17 primers (Invitrogen Life Technologies), in the presence 
of Superscript II reverse transcriptase (Invitrogen Life Technologies).  The expression level of 
FasL, FADD and the 18S rRNA was quantitated using QuantiTech  SYBR Green PCR kit 
(Qiagen).  The primer sequences for the amplification of FasL were FasL-F376-392 (5’-
GGGCCTGGGGATGTTTC-3’) and FasL-R505-488 (5’-TTTTTCAGGGGGTGGACT-3’); 
for FADD: FADD-F271-287 (5’-GCGCCTGGGGAAGAAGA-3’) and FADD-R414-396 (5’-
TGTCAGGTTGCGGGGGTAT-3’).  For the amplification of 18S rRNA, the following 
primers were used, 18S-F (5’-CCTGCGGCTTAATTTGACTC-3’) and 18S-R (5’-
CGCTGAGCCAGTCAGTGTAG-3’).  All PCR reactions were performed in duplicate.  
Standard curves for FasL, FADD and 18S rRNA were generated independently.  The relative
copy number of each sample was calculated according to the corresponding standard curve 
using RotorGene version 4.6 software. Nor
dividi
expression levels were calculated by arbitrarily designating the lowest nor
 
4.2.4 In vivo transduction 
Four groups (n=6) of 6-8 weeks old CB-17 SCID mice were inoculated with 2 x 10 dGli36-
SCID8 cells to form s.c. tumor.  A total of 2 x 10  TU of viral vectors were administered 
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4.2.5 Statistical analysis 
Data are presented throughout this study as means + standard error of the mean.  Statistical 
significance in the in vitro experiments was evaluated by unpaired t-test, p < 0.05 was 
considered significant.  In the in vivo experiments, statistical significance was evaluated by 
one-way ANOVA, p< 0.05 was considered significant.  
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4.3 Results 
4.3.1 Construction of a cell cycle-regulatable HSV-1 amplicon viral vector that contains the 
human FasL and FADD gene 
We have previously constructed a HSV-1 amplicon vector, pC8-36, whereby the transgene 
expression can be regulated in a proliferation-dependent manner (Chapter 3).  To determine 
whether the transcriptional activation mediated by the minimal cyclin A promoter is sufficient 
to elicit a biological response, the luciferase gene is replaced by either FasL (pC8-FasL, 
Figure 4.2b) or FADD (pC8-FADD, Figure 4.2d).   In addition, we have also constructed the 
basic constructs, pIH8GalFasL (Figure 4.2a) and pIH8GalFADD (Figure 4.2c), which contain 
the minimal cyclin A promoter driving either the FasL or the FADD gene, respectively.  
Further descriptions of the cloning strategies can be found in section 4.2.1 and 4.2.2. 
 
4.3.2 Cell death induced by FasL is regulated in a cell cycle-dependent manner 
Recent publications suggested that FADD gene transfer may induce cell death regardless of 
the expression of Fas/APO-1 in the target cells (Juo et al., 1998; Kondo et al., 1998).  To 
confirm if this is true in dGli36 human glioma cells, the human FADD cDNA was also 
employed to induce apoptosis.  Similar experiments were performed for each of the 
therapeutic genes and results relating to FasL will first be discussed.  
 
To determine if apoptosis mediated by FasL gene expression can be restricted to proliferating 
cells, dGli36 human glioma cell line was infected with pC8-FasL and the control vector, 
pIH8GaLFasL at MOI of 1.0.  After 6 h of infection, the cells were replenished with fresh 
medium containing 10 % serum to induce proliferation or treated with medium containing 1 
% serum with 50 µM of lovastatin to induce G1-arrest, which decreased the percentage of S 
phase cells from approximately 52.8 % to 6.51 %.  To determine the level of cell death 
induced by FasL expression, cytotoxicity assay was performed in dGli36 cells infected with 




Approximately 41.2 % cell death was detected in proliferating dGli36 cells infected with pC8-
 (p=0.032; 
1-arested 







and pC8-FasL.  
ll death was 
 
 of FasL is 
FasL, which was 10-fold higher than that of the G1-arrested population (4.2 %)
Figure 4.3a).  In contrast, cell death was not observed in both proliferating and G
populations infected with pIH8GalFasL.  Using TUNEL assay, pyknotic nuc
evident in proliferating cells overexpressing FasL and absent in G1-arrested
(Figure 4.3b).  In comparison to pC8-FasL-transduced cells, apoptotic cell death was n
detected in proliferating and G1-arrested cells infected with pIH8GaLFasL.  These results thus
suggest that cell death mediated by pC8-FasL is dependent on proliferation. 
 
4.3.2.1 Conditioned medium harvested from FasL transduced cells induces apoptosis 
It is worth noting that some of the non-infected cells (as determined by the absence of GFP) 
were also TUNEL positive (Figure 4.4a), indicating that FasL might induced bystander effect
in non-transduced cells.  To determine whether conditioned medium harvested from
transduced cells induces apoptosis, supernatant from both proliferating cells and G
cells were collected after 72 h of infection with pHGCX-FasL, pIH8GalFasL, 
Conditioned medium was then added to dGli36 cells and the percentage of apoptosis-induced 
was analyzed after 72 h.  Approximately 40 % apoptosis was observed when dGli36 cells 
were treated with conditioned medium harvested from proliferating pHGCX-FasL-transduced 
cells (Figure 4.4b).  Similar percentage of cell death was also observed in cells treated with 
conditioned medium harvested from G1-arrested cells.  In contrast, minimal ce
observed in cells treated with pIH8GalFasL, thus confirming the lack of FasL expression 
from this control vector (Figure 4.4b).  Approximately 38 % cell death was also observed in
cells treated with conditioned medium harvested form pC8-FasL-transduced proliferating 
cells (p=0.002; Figure 4.4b).  This data thus confirmed that the expression








4.3.3 Cell death induced by pC8-FADD is also cell cycle-dependent 
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 and FADD 
are able to enhance the apoptotic index, dGli36 cells were infected with (i) pC8-36, (ii) pC8- 
Next, the level of cell death induced by pC8-FADD was also determined in dGli36 cells using
trypan blue exclusion assay.  Twenty two percent cell death was observed in the proliferating 
population in comparison to 4 % in the G1-arrested population (p=0.019; Figu
contrast, minimal apoptosis was detected in the both proliferating and G1
infected with the control vector, pIH8GalFADD (Figure 4.5a).  Similar to FasL, TUNEL 
positive cells were only detectable in proliferating cells infected with pC8-FADD (Figure 
4.5b), while the G1-arrested cells and the control cells did not exhibit any fluore
results thus suggested that FasL and FADD gene expression mediated by the cell cy
regulated HSV-1 amplicon vector was controlled in a proliferation dependent manner. 
 
4.3.4 Expression of FasL and FADD are correlated to cell cycling events 
To correlate the level of protein expression with the degree of cell death induced by FasL or 
FADD overexpression, cellular extracts were harvested from FasL- and FADD-transduc
cells and analyzed using ELISA.  FasL expression in the pC8-FasL-infected
population is 4-fold higher than the corresponding G1-arrested cells (Figure 4.6a).  The
increase in FasL expression observed in the G1-arrested population and the 
infected cells could be due to the combined effect of serum and lovastatin, wh
reported to induce apoptosis in some glioma cells (Jiang et al., 2004; Schmidt et al., 20
The level of FADD expression in pC8-FADD-transduced proliferating dGli36 cells w
fold higher than that of the G1-arrested cells and 5-fold higher than the control (F
Collectively, these data indicate that the level of expression of FasL and FADD is regulated i
a cell cycle-dependent manner, which correlates with their apoptotic-inducing activity.
 
4.3.5 Co-expression of FasL and FADD enhanced apoptosis 
The effect of FasL and FADD overexpression in FasL-sensitive dGli36 cells have be





FasL, (iii) pC8-FADD, and (iv) 1:1 ratio of pC8-FasL and pC8-FADD at MOI of 1.0 for 6 h.  
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The infected cells were either allowed to proliferate or induced to arrest
percentage of apoptosis induced by either pC8-FasL or pC8-FADD in proliferating dGli36 
cells was approximately 40 % and 30 %, respectively (Figure 4.7a).  Th
cytotoxicity in the corresponding G1-arrested cells was comparab
control (12.49 %).  When dGli36 cells were co-infected with pC8-FasL and pC8-FADD, the
percentage of apoptosis increased by 20 % with respect to pC8-FasL and 30% with respect to
pC8-FADD (Figure 4.7a).  Cytotoxicity observed in these co-trans
FADD) proliferating cells was significantly higher (60 %, p=0.04) than the corre
arrested cells (10 %).   
 
This effect of FasL and FADD were also tested on U373MG.  In comp
U373MG was not sensitive to pC8-FasL-induced cell death (Figure 4.7b).  However, 
approximately 20 % of apoptosis could be observed when FADD was overexpr
4.7b).  Interestingly, the percentage of cell death was greatly enhanced when 
co-infected with pC8-FasL and pC8-FADD (Figure 4.7b).  The percentage of ap
co-infected cells was 38 % higher than pC8-FasL-infected (1.5 %) cells and 11 %
pC8-FADD-infected (19.9 %) cells.  The lack of sensitivity of U373MG to FasL-induced cell 
death could be attributed to the absence of functional DISC com
downregulation of the Fas receptor, FADD and caspase 8 proteins.  Analys
extracts obtained from U373MG and dGli36 cells indicated that FADD and 
present in both cell lines (Figure 4.7c).  However, the level of Fas receptor e
only detectable in dGli36, and absent in U373MG (Figure 4.7c).  
of sensitivity to FasL-induced cell death in U373MG is due to the absence of or low level of 
Fas receptor.  These results also suggested that the over-expression of




4.3.6 Expression profile of FasL and FADD  
  The injection 
8-FADD viral 
nistration of the 
nt because this cell 
 
osis, and has more 
or volume 
plantation of 
ID8 cells were 
10 days, 
al ratio 
ster the viral 
rs were injected with 
with both pC8-
DD construct 
and p< 0.01, 
e ranges between 2 
mm  and 19 mm , with 2 out of 5 animals completely devoid of any detectable tumor mass.  
The effect of pC8-FADD expression in dGli36-SCID8 tumor was comparatively weaker than  
The apoptotic effect of pC8-FasL and pC8-FADD was also examined in vivo.
regime was predetermined in vitro according to the kinetics of FasL and FADD expression at 
various time points following infection with either pC8-FasL or pC8-FADD.  Expression of 
FasL peaked on day 10 post-infection (Figure 4.8a), while the level of FADD expression 
peaked on day 3 (Figure 4.8b).  Thus, repeated injection of pC8-FasL and pC
vectors will be administered every 10 days and 3 days respectively.  The admi
control vector will follow the injection regime of FasL, i.e. every 10 days.   
 
4.3.7 FasL and FADD gene delivery in vivo suppresses tumor growth  
dGli36-SCID8 (refer section 2.2.8.3) was used for the in vivo experime
line consistently forms s.c. tumor in immunodeficient SCID mice.  Similar to dGli36 cells,
this derivative is also sensitive to FasL- and FADD-induced apopt
aggressive tumor growth kinetics in immunodeficient mice (data not shown).  Tum
of 121 mm3 (average of five animals) consistently formed at day three post im
dGli36-SCID8 cells into the flanks of SCID mice.  When 1 x 106 of dGli36-SC
intracranially implanted into immunoincompetent mice, the animals died within 
three times faster than its parental dGli36 cells.  In an attempt to ensure an optim
between therapeutic vectors against tumor cells, we have chosen to admini
vectors the next day following tumor cells implantation.   Palpable tumo
2 x 106 TU of (i) pC8-36, (ii) pC8-FasL, and (iii) pC8-FADD viral vectors.  To investigate the 
combine effect of FasL and FADD in vivo, dGli36 tumors were also injected 
FasL and pC8-FADD (iv) viral vectors at a 1:1 ratio.  Tumor volume was documented every 
3-4 days. The tumor volume in animals treated with either pC8-FasL or pC8-FA
was significantly smaller than those in the control vector group (p < 0.001 








pC8-FasL, with tumor volume averages around 25 mm3 (range, 2 mm3 to 85 mm3), with 2 out 
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of 5 mice tumor free.  Interestingly, effective suppression of tumor growth was 
mice co-injected with pC8-FasL and pC8-FADD.  In comparison to other groups of m
mice in this treatment group were tumor free (Figure 4.9).  During the early stages of the
experiment, we noticed that tumor mass in this group of mice were consistentl
(range, approximately 0.77 mm3 to 4.21 mm3) than any of the treatment grou
that co-expression of both FasL and FADD effectively enhanced the apoptotic
xenografts, thus preventing tumor growth.  Although considerable differences 
in the tumor volume among the treatment groups, this difference is not statistically
 
 4.3.8 Suppression of tumor growth is mediated by overexpression of exogenous Fas 
FADD 
To confirm that overexpression of FasL and FADD resulted in the suppression of tum
growth observed in all the animals, real time RT-PCR was performed on the 
(harvested at the end of the experiment from one extra mouse that contains palpable tum
quantitate the level of exogenous FasL and FADD mRNA expressions.  As me
in the Methods section 4.2.3, all samples were normalized to that of 18S rRNA. 
the differential mRNA expressions were expressed as a ratio between tumors
therapeutic vectors or control tumors injected with the backbone vectors.  As sh
4.10, the mRNA level of FasL in tumor injected with pC8-FasL was 5-fold higher than those 
injected with the control vector.  Interestingly, co-infection of pC8-FADD and 
resulted in 20-fold increase in the FasL mRNA activities in comparison to the c
Similarly, the level of FADD mRNA was also higher in tumors that were co
FasL and FADD (2.2-fold higher than control) compared with FADD alone (0.62-fold highe
than control).  The level of FasL or FADD mRNA expression correlates with the 
of tumor growth, such that the tumor volume in mice co-injected with FasL and FADD is the





these results demonstrated that therapeutic gene expression mediated by the cell cycle-
gulated vector suppresses tumor formation in vivo.  re
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4.4 Discussion 
In this study, we incorporated the FasL and FADD gene into the cell cycle-regulated 
amplicon vector and demonstrated that the expression and function of these genes can be 
regulated according to cell cycling event.   
 
The proapoptotic activity of FasL was analyzed in U373MG and dGli36 human glioma cells.  
Overexpression of FasL induced cell death in dGli36 cells, whereas U373MG is resistant to 
FasL expression (Figure 4.7).  Most human glioma cells express Fas receptor and thus are 
sensitive to FasL-induced cell death.  However, some glioma cells acquire mechanisms, such 
as the loss or downregulation of the Fas receptor expression, to evade Fas/FasL mediated cell 
death.  Other possible mechanisms include mutations in the gene encoding the Fas receptor 
resulting in the failure of the receptor to be externalized (Karlsson et al., 2004); the presence 
of the soluble receptor that lack the transmembrane domain (sFas) (Cascino et al., 1996); 
present of the soluble decoy receptor DcR3 that binds to FasL (Roth et al., 2001); and the lack 
of FADD or caspase 8 (Karlsson et al., 2004).  Using western blot analysis, we found that the 
expression level of the Fas receptor in U373MG is relatively low, although it expresses both 
pro-caspase 8 and FADD.  This suggests that a functional Fas receptor is essential for the 
activation of apoptosis. 
 
It has been reported that overexpression of the adaptor protein, FADD, induces apoptosis in 
FasL-insensitive cells (Chinnaiyan et al., 1995; Chinnaiyan et al., 1996; Grimm et al., 1996). 
However the effect of FADD overexpression on glioma cell lines has been controversial.  
Kondo et al. (1998) and Hao et al. (2001) reported that overexpression of FADD induces 
apoptosis in U373MG, while Knight et al. (2001) reported that enforced expression of FADD 
did not sensitize this cell to FasL-induced cell death.  In our study, we observed an increase in 
the percentage of cell death in pC8-FADD-transduced U373MG when compared with the 
control vector (Figure 4.7b).  Moreover, the percentage of apoptosis in U373MG increased by 
approximately 40 % when both FasL and FADD were co-expressed (Figure 4.7b).  In contrast, 
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the effect of FasL and FADD co-expression in dGli36 cells is not as significant.  It is possible 
 a role in dGli36 cells which already express high 
vel of Fas receptor.  At present, we do not know what factors contribute to the tremendous 
owell et al., 1999; Schneider et al., 1998; Tanaka et al., 1998).  The 
poptosis observed in non-infected cells could be due to the binding of the oligomerized 
that both molecules might synergistically enhanced apoptosis in U373MG (Figure 4.7b), 
while additively in dGli36 cells (Figure 4.7a).  Alternatively, it is possible that the presence of 
exogenous FADD does not play that much
le
enhancement observed in one glioma cell line (U373MG) but not the other (dGli36).  
However, we speculate that the different genetic profile of glioma cell lines, with different 
levels of pro-apoptotic or anti-apoptotic molecules, might play a role in this difference. 
 
We noticed that a fraction of the TUNEL positive cells were not GFP positive, indicating that 
these cells were not transduced by our viral vectors (Figure 4.4a).  We hypothesize that the 
cell death observed in non-transduced cells could be due to the binding of secreted soluble 
FasL to Fas receptor.  This observation is confirmed when conditioned medium harvested 
from FasL-transduced proliferating cells induced apoptosis while those from the G1-arrested 
cells do not (Figure 4.4b).  FasL is processed by several metalloproteinases to yield both a 
soluble form and a membrane-associated form. It has been widely reported that FasL induce 
“bystander effect” in untransduced cells, possibly through the action of the soluble form. 
(Kayagaki et al., 1995; P
a
soluble FasL to the Fas receptor on untransduced cells.     
 
The effect of FasL and FADD expression was examined in immunodeficient mice harboring 
s.c. dGli36-SCID8 glioma xenografts.  We observed that 2 out of 5 animals injected with 
either pC8-FasL or pC8-FADD were completely devoid of tumor.  These results indicated 
that FasL and FADD gene expression mediated by this cell cycle-regulated vector is able to 
suppress tumor growth in vivo.  Sandler VM et al (2002) have recently demonstrated that 
HSV-1 amplicon vectors expressing enhanced green fluorescent protein (EGFP) can reliably 
infect neurons after it is injected into cortex, striatum and thalamus in rats, producing 
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sufficient numbers of infected neurons for electrophysiological experiments in acute brain 
slices. Expression of eGFP delivered by these HSV-1 amplicon viruses was detected for up to 
5 weeks post-infection.  Therefore the lack of complete regression of tumors is unlikely to be 
due to the instability of the amplicon DNA.  Complete regression of tumors was not observed 
possibly due to the following reasons; firstly, the expression pattern of FasL and FADD were 
determined in vitro, which might not truly represent the in vivo condition.  Secondly, the 
expression of the therapeutic genes is strictly dependent on cell division.  It is possible that 
the expression of FasL was not activated due to the absence of proliferating cells in the 
jected region. In comparison to FasL or FADD alone, all mice injected with pC8-FasL/pC8-
umor cells completely resulting in 
currences in majority of patients.  Our vector can be employed as adjuvant therapy to 
in
FADD were tumor free.  However, the differences in tumor volume among each treatment 
group are not statistically significant.  We speculate that in order to detect a statistically 
significant difference among each treatment group, we might have to use other glioma cells 
rather than dGli36.  The presence of a functional Fas receptor in dGli36 cells might have 
masked the effect of the overexpression of both FasL and FADD.  Instead, in U373MG, 
which lacks the Fas receptor, the effect might be more apparent, as demonstrated in the in 
vitro experiments (Figure 4.7b).   
 
In summary, our study showed that FasL- or FADD-induced apoptosis in the cell cycle-
regulated amplicon vector is activated specifically in proliferating cells in vitro and in vivo.  
Current combined treatment for glioma fails to remove t
re
complement surgery whereby the viral vectors can be injected directly into the tumor bed; this 
ensures that the transcription of the therapeutic gene is activated when the residual tumor cells 
start to proliferate.  Since gliomas are very heterogeneous, the delivery of more than one 













Strategies for targeting therapeutic gene expression to glioma cells 
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5.1 Background 
ack of tumor specificity is a recurring problem in current gene therapy protocols.  It is 
rucial to target therapeutic agents specifically to tumor cells in order to minimize damages to 
ealthy tissues.  This is especially important in the gene therapy for GBM since it has the 
ndency to invade into surrounding brain tissues, thus rendering complete surgical removal 
ractically impossible.  One way to overcome this difficulty is to design strategies that 
cilitate the expression of therapeutic genes specifically in glioma cells. 
wo different approaches of targeting gene expression specifically to glioma cells will be 
resented in this chapter. Targeting can be achieved at the level of gene expression by the 
incorporation of tissue-specific transc nts or during gene delivery by the 
modification of the gene delivery vectors.    
 
5.1.1 Transcriptional 
One of the factors that influence the stability of transgene expression is the type of promoter 
used.  Ubiquitous promoters such as CMV are frequently employed to drive therapeutic gene 
expression due to their high level of activity (Cooper, 2001).  However, gradual inactivation 
of the ubiquitous viral promoters often results in the silencing of transgene expression in vivo. 
CMV-driven EGFP expression has been shown to decrease rapidly with time in cycling 
hepatocarcinoma cell lines (Gerolami et al., 2000). To overcome this problem, tissue-
specific promoters have been adopted to restrict gene expression to selected cell populations 
(Shibata et al., 2000; Ueno et al., 2001).  However, tissue-specific promoters may also be 
active in normal cells (Vandier et al., 1998).  For instance, the used of the glial fibrillary 
acidic protein (GFAP) promoter to drive cytotoxic gene expression in glioma cells might 
result in unwanted toxicity in normal brain tissues (Vandier et al., 1998).  These could be 
overcome by incorporating the GFAP promoter into the cell cycle-regulated vector described 














GFAP, which was first identified in patients with multiple sclerosis (Eng et al., 1971), is the 
most frequently used marker for glial cells.  It is a major component of the intermediate 
filaments in the brain, and is expressed exclusively in cells of glial origin (Eng, 1985).  GFAP 
is also responsible for modulating the shape and the stability of astrocytes (Eng et al., 2000).  
Elevated level of GFAP is detected during reactive gliosis resulting from injury or trauma to 
the brain (Eddleston and Mucke, 1993).  Several studies have shown negative correlation 
etween the level of GFAP expression and the proliferation state of the astrocytes.  Increased 
as higher when compared with that from the 
ildtype mice.   
scriptional 
start site.  This study demonstrated that GFAP enhancer element was able to direct gene 
b
level of GFAP has been correlated with changes in proliferation (Rutka et al., 1994), in 
extension of cellular processes (Rutka and Smith, 1993), and anchorage-independent growth 
(Rutka et al., 1994).  Pekny et al (1998) demonstrated that the proliferation rate of primary 
astrocytes harvested form GFAP-/- mice w
w
 
5.1.1.2 GFAP promoter for transgene regulation 
The regulatory region controlling the expression of the GFAP gene has been mapped to 
sequences 1.8 kb upstream of the transcriptional start site.  Positive regulatory regions for the 
GFAP gene exist between -250 and -80 bp as well as between -1980 and -1500 bp upstream 
of the transcriptional start site (Besnard et al., 1991; Eng et al., 2000).  The human GFAP 
promoter consensus sequence (hgcs), which confers glial cell specificity, is mapped to the 
positive regulatory regions of the GFAP promoter (Besnard et al., 1991; Masood et al., 1993; 
Rutka et al., 1997).  Although the expression of GFAP is repressed in most GBM due to the 
methylation of the GFAP promoter, GFAP-negative glial cells nonetheless allow in functional 
GFAP promoter activities (Fukuyama et al., 1996).  In 1998, Chen et al. incorporated three 
tandem-repeats of the GFAP enhancer element coupled to a tetracycline transactivator into an 
Ad vector to drive lacZ expression in glioma cells. This glial-specific enhancer element is 
located within the positive regulatory region (-1753 to -1489) upstream of the tran
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expression in cells of glial origins. LacZ expression was detectable not only in GFAP-
bine cell type-specific promoters with inducible expression have been 
eveloped to augment the activity of the transcriptionally weak GFAP promoter (Besnard et 
al. (2000) inserted the tet-off transactivator 
expressing glioma cells (U373 MG and U343 MG), but also in GFAP-negative glioma 
(T98G), medulloblastoma (DAOY) and neuroblastoma (SHEP, LAN-5, KCNR) cells (Chen 
et al., 1998).  In contrast, lacZ expression was not observed in non-glial derived IMR90 
fibroblasts (Chen et al., 1998).     
 
Furthermore, the GFAP promoter was shown to confer gene expression particularly to 
astrocytic cells in transgenic mice (Brenner et al., 1994; Eng et al., 2000).  When incorporated 
into Ad (Smith-Arica et al., 2000; Vandier et al., 2000), retrovirus vectors (Cortez et al., 
2000), and lentivirus (Jakobsson et al., 2003), the GFAP promoter confers glial-cell specific 




al., 1991). To enhance promoter strength, Ralph et 
(tTA) under the control of the GFAP promoter into an Ad vector system.  Infection of primary 
hippocampal cultures demonstrated specific transgene expression in glial cell populations.  
Moreover, when the Ad-GFAP vector was delivered into adult rat hippocampus, it showed a 
similar pattern of glial cell specific expression (Ralph et al., 2000).  McKie et al. (1998) 
further demonstrated astrocyte-specific gene expression mediated by GFAP-lacZ in a HSV-1 
vector.  To study the functions of astrocytes in the developing brain, Delaney et al. (1996) 
expressed the HSV-tk gene under the GFAP promoter in a HSV-1 vector.  LacZ expression 
driven by the GFAP promoter has also been used to study the fate of astrocytes in embryonic 
neural grafts (Quintana et al., 1998).  Gene therapy using FasL for systemic treatment of 
cancer is greatly hampered by the inherent toxicity to non-target FasL-positive cells.  Several 
groups have constructed vectors that limit the expression of FasL in vivo by the incorporation 
of tissue-specific promoters, such as GFAP, smooth muscle-specific promoter, and prostate-
specific promoter (Aoki et al., 2000; Morelli et al., 1999; Rubinchik et al, 2001).   
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5.1.1.3 One step closer to clinical trials 
5.1.1.3.1 Effect of chemotherapy on the cell cycle-regulated amplicon vector 
Chemotherapy is a well-established treatment for gliomas (Stewart, 2002). Chemotherapy can 
be used as a primary treatment regime, or as a post-operative treatment together with 
radiotherapy.  The most commonly used chemotherapeutic drugs for the treatment of glioma 
re procarbazine, CCNU (lomustine), and vincristine (PCV) (Newlands et al., 2003).  The 
t al., 2004a; Chang et al., 2004b; Yamini et al., 2004; Yung et al., 
000; Yung et al., 1999).  TMZ is an alkylating agent that acts by methylating DNA at the N7 
a
effect of these agents on survival is limited and the responses to these drugs were short-lived 
(Georges et al., 1988; Rodriguez and Levin, 1987; Sandberg-Wollheim et al., 1991; Stewart, 
2002).  Moreover, these drugs cause damage to the bone marrow of patients.  A low toxicity 
drug, temozolomide (TMZ), has been employed as an alternative for the treatment of 
recurrent gliomas (Chang e
2
and O6 site on guanine and the O3 site on adenine.  The modification at O6 sites leads to the 
insertion of thymine residue instead of cytosine opposite the methylguanine during DNA 
replication, thus leading to cell death (Clark et al., 1995; Takemoto et al., 2003).  
Chemotherapeutic drugs such as TMZ have been reported to arrest cells at G2/M of the cell 
cycle (Hirose et al., 2001; 2004).  It would therefore be important to determine whether 
transgene expression mediated by the cell cycle-regulated amplicon would be affected in 
TMZ-treated cells. 
 
5.1.1.3.2 Stability of HSV-1 amplicon 
For successful gene delivery in vivo, the gene delivery vehicle must be stable to confer 
reliable gene expression. The HSV-1 amplicon DNA is relatively stable in nondividing cells, 
but is lost after a few cell divisions (Johnston et al., 1997).  Fraefel et al. (1996) demonstrated 
that the viral DNA can be detected for at least 1 month in the midbrain and striatum.  In HSV-
1 vector bearing the rat tyrosine hydroxylase (TH) promoter driving the lacZ reporter gene, 
lacZ expression can be detected up to 2 months in the substantia nigra pars compacta (Wang 
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et al., 1999).  To overcome the problems associated with gene delivery, improvement in 
Gene delivery to the brain presents unique challenges due to the limited and risky access to 
the brain, the sensitivity to volumetric changes, and the difficulty of accessing the BBB and 
blood-tumor barrier (BTB) (Constantini et al., 2000; Lam and Breakefield, 2001).  Most gene 
delivery to the brain involved direct stereotactic injections with restricted number of 
injections and volume.  By this route of delivery, the vector is only taken up by cells in the 
immediate vicinity of the injection site.  Spread of virus to other sites can be facilitated by 
slower injection rates, but still, not comprehensive.  Other modes of administrations include 
the generations of vectors in situ by implantation of retrovirus packaging cells to produce 
viral particles which will infect residual dividing cells (Short et al., 1990) and the passage of 
vectors through the BBB and BTB by intra-arterial, intrathecal or intraventricular routes of 
injection (Constantini et al., 2000). 
 
Despite promising preclinical efficacy of HSV-tk/GCV system, engraftment of retroviral 
producer cells harboring HSV-tk to GBM patients did not produce therapeutic benefits in a 
phase III clinical trial (Rainov, 2000).  The elements of the Epstein Barr virus (EBV), 
Epstein-Barr nuclear antigen 1 (EBNA-1) can confer episomal replication and retention, thus 
increase transgene stability.  Hampl et al. (2003) demonstrated higher transgene expression in 
prolonging transgene expression in vivo needs to be explored. 
 
5.1.1.3.3 Transduction efficiency of HSV-1 amplicon vector 
Although promising results for the delivery of therapeutic agents to tumor cells have been 
reported in vitro and in vivo, the lack of widespread specific vector distribution is one of the 
major limitations for successful gene therapy.  Even with the use of a prodrug activating 
system which has a potent bystander effect, such as the HSV-tk/GCV system or the CD/5-FC 
system, only 2 % of the tumor cells in the tumor mass are effectively transduced (Huber et al., 
1994).   
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tumors when tumor cells were converted into retrovirus producer cells by a HSV/ EBV/RV 
tribrid amplicon vector.  Other methods to increase transgene delivery include multiple-sites 
jections (Qureshi et al., 2000); use of replication competent vectors (Martuza, 1991); 
) and transport across the tumor 
t critical issue in the development of a gene delivery vector system is the potential 
adverse effect to patients.  This issue has been brought into attention by the death of a patient 
after hepatic-arterial infusion during a gene therapy protocol for ornithine transcarbomylase 
(OTC) deficiency whereby the patient reacted to a massive immune response elicited by the 
Ad vector (Hsich et al., 2002; Verma, 2000).   
 
The transduction of cells by gene transfer vectors involves the interaction of the vectors with 
the host immune system.  This introduction of foreign gene products is often compared to 
microbial infection, in which the host first line of defense, i.e. innate immune response is 
activated.  Thus, in both naive and immunized individuals infected with wild-type HSV-1 
vectors, the complement cascade and macrophages are activated; NK cells, dendritic 
precursors, γδ T cells are recruited, activated and matured; also, chemokines and cytokines 
are generated and secreted (Chen et al., 2003; Wakimoto et al., 2003).  Together, these 
molecules coordinate the lysis of virions and virus-infected cells, and also provide a link to 
effective adaptive immunity (Medzhitov and Janeway Jr, 1997; Wakimoto et al., 2003).  
Immune responses elicited by recombinant HSV-1 vectors can arise from the viral particle 
components, expression of viral gene products, cellular debris, and transgene expression 
(Bowers et al., 2003), with viral gene products as the major source of immunogenic antigens.  
Recombinant HSV-1 retains the ability to enter into latency phase in non-dividing cells, 
in
protease digestion of the extracellular matrix (Kuriyama, 2000
vasculature (Nilaver et al., 1995; Rainov et al., 1995).  However, all these methods lack 
demonstratable benefits in clinical trials, thus, indicating a need to improve gene delivery 
modalities. 
 
5.1.1.3.4 Immunogenicity of HSV-1 amplicon 
The mos
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where expression of viral genes except for the LAT is switch-off.  To prevent reactivation 
from latency, multiple immediate early gene products that encode for transactivators, for 
instance ICP0 and ICP4 are mutated or deleted (Krisky et al., 1998).   
 
The amplicon plasmids are dependent upon helper virus function to provide the essential 
replication machineries and structural proteins required for packaging into viral particles 
(Spaete and Frenkel, 1982).  These helper viruses are similar to the recombinant HSV-1 
ectors in that they retain majority of the HSV-1 genome.  Therefore, the final stock of the 
re of varying ratios of helper and amplicon 
ki et al., 2001; Saeki et al., 1998; Stavropoulos 
nd Strathdee, 1998).  This packaging system produces HSV-1 viruses that are virtually free 
v
helper virus-based packaging contains a mixtu
viral particles.  Viral genomes from the helper viruses induce the activation of immune 
responses.  Preferential purification of the amplicon vector from the helper virus is not 
possible since the physical properties of both entities are essentially similar (Olschowka et al., 
2003). A recent improvement to the amplicon system is the development of the helper virus-
free packaging system (Fraefel et al., 1996; Sae
a
from contaminating helper viruses with minimum toxicity or antigenicity (Constantini et al., 
2000).   
 
Olschowka et al. (2003) compared the induction of immune response in C57Bl/6 mice 
injected with HSV-1 amplicon viral vectors carrying lacZ gene (HSVlac), which were 
packaged using either the helper virus-dependent or the helper virus-free system.  All 
injections including saline controls induced inflammation on day 1, indicating an activation of 
inflammatory responses due to the transient breach of the BBB.  However, on day 5 post-
inoculation, mRNA levels of the proinflammatory cytokines, chemokines and ICAM-1 
adhesion molecules in helper virus-free amplicon groups were similar to saline-injected mice.  
In contrast, mice injected with helper virus-packaged HSVlac showed persistent elevated 
level of proinflammatory cytokines, chemokines and ICAM-1 adhesion molecules 
(Olschowka et al., 2003).  This study demonstrates that helper virus-free amplicon 
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preparations exhibit a safer innate immune response profile, presumably as a result of the 
absence of helper virus gene expression.  
 
Majority of humans are seropositive for HSV-1 (Baringer and Swoveland, 1973; Corey and 
ing antibodies to HSV-1.   
Spear, 1986; Herrlinger et al., 1998).  The presence of pre-existing antibodies is a concern in 
HSV-1 mediated gene therapy protocols.  Neutralizing antibodies could prematurely eliminate 
the viral vectors, which could potentially inhibit the infection of target cells or even result in 
the elimination of transduced cells.  The influence of pre-existing anti-HSV-1 immunity on 
HSV-1 vector-mediated transfer of transgenes such as HSV-tk or lacZ gene was studied in 
intracranial rat gliomas with and without prior immunization to HSV-1 (Herrlinger et al., 
1998).   Although the number of HSV-tk- and lacZ-positive cells was reduced in pre-
immunized animals compared with non-immunized animals, the duration of transgene 
expression was similar between the two groups of animals.  Further, there was no apparent 
increase in neurotoxicity caused by the inflammatory response within the brain associated 
with a pre-existing anti-HSV-1 immune response.  These findings support the potential utility 
of recombinant HSV-1 vectors in treatment of brain tumors in humans who have circulating 
neutraliz
 
5.1.2 Vector retargeting 
Stereotactic injection of vectors to the brain is limited by the volume and number of injections. 
The ability to target gene delivery vector would enhance the safety profile of the vector.  
Identification of molecules that mediate the targeted delivery of therapeutic DNA or drugs to 
specific cell types would thus significantly reduce the amount of therapeutic agents required, 
and correspondingly, reduce unwanted toxicity to non-target cells. 
  
There has been much progress in the field of vector targeting using different vector systems.  
Wu and Wu (1987) was the first to report the use of the glycoprotein asialoorosomucoid 
(ASOR) to specifically target the liver parenchyma.  Retroviral vectors have been modified to 
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contain a chimeric envelope to target to breast cancer cells (Tai et al., 2003).  As mentioned 
earlier in the introduction section, EGFR is frequently amplified or mutated in GBM, thus 
roducing a constitutively active receptor in the absence of the EGF ligand (Mischel and 
olecules would greatly facilitate the targeted delivery of 
erapeutic agents.  Biopanning of the phage display library was employed to select for 
for human glioma cells.  Phage display techniques have been used 
p et al., 1998; Barry et al., 
96; Koivunen et al., 1999; Pasqualini et al., 2000; White et al., 2001), and human colorectal 
p
Cloughesy, 2003).  Vectors that target to this growth factor receptor have been designed.  
Doubly ablated Ad vectors, lacking both the coxsackievirus-adenovirus (CAR) receptor and 
the αv integrin binding capacities, together with bispecific single-chain antibodies that 
recognize both the EGFR or the epithelial cell adhesion molecule have been employed for 
specific gene delivery to primary human brain tumors (Samoylova et al., 2003; Van 
Beusechem et al., 2002).  Fusion proteins consisting of peptide toxins fused to the human 
EGF (DAB 389EGF) has been demonstrated to selectively kill cells that overexpresses EGFR 
(Cohen et al., 2003).  The overexpression of EGFR has been reported in esophageal squamous 
cell carcinoma (Sunpaweravong et al., 2004), non-small cell lung carcinoma (Hirsch et al., 
2003) and various cancer (Oh et al., 2000).  Therefore, it is not an ideal targeting molecule 
due to its lack of specificity.
 
5.1.2.1 Phage display technology 
Identification of glioma-specific m
th
epitopes that are specific 
for selection on whole cells to identify peptide ligands directed against particular cell surface 
proteins (Barry et al., 1996; Campa et al., 2002; Liu et al., 2003; Parmley and Smith, 1989; 
Szardenings et al., 1997). Using this technique, peptides that bind to kidney, lung, skin, 
pancreas, intestine, uterus, adrenal gland, retina, fibroblast cells, myoblast, myotubes, human 
neutrophils, human laryngeal carcinoma cells, endothelial cells (Ara
19
cell line (Rasmussen et al., 2002) have been identified.   Recently, peptides that home 
selectively to the vasculature of various organs were isolated by the in vivo biopanning of 
peptide phage display libraries in mice (Arap et al., 2002a; Essler and Ruoslahti, 2002; 
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Pasqualini and Ruoslahti, 1996; Rajotte et al., 1998; Trepel et al., 2002), as well as in human 
(Arap et al., 2002b).  The selected sequence can be used to target therapeutic agents (Arap et 
al., 1998) and diagnostic imaging radiolabels (Schumacher et al., 2002).   
 
5.1.3 Aims of this study 
The ability to direct transgene expression to specific cell types can significantly increase the 
efficiency of gene transfer.  Two approaches were attempted with the aim to: 
(1) control transgene expression specifically to rapidly proliferating glioma cells by 
the incorporation of the GFAP promoter to achieve transcriptionally regulated 
gene expression; and 
(2) target HSV-1 amplicon vector to human glioma cells by first identifying glioma-
specific peptide that would potentiate this targeted delivery. 
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5.2 Methods 
5.2.1 Plasmid constructs 
To generate a glial cell-specific and cell cycle-regulatable HSV amplicon vector, the GFAP 
nhancer element (-1753 to -1489) of the human GFAP promoter region together with the 
er was first released from the parental plasmid, pBluescriptKS-
KpnI and EcoRI 
sites in 
using HindII
YA fusion p c region of pC8-36 (Figure 3.4d) was inserted at the PmeI 
site, res
Gal4/NF-YA tor was excised, and 
inserted into pG8-18.  All plasmids were amplified in E.coli STBL-2, and DNA was extracted 
using QIAprep Spin Miniprep.  All plasmids were verified by DNA sequencing. 
 
5.2.2 In vivo transduction  
Two groups (n=5) of 6-8 weeks old CB-17 SCID mice were subcutaneously injected with 
either HeLa or dGli36 cells (5 x 106).  A total of 2 x 106 TU of either pG8-18 or control 
pIH8GalLuc amplicon viral vectors was administered intra-tumorally when the tumor reached 
80-100 mm3 in volume. Animals in all the groups were sacrificed after 24 h and tumor 
nodules were meticulously harvested. 
 
5.2.3 Determination of the efficacy of FasL in s.c. tumor 
6-8 weeks old CB-17 SCID were subcutaneously injected with either HeLa or dGli36-SCID8 
cells (2 x 106) and divided into 8 groups.  One day following tumor inoculation, a total of 2 x 
106 TU of either pG8-FasL or control vectors was administered intratumorally. Injections of 
viral vectors were repeated every 10 days until necrosis of tumor is observed in the control 
groups.  Tumor volume is measured according to Bergers et al. (1999). 
e
minimal hCMV promot
GFAPtTA (kindly provided by Dr. P Nisen, University of Texas Southwestern Medical 
Center, Dallas, TX), using KpnI and EcoRI, and subsequently cloned into the 
pHGCX (pHGCX-GFAP).  Upon removal of the CMV promoter in pHGCX-GFAP 
I and BglII restriction enzyme sites, the entire DNA fragment encoding Gal4/NF-
rotein and the 8GalLu
ulting in plasmid pG8-18.  To generate pG8-FasL, the entire DNA fragment encoding 
 fusion protein and the 8GalFasL region from pC8-FasL vec
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5.2.4 Determination of the efficacy of FasL in i.c. tumor 
f the therapeutic gene, 1 x 106 dGli36 cells were infected with 
were divided 
to two portions for assessing the cell cycle profile and cell death-induced by TMZ.   
f treatment, the cells were rinsed with PBS twice, and 
plenished with complete medium containing 10 % serum.   
 the brain (left side).  
To maximize the effect o
various amplicon vectors at MOI of 2.0.  The transduced cells were implanted stereotactically 
into the right hemisphere [bregma (0,0); lateral 2 mm; depth 2.5 mm] of immunodeficient 
nude mice.  In general, tumor formation in these mice is marked by an observed loss of food 
intake and gait, resulting in a loss of body weight compared to the healthy mice.  At each time 
point, the weight has been noted and survival kinetics on these animals were employed as a 
mean of evaluating the efficiency of treatment. 
 
5.2.5 Treatment with TMZ 
3x105 dGli36 cells were seeded one day before experiment.  On the day of treatment, varying 
concentrations of TMZ were added directly to the medium and incubated for 1 hr at 37 °C.  
Following treatment, the cells were rinsed three times with PBS and replenished with 
complete medium.  To determine the effect of TMZ on dGli36 cells, the cells 
in
 
To assess the effect of TMZ on luciferase gene expression, cells were first infected with the 
respective amplicon vectors for 6 h.  The transduced cells were divided into three portions; 
one portion of the cells was replenished with complete medium; the other portion of the cells 
was treated with lovastatin to induce G1-arrest.  The third portion of the cells was incubated in 
75 µM of TMZ at 37 °C.  After 1 h o
re
 
5.2.6 Stability of pG8-18 viral vector 
Six-week old SCID mice were used for this experiment.  The mice were separated into 3 
groups.  The right side of the brain of the mice was inoculated with dGli36 (2 x 106) glioma 
cells.  One day post implantation of tumor cells, pG8-18 (1 x 106 TU) viral vector, was 
inoculated into both the tumor bearing region and the normal side of
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Brains were harvested on day 4, day 10 and day 28 post inoculation.  The harvested brains 
groups of animals, brains were harvested and 
ingle cell suspension obtained as follows.  The brains were homogenized in 50 ml falcon 
(Invitrogen Life Technologies) using a 5 ml serological pipette 
nd cell 
ellet resuspended in DMEM containing 10 % serum.  The percentage of GFP positive cells 
 weeks old Balb/c mice were used for this experiment.  The mice were separated into 4 
µl 
were prepared for extraction of viral DNA or protein. 
 
5.2.7 Transduction efficiency of pC8-36 and pG8-18 viral vector 
Six-week old SCID mice were separated into 4 groups of 2 animals each.  The right side of 
the brains was inoculated with 10 µl of either pC8-36 (1 x 104 TU) or pG8-18 (1 x 104 TU) 
viral vector.  Brains were harvested 1 day post injection.  On the day of harvesting, mice were 
perfused through the heart with PBS.  From 2 
s
tube with 12 ml of HBSS 
(Nunc), followed by 1 ml serological pipette and a flamed-polished pasteur pipette until no 
clumps were visible.  0.25 % trypsin was added to the cell suspension and incubated for 15 
min at 37 °C, with mixing every 5 min.  The homogenates were filtered through a 70 µm pore 
size nylon cell strainer (BD Biosciences).  The filtrates were subject to centrifugation at 500 
rpm for 15 min at 4 °C without brake (Beckman Coulter).  Supernatant was removed a
p
was analyzed using FACS analysis.  For the other 2 groups, the brains were fixed in 4 % 
paraformaldehyde solution overnight followed by 30 % sucrose for 48 h, and cryosections 
were performed.  GFP positive cells were visualized using LSM 510 Meta confocal 
microscope (Carl Zeiss Microscopy, Göttingen, Germany) with appropriate filters. 
 
5.2.8 Immunogenicity of HSV-1 amplicon vector 
6
groups of 2 animals each.  The mice were inoculated at the right side of the brain with 10 
of saline in group 1, AdGFP (1 x 102 pfu) in group 2, pC8-36 (1 x 104 TU) in group 3 and 
pG8-18 (1 x 104 TU) viral vectors in group 4.  Brains were harvested on day 1 and day 4 post 
injections.  On the day of harvesting, mice were perfused through the heart with PBS followed 
by 4 % paraformaldehyde.  Brains were harvested and fixed in 4 % paraformaldehyde 
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overnight, followed by incubation in 30 % sucrose/PBS for 48 h, at 4 °C.  Fixed tissues were 
then cryosectioned.  Immunohistochemical staining was performed on consecutive sections.  
lioma cell 
nes, 1 x 106 cells were incubated with 1012 pfu of the isolated phage clone at 37 °C for 2 h.  
 recovered and titered as mentioned.    
 
5.2.9 Phage-display library biopanning  
The phage display library employed for biopanning for glioma specific phage was the Ph.D. 
12 library (New England Biolabs, Beverly, MA).  Phages were selected for binding to human 
glioma cell lines by panning against intact cells in suspension.  Glioma cell lines (dGli36, 
SF767, U87MG, U251MG, and U373MG) were grown in monolayers until confluent, and 
harvested by treating the cells with PBS containing 5 mM EDTA.  The five glioma cell lines 
were mixed together in equal proportions to give a final cell number of 1 x 106.  This was 
followed by incubating the cell mixture with 1 x 1011 pfu of M13 phage at 37 ºC for 2 h.  The 
cells were washed once with PBS containing 0.1 % Tween-20 and nine times with PBS, 
followed by pelleting and resuspension to remove unbound phage.  Bound phages were 
recovered by eluting with 0.2 M glycine, pH 2.2, containing BSA (1 mg/ml), followed by 
neutralization with 1 M Tris-Cl (pH 9.1).  Recovered phages were amplified in ER2537 
bacteria and subjected to two additional rounds of enrichment panning.  These enrichment 
pannings were then followed by three rounds of subtraction panning against A549, CNE2, 
and HepG2 successively.  The isolated phage clones were titered using ER2537 bacteria.    
 
To determine the in vitro specificity of the recovered phage to glioma and nong
li
Unbound phage was removed and bound phage was
 
5.2.10 Amplification of phage clones 
ER2537 bacteria were employed for phage amplification.  To 20 ml of log-phase bacteria 
culture, 1 x 1010 pfu of the phages were added and the mixture was incubated for 4.5 h at 37 
°C in a shaking incubator.  To precipitate the phages, a 1/6 volume of PEG8000/NaCl 
solution was added to the bacteria/phage mixture and precipitated at 4 °C overnight.  The next 
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day, phages were harvested by centrifugation at 13 000 rpm for 10 min at 4°C.  The resulting 
phage pellet was resuspended in 1 ml TBS.  The phages were further precipitated by adding a 
1/6 volume of the PEG/NaCl solution.  After incubating for 1 h on ice, the phages were 
nd resuspended in 200 µl of TBS containing 0.01% 
of 
mor cells, when the tumor volume was approximately 75 mm3.     
old 
CID mice, respectively. Phage was injected via tail vein 7 days post-implantation of tumor 
tely 100 mm3.   
pelleted at 13 000 g for 10 min at 4 °C a
sodium azide.  The amplified phages were titered and stored at 4 °C. 
 
5.2.11 Titering of phage 
To determine the titer, amplified phages were serially diluted in LB.  Each of the diluted 
phage solutions was added to a log culture of the ER2537 bacteria.  After incubating for 5 min 
at r.t. to allow infection to take place, 3 ml of melted 0.7 % agarose (45 °C) was added and 
the mixture was poured onto a LB agar plate containing 40 mg/ml of X-Gal, and 50 mg/ml 
IPTG.  The titer of the phage solution was determined by counting the number of blue plaques 
after 24 h of incubation. 
 
5.2.12 In vivo targeting of MG11 phage to tumor xenograft 
For intracranial tumor, 2 x 106 dGli36 cells resuspended in 10 µl of PBS were stereotactically 
inoculated into the bregma region (2 mm lateral, 0.25 mm depth) of the right hemisphere of 6 
week-old female nude mice.  Phages were injected via tail vein 10 days post-inoculation 
tu
 
For s.c. tumor, 5 x 106 of either SF767, dGli36 glioma cells or CNE2 (nonglioma cells control) 
were suspended in 100 µl of PBS and injected into the right and left flanks of 6-week 
S
when the tumor volume was approxima
 
Tumor bearing mice were randomized into two groups (5 per group), namely the control 
group and the experimental group. Control phage or phage bearing the glioma-specific 
sequence (1 x 1012 pfu), suspended in 400 µl of DMEM, was injected via tail vein into tumor-
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bearing mice, and allowed to circulate for 24 h.  After 24 h, mice were anesthesized and 
perfused through the heart with DMEM.  Tumor and other organs were dissected and weighed. 
The tissues were homogenized in ice-cold DMEM containing protease inhibitor cocktail and 
0.1 % BSA.  After centrifugation to remove the tissue debris, bound phage was rescued by 
mixing the supernatant with 0.5 ml of ER2537 bacteria for 30 min at
 
 37 °C.  The supernatant 
ontaining phage was diluted in LB, after which aliquots were plated on LB agar plates 
G.  As control, unselected phage was administered at the same titer 
 (w/w).  Plasmid DNA was diluted to 10 µg/ml in Ringer's buffer (B. 
raun Melsungen AG, Melsungen, Germany).  The appropriate volume of peptide was also 
g/ml (peptide: DNA ratio, 2:1).  
.2.14 Transfection of tumor cell lines 
mmediately after the 
ddition of peptide/DNA complexes.  Reporter gene activity was assayed after 24 h or 48 h. 
c
containing X-Gal and IPT
in the second group of animals. 
 
5.2.13 Formation of peptide/DNA complexes  
The formation and transfection of peptide/DNA complexes were carried out according to 
Patel et al. (2001) with slight modifications.   Peptide/DNA complexes were prepared at a 
peptide:DNA ratio of 2:1
B
diluted in Ringer's buffer to give a final concentration of 20 µ
The peptide was added dropwise to the DNA solution while vortexing gently.  This mixture 
was allowed to incubate at r.t. for 30 min.  After 30 min, the mixture was diluted to 4 µg of 
DNA per milliliter with DMEM in the presence of 100 µM of chloroquine, and added to cells.   
 
5
For transfection, 3 x 105 cells were seeded into each well of a six-well plate.  After culturing 
overnight, the cells were washed twice with PBS.  Freshly prepared peptide/DNA complexes 
were added into each well and incubated for 2 h at 37 ºC.  For transfection performed in the 






5.2.15 In vitro fluorescent peptide binding assay 
For in vitro binding assay, 1 x 105 cells were seeded into each well of a 24-well dish.  After 
culturing the cells overnight at 37 ºC, the cells were washed once with PBS, followed by 
incubation in blocking buffer containing PBS with 1 % BSA at r.t. for 1 h.  The cells were 
washed twice with PBS.  One hundred nanogram of Lissamine rhodamine-conjugated (K16)-
MG11 peptide (Mimotopes, Victoria, Australia) was added to the blocking buffer containing 
0.1 % sodium azide, and incubated with the cells at 37 ºC for 20 min.  This is followed by 
five washes of PBS with 0.1 % Tween-20 at r.t. at 5-min intervals.  The cells were then fixed 
 4 % paraformaldehyde.  After removal of excess paraformaldehyde, the cells were mounted.  
th a LSM 510 Meta confocal microscope with 
ections were then counterstained with the fluorescein isothiocyanate (FITC)-phalloidin and 
LSM 510 Meta confocal microscope with appropriate 
in
Images were captured digitally and analyzed wi
appropriate filters. 
 
5.2.16 In vivo fluorescent peptide binding assay 
SF767-tumor bearing mice were randomized into two groups (2 per group).  Fifty microliter 
containing 100 µg of Lissamine rhodamine-conjugated (K16)-MG11 or (K16)-H42 was 
injected intratumorally into each of two mice harboring the tumor, and allowed to circulate 
for 20 min.  After 20 min, the mice were anesthesized and perfused through the heart with 
PBS followed by 4 % paraformaldehyde.  The tumors were dissected and cryosectioned.  The 
s
mounted.  Images were examined using 
filters. 
 
5.2.17 Statistical analysis 
Data are presented throughout this study as means + standard error of the mean.  Statistical 
significance was evaluated and p < 0.05 was considered significant. 
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5.3 Results 
For the ease of presenting data, the result section will be divided into two parts, namely 5.3.1 
and 5.3.2, for transcriptional targeting and vector retargeting, respectively. 
 
5.3.1 Cell type-specific and cell cycle-regulated transgene expression mediated by HSV-1 
amplicon vectors in vitro 
To achieve conditional gene expression in proliferating cells of a glial origin, the CMV 
promoter in pC8-36 amplicon plasmid (Figure 3.4d) was replaced by the glial cell-specific 
GFAP enhancer element cloned upstream of a minimal CMV promoter, thus generating pG8-
18 (Figure 5.1).   
 
To verify that the feature of cell cycle regulation was retained in this vector, an experiment 
 Figure 3.9) was performed.  Our results 
sfection.  We further investigated whether the variability in transgene expression was 
ue to the lack of cellular protein required to confer glial cell-specific transgene expression. 
ing showed that unlike dGli36, SF767 and U251MG glioma cells, 
n vector was capable of 
conferring glial cell-specific transgene expression.  Further, luciferase expression was shown, 
at a single-cell level, only in proliferating dGli36 cells transduced with the pG8-18 amplicon 
viral vector (Figure 5.3a).  Confocal microscopy studies demonstrated that pG8-18-transduced 
similar to that described in section 3.3.5 (refer
demonstrated that when transfected with pG8-18 amplicon plasmid, the level of transgene 
expression was comparatively higher in proliferating glioma cells (dGli36, 1300 RLU/µg; 
U251MG, 228.91 RLU/µg; SF767, 689.98 RLU/µg) than in nonglioma cells (HeLa, 5 
RLU/µg; HepG2, 75.36 RLU/µg) (Figure 5.2).  In contrast, luciferase activities were minimal 
in pIH8GalLuc-transfected proliferating cells, as well as in pG8-18 transfected but growth-
arrested cells.  This observation was not due to differential transfection efficiency as these cell 




HeLa and HepG2 nonglioma cells did not express any detectable level of endogenous GFAP 










dGli36 cells, as shown by the presence of exogenous eGFP expression, were positively 
stained for luciferase (blue) and endogenous cyclin A (red).  In contrast, luciferase expression 
was not detected in proliferating but untransduced cells, as indicated by the absence of eGFP 
expression, and yet were positively stained for endogenous cyclin A.  Most importantly, no 
luciferase expression could be detected in pG8-18 amplicon viral vector-infected HeLa cells 
(Figure 5.3b) even though the cells were clearly transduced by the viral vectors and were 
proliferating.  
 
5.3.1.1 Cell type-specific and cell cycle-regulated transgene expression mediated by HSV-1 
amplicon vectors in vivo 
We further investigated the dual-specific regulation in an in vivo setting.  A total of 2 x 106 
TU of either pG8-18 or control pIH8GalLuc amplicon viral vector was administered 
intratumorally to immunodeficient animals harboring s.c. dGli36 tumor xenografts (~80-100 
mm3 in volume).  Luciferase activity was found to be 10-fold higher (Figure 5.4a) in tumors 
injected with pG8-18 amplicon viral vector (3954 RLU/mg) rather than the control virus, 
pIH8GalLuc (380 RLU/mg).  Similarly, luciferase activity was found to be 9-fold higher in 
dGli36-derived tumor (3954 RLU/mg) when compared with HeLa-derived tumor (440 
RLU/mg) (Figure 5.4b).  These results demonstrated that pG8-18 amplicon viral vectors 
could mediate transgene expression in a cell cycle- and cell type-specific manner in vivo. 
 
5.3.1.2 Glial cell specific expression of FasL 
To evaluate the efficacy of an apoptotic inducing gene in the context of HSV-1 amplicon viral 
vectors, the FasL gene was incorporated into pG8-18 to generate pG8-FasL.  Human glioma 
dGli36 cells and nonglioma HeLa cells were infected with pG8-FasL at MOI of 1.0 (Figure 
5.5).  pIH8GalFasL vector was used as negative control.  In section 4.3.2 (refer Figure 4.3b), 
we have shown that expression of FasL induced apoptosis in dGli36 cells by the presence of 
pyknotic nuclei.  The percentage of apoptosis was determined using trypan blue exclusion 






observed in the proliferating populations compared with the G1-arrested populations (p=0.02; 
Figure 5.5a).  In contrast, no significant cell death was detected in pG8-FasL-transduced 
proliferating and G1-arrested HeLa cells (Figure 5.5b) although the transduction efficiency for 
both cell lines is similar.  To determine if the percentage of cell death observed is indeed due 
to the apoptotic effect of FasL, infected cells were examined for the level of FasL protein 
expression using ELISA assay.  Our results showed that FasL expression in proliferating, 
pG8-FasL-transduced dGli36 cells was ~ 2.5-fold higher compared with that of the 
orresponding G1-arrested cells (p=0.03).  The level of FasL expression was similar to that of 
nes (Figure 5.6).  Taken together, the results suggest that cell death 
asL 
as used as positive control; while pC8-36 and pG8-18 were negative controls.  All mice 
ry ten days.  At all time points when the tumor 
c
pG8-FasL-transduced HeLa cells; however, this did not correspond to the extent of apoptosis 
observed in the two cell li
mediated by pG8-FasL is cell type-specific as well as cell cycle-regulated. 
  
5.3.1.3 Suppression of tumor growth is observed in glioma only 
The ability of FasL gene to suppress tumor growth has been demonstrated in pC8-FasL 
infected cells (refer section 4.3.7; Figure 4.9).  In this section, the glioma specific expression 
of the FasL gene in suppressing tumor growth will be explored in SCID mice harboring either 
HeLa- or dGli36-SCID8-derived tumors on its right flank.  The mice were divided into eight 
groups bearing either HeLa- or dGli36-SCID8-derived tumors, and injected with four 
different amplicon vectors, namely, pC8-36, pC8-FasL, pG8-18 and pG8-FasL. pC8-F
w
were subjected to injection of viral vectors eve
volumes were measured, the tumor sizes in both dGli36-SCID8 and HeLa injected with pC8-
FasL vector were significantly smaller than the controls, pC8-36 (Figure 5.7).  This indicated 
that the expression of FasL gene is able to suppress growth of both glioma and cervical 
carcinoma in vivo.  In consensus with results observed from the in vitro studies (Figure 5.5), 
expression of FasL protein mediated by pG8-FasL could not inhibit the growth of HeLa cells 
in vivo, resulting in tumor volume similar to the controls injected with pG8-18 viral vectors 






harboring human glioma xenografts and injected with pG8-FasL, which was significantly 
smaller than those injected with the pG8-18 vector (p=0.007; Figure 5.7a).  The tumor volume 
in pG8-FasL-transduced-dGli36-SCID8 cells ranges between 0.0 mm3 to 69.06 mm3, whereas 
the tumor volume in pG8-FasL-transduced HeLa cells ranges between 282.52 mm3 to 500.09 
mm3 during the final measurement.  These results thus demonstrated that cell death mediated 
by FasL is specific for tumor of glial origins. 
 
The effect of FasL overexpression was also investigated in an intracranial tumor model.  We 
have previously demonstrated that the cell cycle-regulation of the vector is dependent on the 
input viral dosage (refer section 3.3.12; Figure 3.15).  To maximize the effect of the 
therapeutic gene, dGli36 cells were infected with pG8-FasL at MOI of 2.0, to achieve 
fectivity of approximately 98 % by FACS analysis (data not shown).  TUNEL staining 
are apoptotic at the time of 
in
indicated that none of the transduced cells (Figure 5.8a, part i) 
tumor implantation (Figure 5.8a, part ii).  The transduced cells were then implanted 
stereotactically into the right hemisphere [bregma (0,0); lateral 2mm; depth 2.5 mm] of 
immunodeficient nude mice.  pG8-18-infected-dGli36 cells were used as negative controls.  
We observed that the median survival time for FasL-injected mice was longer than that of the 
pG8-18-infected group.  The median survival time for mice injected with pG8-18 is 8 days 
compared with 27 days in the pG8-FasL-infected group (Figure 5.8b).   This difference is 
survival time is statistically significant when examined by Kaplan-Meier survival analysis, 
p=0.042 by log-rank, thus indicating that expression FasL gene is sufficient to induce an anti-





5.3.1.4 Effect of TMZ on dGli36 human glioma cells 
ment with 
















75µM of TMZ for 1 h at 37 °C, followed by incubating in fresh complete medium for another  
5.3.1.4.1 TMZ caused accumulations of cells at G2/M phase 
The effect of TMZ on dGli36 cells was assessed at 24 h and 48 h following treat
TMZ at various concentrations (25 µM, 50 µM, 75 µM, and 100 µM).  Only minor cell death 
was observed at the varying concentrations with respect to the untreated control (data not 
shown).  After 24 h of treatment, we noticed that more cells accumulated at the G2
cells treated with 75 µM of TMZ (Figure 5.9), which is in agreement with a published report
stating that cells treated with TMZ arrest at the G2/M phase (Kanzawa et al., 2003).  
percentage of G2/M cells treated with 75 µM of TMZ after 48 h increased to approximat
%, with a reduction in both the G0/G1 and S phase (Figure 5.9).  Since the effect of TMZ 
µM after 48 h of treatment is much stronger than 100 µM, this concentration was chosen f
subsequent experiments. 
 
5.3.1.4.2 Effect of TMZ on transgene expression mediated by pG8-18 in dGli36 cells 
To determine whether luciferase gene expression can be activated in TMZ-treated cells
dGli36 was first treated with 75 µM of TMZ for 1 h, followed by infection with pG8-
MOI of 1.0 and pIH8GalLuc vector after 48 h.  At the time of infection (48 h post-TM
treatment), the percentage of S phase cells was approximately 40 %, which is sim
untreated but transduced-dGli36 cells, and the percentage of G2/M cells is approximat
%.  Luciferase expression was analyzed 24 h post-transduction. No significant difference in
luciferase expression could be detected between the asynchronized untreated pG8-18-
transduced cells (1831.1 RLU/µg) and the TMZ-treated cells (1468.4 RLU/µg) (p=0.3
Figure 5.10a), suggesting that the effect of TMZ on transgene activities conferred by
is minimal.  
 
To mimic the clinical scenario, dGli36 glioma cells were first infected with either pG8-18 






48 h, 60 h, and 72 h.  For comparison purposes, vector transduced-cells were also incubated in 
l populations; and treated with 
 studied to determine the stability of pG8-18 amplicon viral vector 
 vivo.    dGli36 human glioma cells were implanted via stereotactic injection into the brain 
n viral 
 
days, 10 days and at least 28 days after transduction in both the normal and the 
mor bearing region (Figure 5.11).  However, luciferase protein expression is only detectable 
the presence of fresh complete medium for asynchronized cel
lovastatin to induce G1-arrest.  Luciferase activities were compared with those transduced 
with the control vector, pIH8GalLuc.  Luciferase activities can be detected in all cells treated 
with TMZ, with the level of expression highest at 60 h post-treatment (6178.1 RLU/µg) 
(Figure 5.10b).  Approximately 54 % of the cells are in the G2/M phase of the cell cycle at 
this particular time point.  These two experiments demonstrate that luciferase expression can 
be activated in proliferating glioma cells that are treated with chemotherapeutic drugs. 
 
5.3.1.5 In vivo stability of the dual specific amplicon vector 
The presence of the viral DNA and the expression of luciferase reporter gene at different time 
points post-injection were
in
of SCID mice at the right hemisphere, followed by inoculation of the pG8-18 amplico
vector into both hemispheres.  To determine the stability of the viral vector, the mice were 
sacrificed on 4 days, 10 days and 28 days postinoculation, and the brains were harvested for 
PCR analysis as well as luciferase reporter gene assay. 
 
Viral DNA was extracted from both the tumor bearing region and the normal brain (left side) 
of mice injected with pG8-18 amplicon viral vector.  PCR analysis was performed to amplify 
the exogenous luciferase gene encoded on pG8-18.  18S rRNA was used as an internal control,
luciferase cDNA were employed as the positive control, while uninfected mouse brain as the 
negative control.  Vector DNA, as determined by the presence of the luciferase gene, was 
detected at 4 
tu
at day 4 and day 10 post-injection (Figure 5.12a).  By day 28, the level of luciferase protein 






5.3.1.6 Transduction efficiency in vivo 
To determine the percentage of transduced cells, pC8-36 and pG8-18 amplicon vectors were 
injected via stereotactic injection into the right side of the brain of normal mice.  Twenty four 
hours following transduction, the mice were sacrificed and brains were harvested.  Single cell 
suspensions were collected and the percentage of GFP positive cells in brains injected with 
pC8-36 and pG8-18 were determined to be 25.3 % + 2.02 and 17.83 % + 6.99, respectively 
(Figure 5.13). To confirm these findings, the experiment was repeated similarly in another 
group of mice.  This time, the surface area of GFP positive cells in representative cryosections 
f brains injected with viral vectors was determined using confocal microscopy.  The area of 
a of each brain section (10 µm 
variation of ~6 % between the two 
ethods may be due to the estimation involved in the latter approach when only 
o
dispersion is determined by measuring the total surface are
sections) positive for GFP expression (Table 5.1).  The total area of dispersion is the sum of 
the GFP positive areas in all GFP positive sections.  Therefore, the total surface area of GFP 
positive cells transduced by pC8-36 was determined to be 58.7 mm2, and pG8-18 was 43.3 
mm2.  By taking into account the thickness of each represented section, the volume of viral-
transduced region was then calculated.  Given that the volume of a 4-6 week old SCID mouse 
brain is approximately 358 mm3, this would translate to a transduction efficiency of 16.4 % 
for pC8-36 and 12 % for pG8-18 (Table 5.1).  The 
m
representative cryosections were taken into account.  Nevertheless, pC8-36 viral vectors 









able 5.1.  Determination of transduction efficiency of amplicon viruses in vivo 










Slide 25-28 4 40 17502.79 700111.6  
Slide 29-32 4 40 118833 4753321.2  
Slide 33-38 6 60 118833 7129981.8  
Slide 39-42 4 40 329687.5 13187500  
Slide 43  10 100 329687.5 32968750  
Slide 46 1 10 6411.9 64119  
    58803783.6 58.80 
pG8-18      
Slide 14-19 5 260 7652.18 1989566.8  
Slide 20-24 5 260 24657.61 6410978.6  
Slide 25-28 4 210 24657.61 5178098.1  
Slide 29-32 4 210 20895.96 4388151.6  
Slide 33-42 10 466.7 20895.96 9752144.53  
Slide 42-52 11 513.37 30240.09 15524355  
    43243294.6 43.24 
 
 
5.3.1.7 Assessing the immunogenicity of the cell cycle-regulated vector 
able 5.2:  Comparison of percentage of GFP positive cells in both HSV-1 
amplicon viral vectors infected and AdGFP infected HeLa cells.  
Viral vectors % GFP 
The cell cycle-regulated vectors contain transcriptional elements from the yeast Gal4 protein 
and the mouse NF-YA, which may generate antigenic peptides that might induce an immune 
response following in vivo gene transfer.  Determination of the immunogenicity of these 
vectors is therefore important.  We employed the AdGFP vector as positive control since 
recombinant Ad has been known to elicit immune response.   
 
In order to have a fair comparison between the HSV-1 amplicon vectors and the positive 
control, AdGFP, the virus titer that gave similar percentage of infected cells by both viruses 
was predetermined by infecting permissive cell line, HeLa.  The percentage of infectivity of 
AdGFP that is comparable to MOI of 1 of the HSV-1 amplicon vector was determined.  HeLa 
cells (5 x 104) were infected with pC8-36 amplicon vector at MOI of 1.0.  The transduction 
efficiency of pC8-36 at MOI of 1 was compared with MOI of 10, 102, 104, 106 and 108 pfu of 
AdGFP by analyzing for the percentage of GFP positive cells using FACS analysis.  After 
incubating the viral supernatant with the cells for 6 h, the monolayer was washed once with 
PBS and replenished with complete medium containing 10 % serum.  Twenty four hours post-
infection, HeLa cells were harvested and the percentage of GFP positive cells was determined 
by FACs analysis.  As shown in Table 5.2, the percentage of GFP in AdGFP infected cells at 




pC8-36 MOI of 1.0 21 
AdGFP 106 ~ 95 
AdGFP 104 69 
AdGFP 102 39 
 
 161
The immunogenicity of pG8-18 amplicon vector was determined in immunocompetent mouse 
odel.  Six weeks old Balb/C mice were injected with the viral vector with comparable titers 
 depth 2.5 mm].  
 
  The presence of innate 
 the presence of T 
post inoculation, 
the BBB.  
with AdGFP, 
d 
arable to that of 
11b microglial 
unologic 
 the saline-injected 
 viral vectors 
unogenicity and 
m
via stereotactic injection into the right brain [bregma (0, 0); lateral 2mm;
Saline injections were used as negative control, and AdGFP were used as the positive control. 
All mice were sacrificed either 1-day or 4-day post-transduction.
immune response was determined by immnohistochemistry staining for
lymphocytes (CD4 and CD8) and microglia (CD11b) infiltration.  On 1-day 
all injections induced inflammatory response due to the transient disruption of 
CD4-, CD8- and CD11b-positive cells were observed in all animals injected 
saline, pC8-36 and pG8-18 (Figure 5.14).  On day 4, the expression levels of the CD4 an
CD8 T lymphocytes in both pC8-36- and pG8-18-injected mice were comp
the saline-injected mice (Figure 5.14).  Similar results were observed in CD
infiltration.  In contrast, mice injected with AdGFP elicited an enhanced imm
response and microglia infiltration even on day 4 when compared to
control.  These results suggested that both pC8-36 and pG8-18 amplicon




5.3.2 Identification of glioma specific peptide  
5.3.2.1 Enrichment of “glioma-specific” phage by in vitro biopanning 
The Ph.D-12 phage display library, with a complexity of approximately 2 x 109 sequences, 
was employed for screening peptides that would bind specifically to human glioma cells.  
This library consists of 12-mer peptide sequences fused to the N terminus of the minor coat 
protein of the M13 phage, in a valency of 5 copies per virion.  The library was screened 
gainst a mixture of human glioma cell lines including dGli36, SF767, U87MG, U251MG, 
emaphorin 4B precursor protein.  Semaphorin 4B is a member of the semaphorin 
l signals 
 specify territories inaccessible for growing axons (Rieger et al., 2003).  In addition to 
phage-bearing the MG11 e, we have also isolated two other phage clones 
harboring peptide seque he semaphorin family of proteins.  One of the 
sequences, HHGHSPTSPQVR,  to the protein sequence of semaphorin 3A 
precursor protein, whereas the other peptide sequence, LPYGTSNRHAPV, showed 64 % 
omology with semaphorin 6B precursor protein.  Semaphorin 3A, which binds with high 
affinity to neurophilin-1, induces the collapse and paralysis of neuronal growth cones.   
a
and U373MG at 37 °C to increase the probability of obtaining sequences that could interact 
generically with most glioma cells (Figure 5.15).  Phages rescued were further subjected to 
negative panning using nonglioma cell lines A549, CNE2, and HepG2, to eliminate 
nonspecific background binding (Figure 5.15).  The amino acid sequences of the 79 phage 
clones obtained after such a selection revealed several dominant sequence motifs (Table 5.3). 
The sequence SGHQLLLNKMPN, designated MG2, was found in 24 % of the clones; and 
LWATFPPRPPWL, designated MG11, was found in 19 % of the clones (Table 5.3).  A 
BLAST search of MG2 demonstrated 60 % sequence homology with the human mitogen-
activated protein kinase kinase kinase 12 (MAP3K12).  MAP3K12 was found to be highly 
expressed in brain and kidney, and has been implicated as an activator of the JNK/SAPK 
pathway (Su and Karin, 1996).  Analysis of the second most frequently isolated phage-
bearing peptide sequence, designated MG11, showed it to be 64 % homologous to 
s
superfamily, which is involved in the inhibition of axonal extension by providing loca
to
peptide sequenc








(a)  Db represents sequence from database.  (b)  Qy is the query sequence from phage.  (c) “




19%  Semaphorin 4B 
precursor   
 
     *   *****  * 
 Db 11  WGALPPRPPLL   21 
 Qy   2  WATFPPRPPWL   12 
 




1D subunit   
 
      *    *  *** 
Db 1981 WATPPATPPYR  1991 
Qy       1 WSAAPTKPPYH  11 
 
4 ILANDLTAPGPR  5%  None 
 
5 HHGHSPTSPQVR 4%  Semaphorin 3A 
precursor  
 
               ******  
 Db 575  HHGHSP    580 
 Qy     1  HHGHSP    6 
 




               ****   * ** 
 Db 435  LPYGGADRTAP   444 
 Qy     1  LPYGTSNRHAP   11 
 
7 YVQGWNYHDLTR 4%  None 
 
8 LWAAFPPQASVA 4%  Synaptojanin 1  
 
      ****** * 
Db 1245 AAFPPQSSLP   1254 
Qy       3 AAFPPQASVA   12 
 















kinase 12  
 
       * *** **  c
Dba 599  HDLLLRKMSS   608 




Table 5.3.  Lists of peptides isolated from biopanning of human glioma cell lines. 
 









Neuropilin-1 is a receptor for the vascular endothelial growth factor family and has been 
 with the Flk-1/KDR implicated in blood vessel formation.  It also functions as a co-receptor
receptor tyrosine kinase (Gluzman-Poltorak et al., 2000).   We noticed that several groups of 
the peptides selected are homologous to members of the semaphorin superfamily.  It has been 
previously reported that the semaphorin family of proteins play important roles during neural 
development (Rieger et al., 2003; Schumacher et al., 2002), because MG11 is the most 
common sequence identified among the group of phages isolated, MG11 was thus chosen for 
subsequent studies. 
 
5.3.2.2 Characterization of the binding epitopes of MG11 phage in vitro 
To determine whether MG11 phage binds specifically to glioma cells, tumor cell lines of 
various histotypes were incubated with the phage.  These include dGli36, SF767, U87MG, 
U251MG, U373MG, and T98G glioma cells, and A549, CNE2, HeLa, HepG2, KOSC-3, KZ2, 
and WT18 nonglioma cells as shown in Figure 5.15.  The efficiency of MG11 phage binding 
to glioma cells (range, from 2 x 106 to 2.2 x 107 pfu/ml) was at least 3-fold higher than that of 
nonglioma cells (Figure 5.16).  None of the nonglioma origin tumor cell lines tested exhibited 
considerable binding (range, from 1.5 x 104 to 9.6 x 105 pfu/ml).  Thus, the in vitro phage 
binding assay indicated that MG11 phage binds specifically to glioma cells.  
 
5.3.2.3 MG11 phage targets to human glioma xenograft in vivo 
To determine whether phage bearing the MG11 binding motif can target specifically in vivo to 
human glioma xenografts, 1012 pfu MG11 phage was injected via tail vein to immunodeficient 
SCID mice harboring s.c. dGli36-derived glioma xenograft.  Recovery of phage particles 
from tissues as well as xenografted dGli36 tumor indicated that MG11 phage is specific for 
tumor only (7.94 x 104 pfu/mg), whereas other tissues including brain, heart, kidney, liver, 
lung, and spleen gave only background binding (Figure 5.17).  Minimal binding was observed 
in all tissues when control unselected phage was employed (Figure 5.17).  The tumor 







immunodeficient mice bearing s.c. glioma xenograft (dGli36) and nonglioma xenograft 
(CNE2) on the right and left hind thigh, respectively.  The enrichment factor in homing to the 
s.c. dGli36 glioma xenograft (7.9 x 104 pfu/mg), compared with the s.c. CNE2 tumor (1.67 x 
104 pfu/mg), was 5-fold, (p=0.03; Figure 5.18a, part i).  Similar results were obtained when 
another human glioma, SF767, was used.  The enrichment factor in homing of MG11 phage 
to SF767-derived tumor (8.34 x 103 pfu/mg) was 4-fold higher when compared with the 
CNE2-derived tumor (2.21 x 103 pfu/mg), (p=0.02; Figure 5.18a, part ii), indicating that the 
binding of MG11 to human gliomas cell lines is specific.   
 (Figure 5.18b).  
hese results demonstrated that phage bearing the MG11 epitope target specifically to cells of 
 
5.3.2.4 MG11 phage does not bind to normal brain tissue 
The specificity of MG11 phage binding to human glioma cells in the context of normal mouse 
astrocytes was investigated.  Phage (1012) was injected via tail vein into immunodeficient 
nude mice bearing an intracranial xenograft of dGli36 human glioma cells in the right 
hemisphere.  Phage recovered from the right hemisphere bearing the xenografted tumor (9.2 x 
102 pfu/mg) in mice injected with the MG11 phage gave an enrichment of 20-fold compared 
with those recovered from the normal side of the brain (0.5 x 102 pfu/mg) (left hemisphere) 
(p=0.013; Figure 5.18b).  No significant difference could be detected between tumor-bearing 
mice and normal mice in the control groups injected with unselected phage
T
glial origin and do not bind to normal brain cells. 
 
5.3.2.5 In vitro binding of (K16)-MG11 to human glioma cells 
The amino acid residues that make up the MG11 peptide sequence are very hydrophobic and 
could not be easily purified.  To facilitate the purification procedure, we have inserted 16 
lysine residues into the sequence.  The addition of polylysine residues has been demonstrated 
to enhance the potential of the peptide to interact with the negatively charged plasmid DNA 
as demonstrated by Patel et al. (2001).  In addition, a spacer sequence identical to that used by 
Patel et al. (2001) was also included to facilitate the movement of the peptide. 
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he (K16)-MG11 peptide was chemically synthesized and complexed with a luciferase 
porter plasmid, pNGVL-Luciferase (pNGVL-Luc).  To determine the optimal concentration 
 of gene 
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added as it 
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that would allow DNA and peptide interactions, and to maximize the efficiency
uptake, various peptides:DNA ratios were used in the transfection of SF767 cells.  Various 
ratios of the pNGVL-Luc plasmid and (K16)-MG11 peptide were complexed, followed b
incubation in SF767 glioma cells in the presence of chloroquine.  Chloroquine was 
has been previously demonstrated to prevent lysosomal DNA degradation (Zauner et al.,
1997).  After 24 h, luciferase expression was detected at peptide: DNA ratio 
(39803 RLU/µg protein) (Figure 5.19a).  The level of luciferase expression increas
escalating ratios of peptide to DNA (Figure 5.19a).  This suggests that the abundance of 
lysine residues could facilitate the interaction of the peptide with the DNA molecules; henc
ensuring the majority of the DNA molecules are complexed with the peptide.  At peptide: 
DNA ratios of 10:1 and 20:1, toxicity could be detected as the treated SF767 gliom
were not as healthy as the untreated controls.  This could be due to the presence of high
concentration of polylysine, which is known to be toxic to cells (Zauner et al., 19
subsequent experiments, we therefore adopted the optimal peptide: DNA ratio of 2:1.  
 
To rule out the possibility that the binding of the peptide to the cells is due to the l
residues inserted, we synthesized a control peptide in our experiment to confirm
luciferase activities observed were a consequence of targeting.  A control peptide, comp
of the 16 lysine residue followed by 12 amino acid sequence derived from biopanning 
nonglioma cell line, (K16)-H42, was also synthesized.  H42 bears the sequence
GGPTKEWELYLF.  Similar experiments were carried out with the luciferase DNA and
(K16)-H42 at various peptides to DNA ratios and no significant binding could be detected 






.3.2.6 (K16)-MG11 mediates expression of luciferase reporter gene to glioma cells 
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To further demonstrate the specificity of (K16)-MG11 peptide for glio
determine the optimal time point of luciferase transgene expression, peptide/DNA co
prepared by mixing (K16)-MG11 peptide to pNGVL-Luc DNA at 2:1 (w/w) ratio, was adde
to tumor cell lines of different histotypes.  These included dGli36, SF767, U251MG, A549
HeLa, HepG2, and CNE2 cells.  Binding of peptide/DNA complexes was perf
presence of 100 µM chloroquine, and luciferase expression was assayed 24 h and 48 
transfection.  Luciferase activities in SF767 glioma cell line (85473 RLU/µg) were at le
fold higher than in the CNE2 cell lines (19849 RLU/µg) at 24 h post-transfection.  The leve
of gene expression at 48 h post-delivery is much higher than that at 24 h (Figure 5.20a, 
The level of luciferase expression detected in U251MG, dGli36 and SF767 glio
increased dramatically by 48 h after transfection (Figure 5.20a, part i).  Experime
(K16)-MG11 peptide complexed with the reporter gene encoding eGFP also gave sim
results (Figure 5.20a, part ii).  Strong green fluorescence could be detected
glioma cells but not in HepG2 human hepatocellular carcinoma cells. 
 
Furthermore, when peptide/DNA complexes prepared from (K16)-MG11 or (K16
with pNGVL-Luc were mixed and added to SF767 and CNE2 cells, the lucifera
in SF767 glioma cells transfected with (K16)-MG11: pNGVL-Luc (716940 RLU/µ
fold higher than that of (K16)-H42: pNGVL-Luc (8444 RLU/µg) control pe
cells.  The result thus demonstrate that the binding of (K16)-MG11 peptide is specific, and not
due to the presence of positively charge lysine residues (Figure 5.20b).  When comp
CNE2 nonglioma cell line, the level of luciferase expression observed in SF767 gliom
transfected with pNGVL:Luc/(K16)-MG11 is 151-fold higher (Figure 5.20b).  These results 




5.3.2.7 Characterization of (K16)-MG11 peptide targeted delivery in vitro and in vivo 
o determine the direct specific binding of the (K16)-MG11 peptide to the cell surface of 
HK1) with the 
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glioma cells, (K16)-MG11 peptide was conjugated to Lissamine rhodamine.  After incubating 
the various tumor cell lines (SF767, U251MG, M059K, A549, HepG2, and 
Lissamine rhodamine-conjugated (K16)-MG11 peptide, the cells were exam
confocal microscopy and the levels of fluorescence detected were compared.  
U251MG, and M059K human glioma cell lines exhibited detectable fluorescence as shown by 
the presence of rhodamine on the surface of the cells (Figure 5.21 top).  Little or no 
fluorescence was observed with nonglioma cell lines (Figure 5.21 bottom)
nonspecific red fluorescence was observed in all cell lines studied when incubated with (K
H42 control peptide under similar conditions (data not shown).  Unlike the (K16
peptide, no discrimination between glioma and nonglioma cells could be ascertained with the 
rhodamine-conjugated (K16)-H42 peptide (data not shown).   
 
The binding specificity of (K16)-MG11 peptide to primary human glioma cells and norm
primary human astrocytes was subsequently determined (Figure 5.22).  Primary
glioma cells derived from biopsy or normal primary human astrocytes were in
Lissamine rhodamine-conjugated (K16)-MG11 peptide at 37 °C for 20 min.  Si
binding of the (K16)-MG11 peptide was observed only in primary human glioma cells (Figure 
5.22a).  This binding specificity is comparable to that observed in SF767 human gliom
line (Figure 5.22b). In contrast, no fluorescence could be detected with norma
human astrocytes under similar conditions (Figure 5.22c).  These results clearly dem
that the MG11 peptide is specific for human glioma cells and does not bind to normal hu








To further demonstrate the tumor specificity of the (K16)-MG11 peptide on glioma xenograft, 
act that the receptors for MG11 
eptide are located on the external side of the plasma membrane, whereas F-actin is situated 
SCID mice harboring s.c.-established SF767-derived xenograft were injected intratumorally 
with Lissamine rhodamine-conjugated (K16)-MG11 peptide and (K16)-H42 peptide.  After 20 
min of circulation, the mouse bearing the SF767 glioma xenograft was perfused and tumor 
was harvested.  The tumor sections were counterstained with FITC-labeled phalloidin, which 
stains F-actin, to show the cell surface.  Cryostat sections of the tumors showed red 
fluorescence binding in SF767 glioma xenograft injected with (K16)-MG11 peptide (Figure 
5.23a), demonstrating the binding of the (K16)-MG11 peptide.  This binding, as observed in 
the inset (I), indicated that the (K16)-MG11 peptide interacted with cell surface receptors on 
the tumor cells.  In contrast, red fluorescence was not detected in the SF767 tumor injected 
with (K16)-H42 peptide (Figure 5.23b).  Although the staining obtained with FITC-labeled 
phalloidin (green) and Lissamine rhodamine-conjugated (K16)-MG11 peptide (red) was in 
close proximity, they did not colocalize.  This reflects the f
p
just below this external periphery membrane layer.  Taken together, our results suggested that 
the observed fluorescence can be attributable to the specific binding and subsequent uptake of 
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particular tumor cell type.  To circumvent this problem, tissue-specific promoter has been 
In
vector.  We have shown that incorporation of the GFAP enhancer element will lim
luciferase reported gene expression to proliferating glioma cells, and when FasL was us
a therapeutic gene, the percentage of cell death of observe only in proliferating dGli36 gli
cells, but were absent in infected-proliferating-HeLa cells.  Once the functionality
vector was determined, the issues of immunogenicity, stability and transduction efficiency of
the cell cycle-regulated amplicon vector need to be addressed.  These are important issues a
the success of gene therapy protocol is highly dependent on a safe and stable vector with high
transduction efficiency.  The earlier part of the thesis is focus on the cell cycle-regulated 
vector but not the dual-specific vector.  Therefore, the topics on immunogenicity, stability
transduction efficiency was not included. 
 
Gene transfer to malignant gliomas has been extensively pursued both in cell culture as well
as in animal models.  However, clinical gene therapy trials for recurrent gliomas have not 
fulfilled the high expectations suggested by preclinical laboratory results.  One of the 
significant pitfalls is the low transduction efficiency of tumor cells observed in vivo, resulting 
in insufficient expression of therapeutic gene products to efficiently eradicate the tumo
(Rainov and Kramm, 2001; Rainov and Ren, 2003; Weyerbrock and Oldfield, 1999).
Retrovirus vector was one of the earliest viral vectors to be employed for the delivery
therapeutic genes to gliomas in the clinical settings (Rainov and Ren, 2003).  Although 
phase I and II clinical studies showed favorable safety profiles and some efficacy, the
III study failed to demonstrate significant progression-free or extension of overall survival
(Rainov and Ren, 2003).  The use of adenovirus vectors, as well as HSV-based vectors, h
also been actively pursued both in the laboratory and clinic (Bansal and Engelhard, 2000).  
 
The major challenge of cancer gene therapy is the ability to restrict transgene expression to 
employed to direct cell type-specific gene expression, thus lessen the potential toxicity to non-
target cells. In this study, we have engineered a novel HSV-1 amplicon viral vector that 
incorporates both cell cycle- and cell type-specific regulatory elements.  We incorporated the 
glial-specific promoter, GFAP, into the cell cycle-regulated amplicon vector.  The insertion of 
this glial-specific element enables the transgene to be active only in proliferating glial cells.  
We did not incorporate the entire human GFAP promoter into our amplicon virus system.  
Instead, we incorporated the GFAP enhancer element in three tandem repeats and placed it 
upstream of a PCR-amplified hCMV minimal promoter.  This glial cell-specific 
transcriptional element has been shown to be transcriptionally selective for astrocytic cells 
such as T98G glioma cells, which do not express GFAP (Chen et al., 1998).  We have shown 
that the transcriptional activity is indeed specific to astrocytic cell lines such as dGli36, 
U251MG and SF767 cells (see Figure 5.2) and not present in nonastrocytic cell lines such as 
HeLa and HepG2.  Similarly, when the FasL gene was incorporated into pG8-18 to generate 
pG8-FasL, the expression of FasL was only detectable in proliferating glioma cells (dGli36) 
but not in nonglioma cells (HeLa) cells.  In addition, FasL expression mediated by pG8-FasL 
vector in vivo is shown to suppress the growth of s.c. glioma tumor (Figure 5.7) as well as to 
prolong the survival of mice harboring intracranial dGli36 tumor (Figure 5.8).  These results 
thus suggested that the expression of FasL is indeed regulated in a cell type-specific and cell 
cycle-dependent manner.  This observation is of great importance since the expression of 
FasL in non-target tissue such as liver, has been shown to be detrimental with FasL 
associated-apoptosis, resulting in liver failure (Aoki et al., 2000; Schlosser et al., 2000; 
Schneider et al., 1998).   
 
Targeting of gene delivery vectors to specific tissues is dependent on the identification of 
ligands that interact with cell surface receptor molecules.  For the targeting of HSV-1 vector, 
it is important to select for ligands that bind with high affinity, yet does not enhance receptor 
mediated endocytosis which will impede the delivery of the HSV-1 DNA to the nucleus, 
resulting in the degradation of the amplicon vector in the lysosome.   It is preferable to insert 
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small targeting epitopes to the HSBD region (amino acid 33-123; Tal-Singer et al., 1995) to 
reduce potential interference of the chimeric protein on the virion surface.    
 
We employed a phage display peptide library to isolate and characterize phage bearing 
peptide sequences that bind specifically to a wide array of human glioma cell lines.  Analysis 
of the 79 phage clones obtained after biopanning of the Ph.D.-12 phage library revealed 
several dominant sequence motifs (Table 5.3).  The sequence SGHQLLLNKMPN, encoded 
by the phage MG2 was found in 24 % of the clones and this sequence was shown to have 60 
% homology with the human mitogen-activated protein kinase kinase kinase 12 (MAP3K12).  
The second most frequently isolated phage clone, MG11, bears the sequence 
LWATFPPRPPWL, which matches that of semaphorin 4B precursor, a membrane-bound 
semaphorin.  Interestingly, two other phage clones that harbor peptide sequences with 
homology for the semaphorin family of proteins were also identified (Table 5.3).  The 
sequence HHGHSPTSPQVR matches the protein sequence of secreted semaphorin 3A 
precursor protein, whereas the sequence LPYGTSNRHAPV is homologous to that of 
membrane-bound semaphorin 6B precursor protein.  Semaphorin 3A has been reported to 
bind with high affinity to neuropilin-1 (Rieger et al., 2003), a receptor for the vascular 
endothelial growth factor family (Miao et al., 2000).  Neuropilin-1, together with plexin, a 
receptor for the transmembrane-bound semaphorins (Rieger et al., 2003), form complexes 
with the class 3 semaphorins that are able to direct growing axons to their targets (Tamagnone 
et al., 1999).  Besides modulating the extension of the axonal cones, semaphorins also 
regulate the migration of neural progenitor cells (Marin et al., 2001).  One of the clinical 
features of gliomas is their ability to infiltrate and migrate to distant sites within the brain; it is 
therefore speculated that semaphorins could play a role in the carcinogenesis of glioma.  This 
suggestion is consistent with reports of the presence of semaphorins in the progression of 
mouse mammary tumor and metastatic human lung adenocarcinoma (Martín-Satué and 
Blanco, 1999).  Consistently, it has also been reported that both semaphorin 3 and semaphorin 
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6B could be detected by RT-PCR analysis of human glioma cell lines (Correa et al., 2001; 
been isolated 
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Rieger et al., 2003).  
 
Previous peptide sequences that target to human malignant glioma cells have 
(Spear et al., 2001; Zhang et al., 2001).  However, the reported specificity 
confined to a single glioma cell line.  Spear et al reported a peptide, having
MCPKHPLGC that binds only to U87MG glioma cell line (Spear et al., 2001).  Zhang 
also reported a sequence that binds to glioma cells.  However, this 
specific, as it also binds to other cancer cell lines (Zhang et al., 2001).  In our
bearing the MG11 sequence showed a binding enrichment of more than 5-fold for
cells in comparison to nonglioma cells (Figure 5.16).  Consistent with the in vi
MG11 peptide-encoding phages were able to target specifically to dGli36 and SF7
glioma xenografts, with a 5-fold binding enrichment over that of a nonglioma tumo
under similar conditions (Figure 5.18a and b).  Furthermore, the MG11 peptid
direct and confine the gene expression of the luciferase DNA specifically
cells (Figure 5.20).  Currently, the lack of selectivity of cancer chemothera
in high toxicities.  As MG11 offers selective binding, it could potentially 
targeting molecule.  However, to enhance the effectiveness of targeting, the therapeutic index 
(ratio of binding to target glioma tissue versus binding to normal tissues) for each and every 
toxic molecule that may be conjugated to MG11 need to be determ
challenges for in vivo targeting is to be able to direct the binding of the targeting peptide to
tumor cells.  We have shown that the MG11 peptide binds only to human glio
lines (Figure 5.21) and primary human glioma cells (Figure 5.22a) but not to no
brain cells (Figure 5.22c) or other nonglioma cells (Figure 5.21).  These obser
be of great relevance for designing strategies to treat gliomas.   
 
Viral vectors confer higher efficiency of gene transfer in vivo in comparison
vectors.  However, components from HSV particles or cellular debris co-pur
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packaging or the transgene have been known to induce host immune response (Bowers et al., 
 
1 vector system is the instability of the transgene 
xpression.  Viruses packaged in the presence of the helper viruses produce less stable gene 
ly 
mor cells that are situated at the periphery of the tumor mass are rapidly proliferating while 
2003).  In our study (Figure 5.14) and a study performed by Olschowka et al. (2003), a 
transient immune response was observed in the brain following infusion of helper virus-free 
HSV-1 amplicon vectors with level of activated T lymphocytes and microglial cells returned 
to normal after four days. Similarly, the level of proinflammatory cytokine (IL-1β, TNF-α, 
IFN-γ), chemokines (MCP-1, IP-10) and adhesion molecules (ICAM-1) also returned to 
normal in the following day. This transient immune response was monitored by 
immunohistological staining for the expression of CD4, CD8, and CD11b in our study.  
However, dorsal foot pad analysis, or activation of cytotoxic T-lymphocyte (CTL) has been 
reported to investigate the activation of immune response.    
 
One of the major problems of the HSV-
e
expression when compared with those packaged using the helper virus-free system.  Ho et al. 
(1993) reported that the lacZ expression mediated by helper-virus-dependent pIE1βgalori 
amplicon vector in the rat hippocampus declined to zero by day 7 post-transduction.  In 
contrast, when packaged using helper-virus free system, the percentage of lacZ-positive cells 
was approximately 15 % of that observed at day 4.  Our data demonstrated the persistence of 
the viral DNA in the mouse brain for at least 28 days with a significant reduction in luciferase 
gene expression one month after gene transfer (Figure 5.11 and 5.12).  We have not 
determined the cause of the loss of luciferase gene expression 10 days post-infection.  It is 
possible that the loss of luciferase expression is due to the short half-life of the protein, which 
has been demonstrated to be approximately 2-3 h (Ignowski and Schaffer, 2004; Thompson et 
al., 1991). Using BrdU incorporation assay, we have determine that the percentage of S phase 
cells in 7 day-old intracranial tumor is approximately 8 % (data not shown). Because on
tu
those in the center core are not, we speculate that the significant reduction in luciferase 
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expression could also be due to the lack of proliferating cells resulting in the transgene not 
being activated.  Since the HSV-1 genome is largely extrachromosal, the presence of the viral 
DNA would eventually diminish as more cell divisions take place.  To increase the stability of 
the transgene expression in dividing cells, the HSV-1 amplicons have been modified to 
contain the EBNA1 gene and oriP from the EBV genome, which allow the replication of the 
amplicon DNA together with the host cell DNA (Wang and Vos, 1996).  This would ensure 
equal distribution of the amplicon DNA to daughter cells during mitosis.  Incorporation of 
AAV elements into the HSV-1 amplicon would enhance transgene stability, most likely due 
to the integration of the transgene into the nucleus of the host cells (Constantini et al., 1999; 
Lam et al., 2002; Fraefel et al., 1997; Heister et al., 2002; Johnston et al., 1997).  When the 
gag and pol gene from the retrovirus is incorporated in to the HSV-1 amplicon, the efficiency 
of transgene integration is 50-fold higher in comparison with HSV-1 amplicon (de Felipe et 
al., 2001). Other strategies employed include the development of the Cre/lox P system 
(Rinaldi et al., 1999) and the inclusion of a Tc1-like transposon, sleeping beauty (Ivics et al., 
2004; Yant et al., 2002). 
 
Conventional treatment of GBM involves a combination of surgery, chemotherapy and 
radiotherapy. Multiple cellular signals in the tumor cells are activated following exposure to 
radiation or chemotherapy which may interfere with our cell cycle-regulated amplicon vector. 
Our proposed strategy would serve as an “adjuvant” therapy to complement craniotomy in 
destroying any residual tumor cells that may remain at the resected tumor region.  The cell 
cycle-regulated amplicon vector can be injected directly into the tumor bed following surgical 
section of the core tumor mass.  The patient might be subjected to chemotherapy, in which re
case, we are interested to know whether this treatment will affect the viral vector and the 
transgene activation.  We have demonstrated that treatment with TMZ, the most common 
chemotherapeutic drug for GBM treatment, induces G2/M arrest in dGli36 cells, but it does 
not affect the cell cycle-regulated transgene expression (Figure 5.10).  On the other hand, 
ionizing radiation (IR) has been shown to induce transient G2/M accumulation in 
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radiosensitive glioma cells, such as p53 mutated M059K cells that have the ability to repair 
DNA double-strand break (Xu et al., 2002; Holgersson et al., 2005).  However, IR does not 
ffect HSV-1 amplicon vector.  In fact, it has been shown that IR provides a conducive local a
environment for the replication of HSV-1 viral vector (Advani et al., 1998, Bradley et al., 
1999).  In addition, IR can target enhanced viral replication specifically to the irradiated 
tumor bed, possibly by inducing expression of genes from the glioma cells that stimulates 
viral replication (Advani et al., 1998).  Thus, cell cycle-regulated HSV-1 amplicon-transduced 
cells that survive IR may continue to divide.   
 
In summary, transgene expression mediated by the amplicon vector can be restricted to 
glioma-cells by the incorporation of the GFAP promoter and the use of the MG11 targeting 
peptide. This approach would significantly enhance the efficiency of gene transfer and at the 















Vector targeting is one of the most unambiguous lessons to derive from human clinical trials.  
Most current modes of vector entry into cells are not specific to cell type, and rely on the 
route of delivery to target certain cell populations.  In the present study, focus has been placed 
on generating a viral vector that confers transgene expression in a cell type-dependent manner, 
and later, “fine-tuning” it to be cell type-specific by adopting a glial-cell specific promoter.  
This vector, denoted as pG8-18, is studied with respect to its ability to confer stable transgene 
expression, its infectability and mobility of the pG8-18 HSV virions are explored 
intracranially and more importantly, the amount of immune responses elicited by these 
viruses are also determined.  To envisage the behavior of these viruses in a clinical setting, 
pG8-18 viral vectors are further evaluated in the presence of a chemotherapy drug commonly 
sed for the treatment of human gliomas.  Last but not least, the pursuit of a glioma-specific 
 
u
sequence is also presented, with the ultimate goal of incorporating the peptide sequence into 
the enveloped coat protein of pG8-18 amplicon vectors for targeting purposes.  Currently, we 
have demonstrated that the vector is stable in vivo, relatively non-immunogenic and that the 
dual-specific regulation is retained even after treatment with drug, indicating that this vector 
may potentially be of clinical relevance for gene delivery.  Despite of these encouraging 
findings, the system nonetheless has its limitations.  Unlike the tetracycline or the dimerizer-
regulated system, the cell cycle-regulated transcriptional activation system does not require 
the application of exogenous drugs or dimerizations of two protein domains.  Instead, this 
system is strictly dependent on the activation of cellular proliferation, which in turns will 
activate transgene expression.  This ensures that infected but “dormant” tumor cells will be 
killed once the cells enter the cell cycle, thus switching-on the therapeutic gene expression.  
However, the transgene regulation needs to be enhanced to ensure only proliferating tumor 
cells are affected.  In addition, new avenues relating to the choice of therapeutic genes and 




6.1 Enhanced transgene regulation 
We have demonstrated that transgene expression regulated by the cell cycle-dependent vector 
is specific for proliferating cells (Chapter 3).  The degree of cell cycle regulation, measured as 
a ratio of luciferase activity (expressed as RLU/ug) of the proliferating and G1-arrested cells, 
ranges between 0.2-3.7 and 4.3-57.6 fold in pIH8GalLuc and pC8-36 constructs, respectively.  
To further increase the tightness of regulation, we propose to multimerize the binding sites 
(CDE/CHR elements) for CDF-1 located within cyclin A promoter.  We hypothesize that the 
availability of more binding sites for CDF-1 repressor binding would tighten the transgene 
regulation during G0/G1 arrested stage.  This is supported by preliminary findings that cell 
cycle-dependent transgene expression can be regulated in a viral dosage dependent manner 
(section 3.3.12).  In parallel, other promoters, which contain the CDE/CHR elements, will be 
tested for their promoter strength in comparison to cyclin A promoter for stronger 
transactivation capability.  Promoter such as cyclin B is a potential candidate.  Cyclin B forms 
a complex with cdc2, which is required for cells to undergo mitosis.  The expression level of 
cyclin B is maximal in G2 phase of the cell cycle.  In addition, the cyclin B promoter contains 
ree CCAAT-boxes that can bind to and activated by NF-Y (Wasner et al., 2003).  Moreover, th
overexpression of cyclin B has been associated with colorectal cancer (Sarafan-Vasseur et al., 
2002) and lung carcinoma (Hofmann et al., 2004).   
 
6.2 Alternative therapeutic genes and glioma-specific promoters 
Currently, we have employed the FasL and FADD genes to assess the therapeutic efficacy of 
our system.  The level of cytotoxicity induced by these two molecules using either the pC8-36 
or pG8-18 based vector is not strong enough to achieve 100 % killing.  In addition, the 
apoptotic effect of soluble FasL could be undesirable due to possible toxicity to normal tissue 
that expressed the Fas receptor.  To circumvent this problem, multiple therapeutic gene 
cassettes such as p53 and FasL (Shinoura et al., 2000), p53 and Bax, FasL and FADD, FasL 
and TRAIL (Rubinchik et al., 2003), caspase-1 and interferon γ could also be evaluated.  In 
addition, non-cleavable FasL which contains mutations in the metalloproteinase cleavage sites 
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has been demonstrated to induce potent apoptotic effect, and at the same time, reduce by-
stander effect (Knox et al., 2003).  The incorporation of these genes into one single vector 
would not only increase the therapeutic efficiency of the target cells, it would also overcome 
the low viral titer limitation of the HSV-1 amplicon vector.   
 
The utilization of GFAP promoter to drive luciferase gene expression in pG8-18 is promising.  
However, one of the anticipated problems in vivo would be the expression of GFAP in normal 
human astrocytes and neural progenitor cells (Johansson et al., 1999; Laywell et al., 2000).  
ince our vector is capable of infecting normal astrocytes, the transgene could be activated 
n level by the telomerase 
catalytic subunit, human telomerase reverse transcriptase (hTERT).   Several groups have 
demonstrated the use of hTERT promoter to regulate the expression of apoptotic gene such as 
FADD (Koga et al., 2001), caspase 8 (Komata et al., 2002), caspase 6 (Komata et al., 2001) 
and HSV-tk (Takeda et al., 2003).  Although this approach may have added advantage to 
restricting transgene expression in proliferating tumor cells, it does not overcome the non-
selective bystander effect of FasL (as shown in Figure 4.4) and may be hazardous to the 
untransduced cells surrounding the tumor border regions.  Numerous studies have reported on 
the over-expression of the interleukin-13 receptors (IL-13R) on human glioma cell lines and 
virtually all high-grade human glioma samples (Debinski et al., 1995; Joshi et al., 2000; 
Husain et al., 2001).  Analysis of the subunit composition of IL-13R in primary explants of 
malignant glioma cells has demonstrated that IL-13R composed of three different chains 
namely; IL-13Rα1 (also known as IL-13Rα’); IL-13Rα2 (also known as IL-13Rα) and IL-
4Rα (also known as IL-4Rβ) (Husain et al., 2003).  Human glioma cells overexpress IL-
13Rα2, which is only marginally expressed or completely deficient in normal brain tissues, B 
S
during reactive gliosis, resulting in the elimination of these proliferating cells in addition to 
the tumor cells.  The system could be improved by the use of tumor-specific promoter such as 
the telomerase promoter which is highly expressed in malignant tumor cells but not in normal 
cells.  The activation of telomerase is regulated at the transcriptio
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cells, monocytes, T lymphocytes and endothelial cells (Joshi et al., 2000; Husain et al., 2003).  
e have confirmed the over-expression of IL-13Rα2 transcripts in some of the human glioma 
ell lines (data not shown) and would like to further examine the expression level in primary 
uman glioma cells.  To target IL-13R, IL-13 cytotoxin (IL13-PE38QQR) composed of IL-13 
nd a mutated short form of Pseudomonas exotoxin moiety (PEA) have been shown to be 
ighly selective and lethal for glioma cells (Debinski et al., 1995).  Normal cells including 
mune cells, endothelial cells and normal brain cells are spared from the cytotoxic effect of 
e IL-13 cytotoxin (Husain et al., 2003; Souweidane et al., 2004).  Cytotoxicity could be 
demonstrated in glioma cells at concentrations as low as 0.001 µg/ml (Debinski et al., 1995; 
Liu et al, 2000).  Due to the tumor specificity d large therapeutic index, the IL-13 cytotoxin 
is currently being tested in PhaseI/II stu nt supratentorial malignant gliomas in 
adults.  We hypothesize that th  could potentially enhance the 
specificity of the therapeutic gene expression.   
 
6.3 Clinical application of the cell cycle-regulated amplicon vector 
Our proposed strategy would serve as an “adjuvant” therapy to complement craniotomy in 
destroying any residual tumor cells that may remain at the resected tumor region.  The cell 
cycle-regulated amplicon vector can be injected directly into the tumor bed following surgical 
resection of the core tumor mass.  Since majority of the tumor mass has been removed, the 
dose of viral vectors required to eradicate residual tumor cells is expected to be 
correspondingly small.  By doing so, one would minimize the likelihood of harming distant 
normal, dividing cells.  In fact, this treatment protocol mimic gliadel wafers which have been 
clinically applied for implantation into the tumor sites at the time of surgery to slowly release 
a chemotherapy drug such as BCNU (Brem and Gabikian, 2001).  Thus, the 10-fold 
difference observed in vivo (Figure 5.4) would have a significant impact considering that 
these viruses will be inoculated into the resected cavity rim, harboring mainly replicating 










e use of IL13-PE38QQR
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the problems associated with implantation of vector producing cells (VPC), such as the 
inability to distribute the VPC and the instability of the VPC (Rainov and Ren, 2003).  
However, the low percentage of transduced cells in vivo would still pose a problem.  
Therefore, injections at multiple sites need to be carried out to ensure majority of the residual 
tumor cells are infected by the amplicon viral vectors.   
 
6.4 Combining vector targeting with transcriptional targeting  
The HSV-1 genome contains more than 80 genes with one-fifth of the genes encoding for 
virion surface proteins and the envelope glycoproteins.  Initial attachment and subsequent 
entry of the virus to the host cells are dependent upon 5 major glycoproteins, namely, gC, gB, 
gH, gL and gD.  To retarget HSV, the membrane glycoproteins can be modified such that the 
natural tropism of the virion is reduced, and the modified glycoproteins that contain those 
new ligands are able to infect and penetrate target cells.  During the infection process, binding 
of HSV to the cell surface heparan sulfate (HS) is primarily mediated through gC, which is 
located in the UL segment of the HSV-1 genome and encoded by the UL44 gene.  gC contains 
a well characterized heparan sulfate binding domain (HSBD) which can be modified with 
ligands that target to specific cell types (Tal-Singer et al., 1995).  Deletion in the HSBD in gC 
resulted in significant reduction in infectivity to HSV-1 natural target cells. 
 
Several groups have created chimeric gC that carries insertion in the HSBD between amino 
acids 33 and 123 (Grandi et al., 2003; Laquerre et al., 1998; Spear et al., 2003).  Laquerre et 
al. (1998) inserted the erythropoietin binding domain into the HSBD region of gC in a gB-
deleted mutant.  The results demonstrated that this modified HSV is targeted to murine cells 
expressing the erythropoietin receptor.  However, deletion of gB, which is required for 
membrane fusion, resulted in endocytosis of the vector leading to aborted infection. In 2003, 
pear et al. constructed a novel amplicon vector, pCONGAH, which has a higher affinity to 
ells expressing the pseudo-histidine (his) tag.  This vector contains the standard amplicon 





 gC, which was modified to contain 6 successive his-also contains the gene encoding for
residues (Spear et al., 2003).  The authors demonstrated at least 4-fold higher affinity of 
pCONGAH viral vector to cells that expresses the pseudo-his tag in vitro compared to the 
parental cell line that does not overexpress the pseudo-his tag (Grandi et al., 2004; Grandi et 
al., 2003).  Unlike the erythropoietin-targeting HSV, the infectivity of pCONGAH is not 
affected (Grandi et al., 2004; Grandi et al., 2003).  This is the first attempt at modifying the 
envelope of a HSV-1 amplicon vector.   
 
Thus, the generation of pCONGA-MG11 will allow us to test the homing potential of MG11 
in the context of a HSV-1 amplicon peptide display vector.  Once the targeting ability of 
MG11 peptide sequence mediated by amplicon vector is determined in vivo, modification of 
the envelope glycoprotein of the cell cycle regulated HSV-1 amplicon vector, pG8-18, to 
express the MG11 peptide sequence, will be attempted to enhance homing specificity and 
potentially target the infiltrated invasive cells.  The combination of the two targeting systems 
would ensure only those rapidly proliferating glioma cells that express the receptor for the 
MG11 peptide be infected by pG8-18.  More importantly, the amount of viruses needed to 




In summary, we have designed a HSV-1 amplicon based “ideal” gene delivery system that is 
(i) capable of incorporating a large transgene; (ii) stable; (iii) safe; (iv) regulatable; (v) 
capable of targeting to a specific cell type.  Transgene expression mediated by this vector can 
be regulated in glioma-specific and cell cycle-regulated manner.  Coupling of this vector 
system with the targeting peptide could potentially be useful in the removal of the residual, 
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